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SUMMARY 
Protein kinase CK2, constituted by two catalytic (a and/or a’) and two regulatory (b) 
subunits, is a highly conserved kinase which phosphorylates a huge number of substrates 
and is involved in different cellular pathways and functions. It has a major anti-apoptotic 
role, it enhances the apoptosis resistance (MDR) phenotype, and it is abnormally 
expressed in a wide variety of cancers, where it operates as a “cancer driver” by creating a 
cellular environment favorable to the development, growth and propagation of 
malignancy. Since CK2 expression is not linked to a specific type of cancer, its targeting 
could be a successful strategy, because of its very general applicability and widespread 
effects. Importantly, tumor cells are more sensitive to CK2 inhibition than normal ones, 
probably because they rely more on CK2 for their survival, accordingly to the concept of 
cancer addition to CK2 (Ruzzene and Pinna, 2010). Therefore, CK2 represents a suitable 
target for developing anticancer drugs.  
Different compounds have been developed so far as CK2 inhibitors, useful not only for 
investigating CK2 physiological functions, but also as possible therapeutic tools. The 
majority of them act targeting the ATP-binding site of CK2; some compounds have 
shown high potency and specificity toward the kinase, and have disclosed a proapoptotic 
effect in cancer cells more evident than in normal ones. 
The research presented in this thesis provides examples of different strategies to target 
protein kinase CK2, in order to selectively reduce its activity in tumor cells and to 
produce cellular effects which can counteract the malignant transformation. In particular, 
we used: 1) CX-4945 and CX-5011, ATP-competitive CK2 inhibitors (Pierre et al. 2011); 
2) K137-E4, a bi-functional inhibitor designed to compete with both the ATP and the 
peptide binding sites of CK2; 3) a compound called CRIBI-300, derived from CIGB-300, 
designed to prevent the phosphorylation of specific CK2 substrates (Perea et al., 2004). 
The three studies are summarized below. A fourth study is also described, which 
exploited a compound, TBID, developed from a CK2 inhibitor but modified to become 
selective toward another protein kinase, HIPK2. 
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Effects of the ATP-competitive CK2 inhibitors CX-4945 and CX-5011 in apoptosis-
resistant cells 
 
CX-4945 and CX-5011 inhibitors (developed by Cylene Pharmaceuticals) act competing 
with ATP for the binding to the catalytic pocket of the CK2. These compounds are very 
potent and selective in inhibiting CK2 (Pierre at al., 2011; Battistutta et al., 2012): CX-
4945, in particular, has shown good pharmacological features and has advanced in 
clinical trials with promising outcomes. However, the CX compounds had never been 
used in apoptosis-resistant cells. In this work we demonstrate that CX-4945 and CX-5011 
are efficient in reducing endogenous CK2 activity and in inducing apoptosis in several 
pairs of apoptosis-sensitive and resistant tumor cell lines. Furthermore, we also observed 
that resistant cells which express the drug-extruding pump P-gp are sensitized by CX-
4945 towards conventional antitumor drugs. In fact, we found that doxorubicin uptake in 
resistant cells is increased, and that combined treatment with CX-4945 and vinblastine 
produces synergistic effects on cell death. In summary, our data suggest that CX 
inhibitors can be considered as a valid therapeutic strategy also in case of 
pharmacological resistance.  
Effects of CK2 bi-functional inhibitors in tumor cells 
A very new strategy to target CK2 is based on compounds denoted as bi-functional or bi-
substrate inhibitors, designed to hit both the ATP and the substrate sites of the kinase at 
the same time, in order to improve selectivity toward CK2. Among these compounds, 
K137-E4 has been recently developed in our laboratory and characterized by in vitro 
studies; it was found to strongly inhibit recombinant CK2 (IC50=0.025 mM) and to be very 
selective. In the study presented in this thesis, we had the aim of investigating the 
employment of this compound in cells. We first demonstrated that it is also able to inhibit 
the activity of native CK2 towards cellular substrates. However, this was performed by 
means of in vitro phosphorylation assay, while, when we used K137-E4 for cell treatment 
we did not observed any effect on CK2 activity and cell viability. We therefore supposed 
that the compound, quite hydrophilic, is not cell permeable. Studies are under 
investigation to modify the molecule structure in order to improve its cell permeability, 
without significantly decreasing its inhibitory capacity. At present, we found that the 
K137-E4 molecule, in virtue of its impossibility to cross plasma membrane, can be useful 
to study CK2 ecto-kinase, that portion of this enzyme that resides at the external surface 
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of cells (Kubler et al., 1989). We demonstrated that it is able to inhibit CK2 ecto-kinase, 
but this has not effect on cell viability of tumor and non-tumor cells. This finding, in 
conjunction with the observation that CK2 ecto-kinase activity seems to be similar in 
tumor and not-tumor cells, suggests that CK2 ecto-kinase is not implied in cell survival 
and tumor-related events.  
In vitro and in cell effects of peptides targeting CK2 substrates 
A recently introduced approach to target CK2 is based on the development of a cyclic 
peptide called CIGB-300, which interferes with the phosphorylation site of specific CK2 
substrates, rather than inhibiting the enzyme per se (Perea et al., 2004). CIGB-300 is 
already employed in clinical trials (Perea et al., 2011), however, its mechanism of action 
is only partially understood. We therefore exploited a new synthetized peptide, denoted as 
CRIBI-300, with the same functional domain of the parental CIGB-300, and we 
performed in vitro and in cell studies, comparing it with CIGB-300 and several other 
derivatives. We found that CK2 activity in vitro is affected by CRIBI-300 peptide, but 
with different effects accordingly to the type of substrate used: inhibition is observed only 
towards substrates which are strictly dependent on the presence of CK2 b for their 
phosphorylation by CK2, while the activity towards substrates which are preferentially 
phosphorylated by the CK2 monomeric a is rather stimulated by CRIBI-300. This 
suggests that CRIBI-300 could interfere with the CK2 holoenzyme structure, producing an 
unstable and/or unfunctional tetrameric conformation which prevents the phosphorylation 
of b-dependent substrates.  
When we performed cell treatment experiments, we also found that CRIBI-300 induces a 
strong reduction of endocellular CK2 activity, but this is accompanied by an early and 
rapid loss of CK2 protein amount. In parallel, cell death was also induced by CRIBI-300, 
but it was not due to apoptosis. Moreover, we observed a loss in the amount of also other 
proteins beside CK2; alteration in the activity of proteolytic systems occurs as well, with 
the activation of lysosomal proteases and the blockage of proteasome machinery. All the 
effects appear more evident in tumor than in non-tumor cells.  
We then analyzed the effects of CRIBI-300 derived peptides, with single aminoacid 
substitutions or large sequence differences. Interestingly, we found that the Tat sequence 
(the portion of CRIBI-300 introduced to render it cell permeable (Holm et al., 2006)) is 
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essential for its activity towards CK2 in cells, but not sufficient per se, being specific 
aminoacids in the remaining part of CRIBI-300, crucial for producing effects.  
Of the many effects evoked by CRIBI-300, we wondered if and which ones are mediated 
by its action on CK2. We found that the reduction of CK2 expression (obtained by RNA-
interference cellular experiments) also attenuates some of the CRIBI-300 effects, although 
not all. Moreover, those CRIBI-300 sequence alterations which prevent in vitro effects on 
CK2 are also able to reduce cellular effects. We therefore concluded that CK2 is indeed an 
early and important target of CRIBI-300. However, additional mechanisms of action of 
this compound should exist to explain all the observed effects, and this suggests that 
extreme caution is required for its employment at a clinical level.  
 
Effects of TBID inhibitor on cellular HIPK2 activity 
A collateral study presented in this thesis concerns a compound, TBID, derived from a 
CK2 inhibitor (TBI) but modified in structure to become selective for a different kinase, 
HIPK2 (homeodomain-interacting protein kinase 2), a Ser/Thr kinase controlling cell 
proliferation and survival (D’Orazi et al., 2012), whose investigation has been hampered 
by the lack of specific inhibitors able to dissect its cellular functions. TBID is an ATP-
competitive inhibitor very potent towards HIPK2 in vitro (IC50= 0.33 μM) and very 
selective. Here we show that it is also cell permeable, being able to inhibit endocellular 
HIPK2 activity, and to reduce the phosphorylation state of a HIPK2 target, Ser46 of p53 
protein. Since TBID is not cytotoxic under the conditions used to check its effects on 
cellular HIPK2 activity, we propose TBID as the only tool presently available to down 
regulate cellular HIPK2. 
 
Altogether, the results presented in this thesis demonstrate that kinase inhibition is an 
extremely versatile tool to be used in cells, exploitable either to investigate on the role of 
a specific kinase or to block an unwanted hyperactivity. In particular, in the case of CK2 
inhibitors, we analyzed different strategies. Although for the moment the more effective 
and convincing one is still that represented by the classical ATP-site directed compounds, 
other approaches are also presented, which need further investigation but could be 
promising in term of improved specificity or more targeted effects.  
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RIASSUNTO 
La proteinchinasi CK2, costituita da due subunità catalitiche (a e/o a ') e due subunità 
regolatorie (b), è un enzima altamente conservato, che fosforila un gran numero di 
substrati ed è coinvolto in diverse vie di segnale e funzioni cellulari. CK2 svolge un 
importante ruolo anti-apoptotico, è coinvolta nel fenomeno della farmacoresistenza 
all’apoptosi, ed è altamente espressa in un'ampia varietà di tumori, dove opera come un 
"promotore cancerogeno" creando un ambiente cellulare favorevole alla sviluppo, alla 
crescita, e alla propagazione della malignità. Poiché la sua sovraespressione non è 
direttamente connessa ad uno specifico tipo di tumore, colpire CK2 può diventare un’ 
interessante strategia di successo data la sua generale applicabilità e suoi diffusi effetti. È 
importante sottolineare che le cellule tumorali sono più sensibili all'inibizione di CK2 
rispetto a quelle normali, probabilmente perché sono più dipendenti da CK2 per la loro 
sopravvivenza, e questo va in accordo con il recente concetto di “cancer addiction” a 
CK2 (Ruzzene e Pinna, 2010). Pertanto, CK2 rappresenta un obiettivo adatto per lo 
sviluppo di farmaci antitumorali. 
Finora sono stati sviluppati diversi inibitori di CK2, utili non solo per indagare il suo 
ruolo fisiologico, ma sfruttati anche come possibili strumenti terapeutici. La maggior 
parte di questi composti agisce bloccando il sito di legame per l’ATP dell’enzima; alcuni 
di questi hanno dimostrato elevato potere inibitorio e specificità verso la chinasi, e si sono 
rivelati più efficaci nell’indurre apoptosi in cellule tumorali rispetto a quelle normali. 
La ricerca presentata in questa tesi fornisce esempi di diverse strategie di inibizione 
mirate a bloccare CK2, al fine di ridurre selettivamente la sua attività nelle cellule 
tumorali e di produrre effetti cellulari che possono contrastare la trasformazione maligna. 
In particolare, abbiamo utilizzato: 1) CX-4945 e CX-5011, inibitori di CK2 ATP- 
competitivi (Pierre et al., 2011); 2) K137-E4, un inibitore bifunzionale progettato per 
competere simultaneamente con ATP e con il sito di legame per il peptide substrato di 
CK2; 3) CRIBI-300, un composto derivato da CIGB-300, progettato per impedire la 
fosforilazione di substrati specifici da parte di CK2 (Perea et al., 2004). Questi tre 
argomenti di ricerca sono riassunti di seguito. Viene presentato anche un quarto studio 
che ha riguardato un composto, TBID, sviluppato partendo da un inibitore di CK2, 
modificandolo per renderlo selettivo nei confronti di un'altra proteinchinasi, HIPK2. 
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Effetti degli inibitori di CK2 ATP-competitivi CX-4945 e CX-5011 in cellule resistenti 
all’apoptosi 
Gli inibitori CX-4945 e CX-5011 (sviluppati dalla Cylene Pharmaceuticals) agiscono 
competendo con l’ATP per il legame nella tasca catalitica di CK2. Questi composti sono 
molto potenti e selettivi nell’inibire CK2 (Pierre et al., 2011; Battistutta et al., 2012), il 
CX-4945 in particolare ha mostrato buone proprietà farmacologiche ed è in 
sperimentazione clinica nell’uomo con promettenti risultati. Tuttavia, i composti CX non 
sono mai stati utilizzati in cellule resistenti all’apoptosi. In questo lavoro dimostriamo 
come CX-4945 e CX-5011 siano efficaci nel ridurre l’attività endogena di CK2 e 
nell’indurre apoptosi in diverse linee cellulari tumorali sensibili e resistenti all’apoptosi. 
Abbiamo inoltre trovato che le cellule resistenti che esprimono una pompa di estrusione 
dei farmaci, la P-gp, vengono rese sensibili a farmaci antitumorali convenzionali grazie 
all’uso di CX-4945. Infatti abbiamo trovato che l’accumulo di doxorubicina viene 
incrementato in cellule resistenti e che il trattamento combinato con CX-4945 e 
vinblastina produce effetti sinergici sulla morte cellulare. Pertanto, i nostri dati 
suggeriscono che gli inibitori CX possono essere considerati come una valida strategia 
terapeutica anche nei casi di resistenza farmacologica. 
Effetti di inibitori di CK2 bifunzionali in cellule tumorali 
Una nuova strategia per inibire CK2 è basata su composti definiti come inibitori 
bifunzionali o bisubstrato, disegnati per legarsi contemporaneamente ai siti di legame per 
l’ATP e per il substrato di CK2, con lo scopo di aumentarne la selettività per CK2. Tra 
questi composti il K137-E4 è stato recentemente sviluppato e caratterizzato in vitro nel 
nostro laboratorio: è stato dimostrato che è molto potente nell’inibire la CK2 
ricombinante (IC50 = 0,025 mM) e che ha buona selettività. Nello studio presentato in 
questa tesi, ci siamo proposti di analizzare la possibilità di utilizzo di questo composto 
anche in cellule. Innanzitutto abbiamo dimostrato che il K137-E4 è in grado di inibire 
l’attività di CK2 nativa nei confronti di substrati cellulari. Tuttavia, questo si riferisce ad 
esperimenti in vitro, mentre quando abbiamo trattato le cellule con il K137-E4 non 
abbiamo osservato alcun effetto né sull’attività di CK2 né sulla vitalità cellulare. 
Abbiamo pertanto ipotizzato che il composto, essendo piuttosto idrofilico, non fosse in 
grado di attraversare la membrana cellulare. Sono tuttora in corso modifiche strutturali 
della molecola mirate ad aumentarne la permeabilità cellulare senza diminuirne 
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significativamente la sua capacità inibitoria. Ad oggi, abbiamo pensato che il K137-E4, in 
virtù della sua impossibilità di attraversare la membrana plasmatica, può essere utile per 
studiare l’attività ectochinasica di CK2, cioè di quella porzione di enzima che risiede sulla 
superficie esterna delle cellule (Kubler et al., 1989). Abbiamo infatti dimostrato che 
questo composto è capace di inibire CK2 ectochinasica, ma che ciò non ha alcun effetto 
sulla vitalità cellulare né di cellule tumorali né di cellule non tumorali. Questa scoperta, 
assieme all’osservazione che l’attività ectochinasica di CK2 sembra essere simile in 
cellule tumorali e non, suggerisce che la CK2 ectochinasica non è implicata nella 
sopravvivenza cellulare e negli eventi correlati alla tumorigenesi. 
Effetti in vitro e in cellule di peptidi mirati a legare substrati di CK2 
Un nuovo approccio recentemente introdotto per colpire CK2 è basato sullo sviluppo di 
un peptide ciclico, chiamato CIGB-300, che interferisce con la fosforilazione di specifici 
substrati di CK2 piuttosto che inibire con l’enzima per se (Perea et al., 2004). CIGB-300 
è già impiegato in studi clinici (Perea et al., 2011), tuttavia il suo meccanismo d’azione è 
solo parzialmente conosciuto. Abbiamo dunque sfruttato un nuovo peptide sintetico, 
chiamato CRIBI-300, con lo stesso dominio funzionale del CIGB-300, e abbiamo 
effettuato studi in vitro ed in cellule, comparandolo con il CIGB-300 e altri suoi derivati. 
Abbiamo scoperto che l’attività di CK2 in vitro può essere influenzata dal peptide CRIBI-
300, ma con effetti differenti a seconda del tipo di substrato utilizzato: abbiamo osservato 
inibizione solo per quei substrati la cui fosforilazione da parte di CK2 è strettamente 
dipendente dalla presenza della subunità regolatoria b, mentre troviamo stimolazione da 
parte del CRIBI-300 nei confronti di substrati che sono fosforilati preferenzialmente dalla 
subunità catalitica a. Questi dati suggeriscono che il CRIBI-300 potrebbe interferire con 
la struttura dell’oloenzima CK2, dando luogo ad una conformazione tetramerica instabile 
e non funzionale e impedendo la fosforilazione di substrati b-dipendenti. 
Anche in esperimenti di trattamento cellulare, abbiamo trovato che CRIBI-300 induce una 
forte riduzione dell’attività cellulare di CK2, che è però accompagnata da una precoce e 
rapida perdita della quantità proteica di CK2. In parallelo, CRIBI-300 induce anche morte 
cellulare, ma non per apoptosi. Inoltre, abbiamo osservato diminuzione delle quantità di 
altre proteine, oltre a CK2, e un’alterazione dell’attività dei sistemi proteolitici con 
l’attivazione di proteasi lisosomiali e il blocco del proteasoma. Tutti questi effetti 
appaiono più evidenti in cellule tumorali che in cellule non tumorali.  
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Abbiamo poi analizzato gli effetti di derivati peptidici del CRIBI-300, con sostituzioni di 
singoli aminoacidi o con sequenze diverse. E’ interessante il fatto che abbiamo trovato 
che la sequenza Tat (la porzione del CRIBI-300 introdotta per renderlo permeabile alla 
cellula (Holm et al., 2006)) è essenziale per la sua attività su CK2 in vitro e in cellula, ma 
non è sufficiente di per se dal momento che specifici amminoacidi nella parte funzionale 
del CRIBI-300 (la sequenza non corrispondente a Tat) risulta essere cruciale per produrre 
gli effetti. Dei molti effetti causati dal CRIBI-300, abbiamo cercato di capire quali fossero 
mediati dalla sua azione su CK2. Abbiamo trovato che la riduzione dell’espressione di 
CK2 (ottenuta mediante esperimenti di “RNA interference”) attenua alcuni degli effetti 
del CRIBI-300, sebbene non tutti. Inoltre, quelle modifiche della sequenza del CRIBI-300 
che impediscono i suoi effetti in vitro su CK2 sono anche capaci di ridurne gli effetti a 
livello cellulare. Possiamo perciò concludere che CK2 è sicuramente uno dei più 
importanti bersagli di CRIBI-300. Tuttavia altri meccanismi d’azione di questo composto 
devono esistere per spiegarne tutti gli effetti osservati, e ciò suggerisce quindi che 
un’estrema cautela è richiesta per l’utilizzo di questo composto. 
Effetti dell’inibitore TBID sull’attivita’ cellulare di HIPK2 
Uno studio collaterale presentato in questa tesi riguarda il composto TBID, che deriva da 
un inibitore di CK2, il TBI, ma che è stato modificato nella struttura per renderlo selettivo 
nei confronti di un’altra chinasi, HIPK2 (Homeodomain-interacting protein kinase 2), una 
Ser/Thr chinasi che controlla la proliferazione e sopravvivenza cellulare (D’Orazi et al., 
2012) il cui studio è stato rallentato dalla mancanza di inibitori specifici capaci di 
svelarne le funzioni cellulari. TBID è un inibitore ATP-competitivo molto potente nei 
confronti di HIPK2 in vitro (IC50 = 0,33 mM) e molto selettivo. In questa tesi mostriamo 
che TBID è anche in grado di entrare nelle cellule, dimostrando che inibisce l’attività di 
HIPK2 intracellulare e riduce la fosforilazione della Ser46 di p53, un sito fosforilato da 
HIPK2. Dal momento che TBID non è citotossico nelle condizioni utilizzate per 
analizzarne gli effetti sull’attività di HIPK2 cellulare, proponiamo TBID come l’unico 
strumento attualmente disponibile per inibire HIPK2 in cellule. 
I risultati presentati in questa tesi dimostrano che l’inibizione di chinasi rappresenta uno 
strumento estremamente versatile per l’utilizzo nelle cellule, sia per analizzare il ruolo di 
una specifica chinasi, sia per bloccarne una non desiderata iperattività. In particolare, nel 
caso di inibitori di CK2 abbiamo analizzato diverse strategie. Sebbene al momento la più 
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efficace e convincente rimanga quella rappresentata dai classici composti ATP-
competitivi, abbiamo presentato altri approcci che, pur necessitando di ulteriori studi, 
potranno in futuro dimostrarsi promettenti in termini di aumentata specificità o di 
maggiore selettività degli effetti prodotti. 
 
 
 
 
 
XIII 
 
ABBREVIATIONS 
 
AMINOACIDS 
 
 
 
Ala    Alanine   A 
 
Arg   Arginine    R 
 
Asn    Asparagine    N 
 
Asp    Aspartic Acid   D 
 
Cys    Cysteine   C 
 
Gln    Glutamine    Q 
  
Glu    Glutamic acid   E 
 
Gly    Glycine    G 
 
His    Histidine    H 
 
Ile    Isoleucine   I 
 
Leu   Leucine   L 
 
Lys    Lysine     K 
 
Met    Methionine   M 
 
Phe    Phenylalanine   F 
 
Pro    Proline    P 
 
Ser    Serine     S 
 
Thr    Threonine    T 
 
Trp    Tryptophan    W 
 
Tyr    Tyrosine    Y 
  
Val    Valine     V 
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ACRONYMS 
 
ATP     Adenosine 5'-triphosphate  
DMSO    Dimethyl sulfoxide  
DC50     Half maximal death concentration 
DNA     Deoxyribonucleic acid  
EDTA    Ethylenediaminetetraacetic acid  
EGTA    Ethylene glycol tetraacetic acid  
FBS     Fetal bovine serum  
GTP     Guanosine 5'-triphosphate  
HRP     Horseradish peroxidase  
IC50     Half maximal inhibitory concentration  
IgG     immunoglobulins  
kDa     KiloDalton  
Kd    Dissociation constant  
Ki     Inhibition constant  
MTT     Tetrazolium  
Mw     Molecular weight  
PVDF     Polyvinylidene difluoride  
RNA     Ribonucleic acid  
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis  
TBS     Tris buffered saline  
TRIS     Tris (hydroxymethyl) aminomethane  
WB     Western blot 
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PROTEIN PHOSPHORYLATION 
Protein phosphorylation is a post-translational biological event, which regulates any 
function of a eukaryotic cell life such as division, metabolism, movement, survival 
and apoptosis. Hence, any alteration of phosphorylation events will alter cell 
functions and may cause disease (Cohen et al, 2002). Phosphorylation reactions are 
catalyzed by enzymes known as protein kinases (PKs). In eukaryotic cells About 
one-third of the potential 30,000 proteins in the human proteome are estimated to be 
substrate for phosphorylation in their stage of life cycle (Cohen et al, 2000). The 
mechanism of action by which PKs act is very simple: they exploite the γ-phosphate 
of ATP (or rarely GTP) to generate phosphate monoesters using mainly protein 
alcohol groups on Ser and Thr residues and/or phenolic groups on Tyr residue as 
phosphate acceptors. The transfer of the phosphate group (γ-PO3
2-) is generally 
facilitated by magnesium (Mg2+) or manganese (Mn2+) (in some class of kinases), 
which chelate the γ- and β-phosphate groups of ATP. This reaction is 
unidirectional, due to the high free energy that is released when the phosphate-
phosphate bond of ATP is broken to form adenosine diphosphate (ADP).  The 
transfer of the phosphoryl groups onto target proteins, as schematically illustrated in 
Fig.1 produces an alteration that can affect them in several ways.  
 
 
 
 
 
 
 
 
Figure 1. Schematic representation of serine phosphorylation.  
Enzyme-catalyzed proton transfer from the (–OH) group on serine stimulates the nucleophilic attack 
of the γ-phosphate group on ATP, resulting in transfer of the phosphate group to serine to form 
phosphoserine and ADP. (—B:) indicates the enzyme base that initiates proton transfer (From 
Thermo Scientific site). 
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Firstly, proteins can undergo to conformational changes that regulate their catalytic 
activity, activating or inactivating them (illustrated in the left panel of Figure 2). 
Secondly, phosphorylated proteins can recruit neighboring proteins having 
structurally conserved domains that recognize and bind to phospho-motifs. These 
domains show specificity for distinct amino acids and are critical for signal 
transduction, in which downstream effector proteins are attracted to phosphorylated 
signaling proteins.                                                                                    
Protein phosphorylation is reversed by the action of phosphatases, which remove 
phosphoryl groups from target proteins (Blagden and De Bono, 2005), as illustrated 
in Figure 2. Thus kinases and phosphates play a crucial role for the conservation of 
the natural phosphorylation state of a protein in a cell. In fact, the cellular 
phosphoproteome depends on the temporal and spatial balance between kinase and 
phosphatase activities.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Phosphorylation is a reversible protein modification that regulates protein function. Left 
panel: Protein kinases mediate phosphorylation at serine, threonine and tyrosine residues, and 
phosphatases reverse protein phosphorylation by hydrolyzing the phosphate group. Right panel: 
Phosphorylation causes conformational changes in proteins that either activate (top) or inactivate 
(bottom) protein function. (From Thermo Scientific site). 
 
 
Some PKs phosphorylate only one partner protein substrate while others, such as 
CK2 on which this thesis is focused can phosphorylate up to hundred targets. 
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Phosphorylation of specific proteins leads to the activation of signal-transduction 
pathways, and therefore it represents a fundamental mechanism by which intra and 
extra-cellular signals are transmitted throughout the cell and to the nucleus. For 
example, all phases of the cell cycle are driven by PKs, which undergo to timely 
destruction and/or inactivation after they have performed their functions. This 
enables the cell to properly proceed through the life cycle (Blagden and de Bono, 
2005).  
In accordance with their role in signaling transduction, most protein kinases are 
inactive (“off”) in the basal conditions and they are switched “on” in response to 
one or more signals. CK2 is an important exception, being constitutively active, as 
it will be extensively describe above. 
Manning et al. (2002) have defined the human “kinome space“, consisting of 518 
protein kinase genes. It has been reported that about half of the protein kinases 
encoded by the human genome are expressed from loci associated with specific 
diseases or regions amplified in human cancer (Blume-Jensen and Hunter, 2001; 
Manning, 2009; Brognard and Hunter, 2010). Therefore, it is not surprising that the 
interest in elucidating protein phosphorylation machinery is always very high, and 
more and more protein kinases and phosphatases are becoming targets for drug 
development. 
 
PROTEIN KINASES CLASSIFICATION 
Protein kinases are among the largest families of genes in eukaryotes, and they can 
be classified in different manner. The two most conventional classifications are 
based on substrate specificity and amino acid sequences of the catalytic domains, 
respectively. The first one divides PKs into two subfamilies that show specificity 
for distinct catalytic domains and identifies tyrosine kinases (TKs) or 
serine/threonine kinases (S/TKs). More than 90% of the phosphoproteome consists 
of pSer and pThr. Indeed, studies have shown that the relative abundance ratio of 
pS:pT:pY in a cell is 1800:200:1 (Mann, 2002). Although pTyr is not as abundant 
as pSer and pThr, global tyrosine phosphorylation is particularly interesting from a 
clinical point of view because of its correlation to human disease caused by 
dysregulation of receptor tyrosine kinases (RTKs). In addition to these two classes 
there are protein kinases that phosphorylate histidine residues (Hanks and Hunter, 
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1995; Johnson and Lewis, 2001). The second classification takes into account the 
sequence comparison of the catalytic domains, and also other structure domain and 
known biological functions (Manning, 2002). In this classification, the total 518 
human kinases can be subdivided into 478 eukaryotic protein kinases (ePKs) and 40 
atypical protein kinases (aPKs), but also 106 pseudokinases have been identified 
among human kinome (Manning, 2002). The aPKs possess catalytic kinase activity 
even if they lack sequence similarity to the ePKs catalytic domain. Several more 
aPKs have been later identified and the number of human ePKs is now believed 480 
(Braconi-Quintaje and Orchard, 2008). The schematic illustration in Figure 3 shows 
the major ePK groups: the tyrosine kinases (TK), cyclic nucleotide- and calcium-
phospholipid-dependent kinases (AGC, which comprises PKA, PKG and PKC 
families), Ca2+/calmodulin-regulated kinases (CAMK), the CMGC group 
(including cyclin-dependent kinase (CDKs), mitogen-activated protein kinase 
(MAPKs), glycogen synthase kinase (GSK), homeodomain-interacting protein 
kinases (HIPKs), and casein kinase 2 (CK2)), homologs of yeast Sterile 7, Sterile 
11, Sterile 20 kinases (STE), tyrosine kinase-like (TKL) and casein kinase 1 family 
(CK1); in addition an eighth group, RGC (receptor guanylate cyclase kinases),was 
added. 
 
 
 
 
 
 
 
 
  
 
 
Figure 3. Dendrogram of the 478 human ePK. The left figure schematically shows the ePK groups 
and branches (From Manning et al, 2002) while in the right figure all the ePK known at 2002 are 
reported (from cell signaling site). 
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PROTEIN KINASE STRUCTURE AND FUNCTION 
The architecture of a kinase can be partly predicted by its sequence, but only x-ray 
crystal structure can give precise information. The first structure to be solved was 
PKA in (Taylor et al., 1993). Since then, many other kinase structures have been 
solved so far. The architecture of the kinase can reveal the way by which a kinase 
can recognize a peptide/protein substrate (Knighton et al., 1991), can suggest 
potential inhibitor, and can disclose similarities between different enzymes. 
Comparing many protein kinase structures and looking for spatially conserved 
residues, the global architecture for an active protein kinase was revealed. In ePK 
the internal architecture permits distal parts of the enzyme to be linked by 
conserved hydrophobic elements in the active state, whose vicinity is instead 
disrupted upon inactivation. This complex regulatory machinery distinguishes the 
ePKs from most metabolic enzymes, which generally are highly regulated by 
allosteric mechanisms and by post-translational modifications. Indeed, ePKs have 
evolved not to efficiently turn over lots of product, but rather to be transiently 
activated (Taylor et al., 2011).  
The catalytic domain of all ePKs possesses three separated roles: (i) binding and 
orientation of the ATP (or GTP) phosphate donor as a complex with divalent cation 
(usually Mg2+ or Mn2+); (ii) binding and orientation of the protein (or peptide) 
substrate; and (iii) transfer of the γ-phosphate from ATP (or GTP) to the acceptor 
hydroxyl residue (Ser, Thr, or Tyr) of the protein substrate.  
In detail, the structure of each kinase consists of two structurally and functionally 
distinct lobes, N- and C-terminal that permit catalysis and possibly regulation. The 
N-terminal lobe is smaller, and is composed of five stranded b-sheet coupled to a a-
helical subdomain known as C-helix (Figure 4, panel A). There are conserved 
motifs: the first motif GxGxxG, known as Glycine-rich Loop, is located over the 
nucleotide and responsible for the ATP (or GTP)phosphates orientation; it is the 
most flexible part of the N-lobe. Another important motif, AxK, in the b3 strand, is 
represented by Lys72 that bind the phosphates of ATP to the C-helix. The C-helix is 
a unique, very dynamic regulatory element of each protein kinase, structurally 
belonging to the N-lobe, but occupying a strategically important position between 
the two lobes. In the contrary, the C-terminal lobe is larger, and rich, in a-helices. 
This domain, which is extremely stable, forms the core of the kinase and function as 
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a surface for protein/peptide substrates. Spatially conserved hydrophobic motifs, 
termed Spines, link the two lobes; they were found in every active kinase but not in 
inactive kinases (Figure 4, panel B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Structural conserved elements of a protein kinases. A. Protein kinase core is 
bilobed. The N-terminal lobe (N-lobe) contains five b-strands (colored teal) and a 
universally conserved aC-helix. The C-lobe is mostly helical (colored red). An ATP 
molecule is bound to a deep cleft between the lobes in black. Major catalytically important 
loops are colored yellow. B. Multiple alignments of four residues spines from 25 human 
kinases and two simpler eukaryotic-like kinases (eLKs), (PknB and Aph) is shown. All 
structures of active ePKs have conserved structural motifs in their core which form highly 
conserved spatial patterns. These patterns, termed “spines”, do not form sequential motifs 
coming from different parts of protein kinases sequence. (From Taylor et al, 2011). 
 
 
PROTEIN KINASE SPECIFICITY 
 
As protein kinases are implicated in a wide variety of cellular processes, but affect 
only one or few of the many potential phosphoacceptor residues in their targets, 
they must be endowed with very high selectivity (Pinna and Ruzzene, 1996). The 
sequence of the substrate close to the phosphorylatable Ser/Thr or Tyr residue is an 
important determinant of specificity and different protein kinases show different 
“consensus sequences” with respect to the neighboring sequence of the residues to 
be phosphorylated (Figure 5). Also co-localization of protein kinases and their 
substrates at specific subcellular compartments and particular association mediated 
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by targeting elements outside the catalytic domain, strongly enhance the specificity 
of the kinase reaction (Pinna and Ruzzene, 1996).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Two-sample logo based on 10,899 phospho-sites in humans. Upper, the most 
representative residues found in the neighbourhood of phosphorylated Ser/Thr in 
phosphopeptides; bottom, the most depleted. (from Pinna, 2009, Screening, MedChem and 
ADMET Europe, Berlin, Germany). 
 
In addition to phosphorylating other proteins, many protein kinases are able 
autophosphorylate themselves. The phosphate of the phosphodonor may be 
incorporated either in the enzyme catalytic domain or in the regulatory domain(s). 
One of the most dynamic regions of the protein kinase core, the activation loop, 
which retains the substrate close to the ATP binding site, often contains one or more 
critical phosphorylation sites, and its phosphorylation represents a common tool 
regulating the activity of most protein kinases (Smith et al., 1993). 
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Ser/Thr KINASES 
About 400 of the total 518 eukaryotic kinases identified in mammals are Ser/Thr 
protein kinases, covering the 80% of the total kinome. Ser/Thr kinases are divided 
in many different subfamilies and all show a particular specific sequence required 
for phosphorylation. Among them, the following are included: protein kinases 
regulated by cyclic nucleotides (i.e. protein kinase A, PKA), diacylglycerol-
regulated protein kinases (i.e. protein kinase C, PKC), Ca2+/calmodulin-regulated 
protein kinases, G-protein-coupled receptor protein kinases, protein kinase CK1, 
protein kinase CK2, glycogen synthase kinase (GSK), cyclin-dependent kinases 
(CDK), and mitogen-activated kinases (MAP kinases), and HIPKs family. There are 
many other protein kinases that do not show any close relationship to these 
subfamilies. It is worth to mention that among Ser/Thr protein kinases, enzymes 
with dual specificity are to be included, in that they can phosphorylate Ser/Thr and 
also Tyr residues. The only physiologically relevant example of dual specificity 
protein kinase is given by MAP kinase kinase (MEK) family (Pinna and Ruzzene, 
1996). How and why Ser/Thr kinases prefer to target a Serine residue rather than 
Threonine remain obscure; however, in general, Serine is preferred respect to 
Threonine. According to the specific consensus determinants of the substrate 
recognition site, Ser/Thr protein kinases can be divided in three distinct groups: (1) 
basophilic protein kinases: they use basic and, often, also hydrophobic residues as 
specificity determinants, usually located in the N-terminal side of the target residue 
(this group includes the whole of the large ACG group, e.g. PKA, Akt, PKC, and all 
the members of CAMK group); (2) proline-directed protein kinases: they share the 
absolute requirement of the Ser/Thr-Pro motif and these comprise members of the 
CMGC group that belong to the families of cyclin-dependent kinases, MAP kinases 
and also HIPK kinases; (3) acidophilic and phosphate-directed Ser/Thr protein 
kinases: they use carboxylic and/or phosphorylated side chains as specificity 
determinants, among them there are CK2, GSK3, CK1 and the Golgi apparatus 
casein kinase G-CK (Ruzzene and Pinna, 1996). A recent study conducted by Salvi 
and co-workers, 2009, has highlighted that the majority of the phosphoproteome is 
not generated by basophilic protein kinase (the largest branch of Ser/Thr-specific 
protein kinases) but by proline-directed and by acidophilic protein kinases. This 
latter represents a small minority of the kinome but, among them, CK2 could be 
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responsible alone for the generation of a substantial proportion of the eukaryotic 
phosphoproteome. 
Although some Ser/Thr-specific protein kinases are constitutively active in the cell 
(see CK2 above), most of them are tightly regulated. In accord with the general rule 
that a protein kinase can be in a “off” or a “on” state depending on which signaling 
stimulus is picked up, there are multiple modes for keeping Ser/Thr protein kinase 
domains in the inactive state at rest. One mechanism is to a have regulatory 
domains as separate subunits which function as combinatorial platform on which 
protein-protein interactions, such as kinase with substrates and regulators, can be 
assembled (Newton, 2001). Moreover, regulatory domains or subunits can be 
autoinibitory or they can be activating (Kobe and Kemp, 1999). An ″autoinhibitory″ 
domain can be located within the enzyme, in its catalytic site, blocking binding of 
substrates. It has been proposed that the binding of allosteric activators induces 
conformational changes in the autoinhibitory domain that disrupt its interaction 
with the catalytic domain, hence activating the kinase to phosphorylate exogenous 
substrates (Soderling, 1990). An example of this regulation is provided by protein 
kinase CK1, which displays an autoinhibitory autophosphorylation site that in vivo 
is maintained in the dephosphorylated, active state by cellular protein phosphatases 
(Rivers, 1998). The regulatory subunits can instead be activating if they allow 
productive orientation of ATP and protein substrate in the active site of the catalytic 
subunit. 
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STRUCTURAL BIOLOGY  
 
CK2 is generally described as a stable tetramer composed of two catalytic (a and/or a’) 
and two regulatory subunits (b). In the following paragraph the features of the single 
subunits and of the holoenzyme will be described. 
 
The a and a’ subunits 
 
Two isoforms of CK2 catalytic subunit, (a and a’) are coded by two distinct genes, 
CSNK2A1 and CSNK2A2 (Wirkner et al., 1994; Yang-Feng et al., 1994), respectively, 
and are related to the CMGC kinase subfamily group. Their eukaryotic primary sequences 
are well conserved among the species, presenting the canonical kinase structural motifs: 
(i) the P-loop (phosphate-binding loop, also known as glycine-rich loop, G-loop); (ii) the 
substrate binding site; (iii) the catalytic loop; (iv) the activation loop (also called T-loop).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Phylogenetic tree of eukaryotic CK2 (from Cozza et al., 2010). 
 
CK2 a is composed of 391 aminoacids, for a Mw of 45 kDa, while CK2 a’ isoform is 
composed of 350 aminoacids, for a Mw of 41 kDa. CK2 a general architecture is shown 
below (in Figure 7); it presents two main topological determinants: a small b-strands-rich 
lobe and a large lobe dominated by a-helix. The ATP binding site is localized between 
these two lobes linked through a short loop, called ‘‘hinge region’’. The CK2 N-terminal 
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region from Ser7 to Glu36 is very peculiar and unique, and it seems to play a key role in 
the CK2 “always active conformation’’.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. A: Representation of most important human CK2 subdomains B: Representation of CK2 
substrate binding region. The most important interactions with the substrate peptide RRRADDSDDDDD 
(in yellow) are highlighted (from Cozza et al., 2010). 
 
Differently from almost all the other protein kinases, CK2 is able to use both ATP and 
GTP as phosphate donor due to its particular P-loop. 
The global sequence similarity between a and a’ is about 75%, and this value increases 
to 86% if the 1–329 sequence (1–330 in a’) is considered. On the contrary, there are 
differences in C-terminal domain length (a’ is 41 residues shorter thena) and sequence 
(only 38% similarity); however, this have no significant influence on the kinase activities. 
A specific role for the two catalytic isoforms has not been assigned until now; however 
there are evidences of implication of CK2 a’ subunit in cell proliferation and 
spermatogenesis (Litchfield et al., 2001; Lou et al., 2008). Also specific partner 
substrates have been reported, such as Pin1, which interacts with only a (Messenger et 
al., 2002) and caspase-3, specifically phosphorylated by a but not a’ (Turowec et al., 
2013). 
CK2 catalytic subunits show some unique sequence characteristics that differ from the 
other kinases of the CMGC group. First, both a and a’ subunits present a considerable 
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number of basic residues around the substrate recognition site. In particular, there are ten 
basic amino acids available for the interaction with the acidic substrates of CK2, while no 
other kinase of the CMGC group displays such a number of basic residues in the same 
positions. 
Another unique feature of CK2 is the absence of a typical phosphorylation site in the 
substrate recognition domain. In many kinases this phosphorylation site controls the 
conformational changes of the substrate-binding domain and represents an important 
regulatory mechanism of the substrate-phosphorylation process. On the contrary, unlike 
all the other CMGC and most of the other eukaryotic Ser/Thr kinases, the activation loop 
of CK2 does not require its phosphorylation to promote the maximal activity of the 
enzyme since it is maintained in the active conformation by the N-terminal region. 
Also the CK2 glycine-rich loop displays some unique characteristics respect to the 
classical “GXGXXG” motif (present in the 84% of the CMGC kinases); in fact, it 
presents only two instead of three glycine residues (GXGXXS) (Sarno et al., 1997). 
Finally, CK2 presents a particular stretch of four histidines at a distance of five residues 
each other (at the positions 148, 152, 154, 160, and 166 in the human CK2). Interestingly, 
while the His148 and His152 are conserved among almost all CMGC members, His160 
and His166 are unique. The role of this stretch is still not clear, but it may contribute to 
the substrate recognition upstream to the phosphorylated residue (Dobrowolska et al., 
1994). 
 
 
 
The b Subunit 
 
CK2b regulatory subunit has a sequence composed of 215 aminoacids, very conserved 
among the eukaryotic kingdom, with a number of peculiar features related to its function. 
Thanks to structural and biochemical data the functions of the N- and C-terminal regions 
have been explained. The sequence including residues 55-64 is an acid region exerting a 
negative regulation of CK2, whose effect can be partially removed, by polybasic proteins 
or polyamines (Meggio et al., 1994). In fact, polyamines are able to bind to this acidic 
stretch of CK2b and activate CK2.  Interestingly, mutations of specific residues in the 
acidic region of the CK2b subunit suppress stimulation by polyamines and augment the 
basal activity of the enzyme. Moreover CK2 b MSSSEE N-terminal sequence contains an 
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autophosphorylation site at Ser2. The CK2b C-terminal region, in particular the sequence 
between 181-203 residues, is a positive regulatory domain, able to stabilize and improve 
the CK2 catalytic activity; moreover CK2b C-terminal is necessary for the b-b 
dimerization, for the protection from proteolysis and unfolding, and for the association 
with the catalytic subunit a (Pinna et al., 1997). The C-terminal region of CK2b contains 
also another phosphorylation site, Ser209, which is phosphorylated in cell and in vitro by 
p34cdc2 in a cell cycle-dependent manner (Lithcfield et al., 1995). 
CK2b contains a sequence very similar to the “destruction box”, a domain that confers 
mitosis-specific degradation to cyclin B (King et al., 1996); it seems to regulate CK2b 
stability and/or degradation during mitosis. (King et al., 1996; Zhang et al., 2002).  
CK2b sequence includes a zinc finger motif containing four cysteine residues (Cys109, 
Cys114, Cys137, and Cys140) responsible for the b-b dimerization (Figure 8). Mutations 
of Cys109 and Cys114 disrupt the zinc finger and prevent the interaction between the b 
subunits and between b and a subunits. This region is rich in b sheet strands, and its high 
hydrophobicity is responsible of the many hydrophobic interactions between monomers 
(Chantalat et al., 1999). It has been proposed that CK2b is synthetized in excess respect 
to a in cells, so that the b-b dimerization can occur without the presence of a (Gietz et 
al., 1995; Graham et al., 2000; Canton et al., 2001; Chantalat et al., 1999). CK2b mutants 
unable to form dimers fail in the holoenzyme formation, indicating that the b-b 
dimerization is a prerequisite to form a stable complex with catalytic subunits.  
It has been proposed that CK2b is an independent entity, which functions as partner also 
for other kinases. This is suggested by its localization in cell compartments where CK2a 
is not detected (Krek et al., 1992). Authors reports that CK2b interacts with c-Mos and A-
Raf protein kinases, by means of its C-terminal region, as in the case of CK2a interaction 
(Chen et al., 1997). In the case of c-Mos, interaction with b has a negative effect, while in 
the case of A-Ras b induces an enhanced kinase activity. Other partner proteins have been 
reported to interact with CK2b in an in vitro screening (Arrigoni at al., 2008); other 
studies reported the tumor suppressor BRCA1 (O’Brien et al., 1999), the traffic regulator 
LYST ( Tchernev et al., 2002) and the superoxide radical production enzyme p47-phox 
(Kim et al., 2001). 
 
 
16 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Molecular representation of b-b dimer, focusing on the Zinc finger domain (from Cozza et al., 
2010). 
 
The CK2 Holoenzyme  
The first crystal structure of the CK2 holoenzyme has published in 2001 (Niefind et al., 
2001). It emerged that the catalytic subunits (a and/or a’) are linked to the b-b dimer by 
means of C-terminal domain of the regulatory subunits. The tetrameric complex is 
frequently defined as “butterfly”-shaped for its architecture, shown in Figure 9. It is 
generally more stable than the monomeric form and, its catalytic activity is usually higher 
than that of the catalytic a subunit alone (Antonelli et al., 1996; Boldyreff et al., 1993) 
although this depends on the substrate type (see below Figure 12). As reported in the 
previous paragraph, an autophosphorylation site exists in the N-terminal region of b 
subunit but it does not represent a regulatory mechanism, since mutants of the 
autophosphorylation site display activities similar to w.t. protein (Bodenbach et al., 
1994). However, b autophosphorylation could contribute to confer higher stability to the 
regulatory subunit itself. Structural data from CK2 crystallographic analysis have 
confirmed that the autophosphorylation event on b subunits occurs between two 
holoenzymes. In fact, the autophosphorylation site is more than 30 Å distant to the nearest 
catalytic site and it is inconsistent with an intra-molecular autophosphorylation unless 
conformational changes in the ‘‘butterfly’’-shaped structure of the holoenzyme occur.  
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Figure 9. Molecular representation of the human CK2 tetramer (from Cozza et al.2010). 
 
Multimeric structures of CK2 tetramers have been frequently proposed: forms of CK2, at 
physiological ionic strength, were very early detected in Drosophila, by electron 
microscopy techniques, suggesting that this form might be present in cells (Glover et al., 
1986). Later, Valero and coworkers (Valero et al., 1995) observed the formation of ring-
shaped structures composed of four tetramers using recombinant Drosophila CK2. In both 
cases authors confirmed that the filamentous and ring-shaped forms of CK2 could be 
dissociated into the standard a2b2 tetramers by the addition of high salt concentration. 
Moreover, a new hypothesis consistent with the existence of trimeric aggregate of three 
CK2 tetramer has been published (Olsen et al., 2008). Very recently, Lolli et al. (2012 
and 2013) demonstrated that the supramolecular CK2 structure would be a trimer of 
tetramers, and that polymers of these trimers  can possibly form(Figure 10) with a 
regulatory valence. In the CK2 trimeric structure, the N-terminal domain of b subunit of a 
tetramer interacts with the catalytic a subunit of another one; in these forms the 
autophosphorylation of b in Ser2 (or Ser3) would represent an autoinhibitory mechanism 
of CK2, leading to a non-productive conformation. However, the occurrence of this 
structure in vivo is still to be demonstrated. 
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Figure 10. A functional model of CK2 holoenzyme supramolecular organization is presented. When co-
localized in time and space, CK2 α and β subunits readily assemble into symmetric active tetramers (A). 
Activity is switched off through their organization (essentially via electrostatic interaction) in inactive 
trimers of tetramers and higher-order interactions generating filaments (B). Activity is restored upon a 
depolymerization process triggered by variations in the physical-chemical local environment (pH, ionic 
strength, etc.), action of substrates or effectors (e.g., polyamines), or other events (from Lolli et al., 2013). 
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CK2 SUBSTRATE SPECIFICITY 
 
CK2 is an acidophilic kinase able to phosphorylate substrates in which the 
phosphoacceptor site is surrounded by acidic aminoacids. The minimum consensus 
sequence of CK2 requires an acidic residue at position n+3 downstream from the 
phosphoacceptor site; this acidic residue can be represented by glutamic or aspartic acid, 
but also by previously phosphorylated serine or tyrosine (S/T-x-x-D/E/pS/pY) (Marin et 
al., 1999). The target aminoacid is a serine or a threonine, but also tyrosine can be 
exceptionally phosphorylated (Marin et al., 1999). It is important to note that, in general, 
this minimal requirement is associated with additional acidic residues which play a 
positive role in any position between n-7 and n+7; moreover the absence of basic residues 
in the proximity of the target aminoacid is preferred (Meggio and Pinna, 2003; Salvi et 
al., 2009). The presence of a proline residue in n+1 negatively affects phosphorylation. 
The CK2 residue preference around its known phosphoacceptor sites, has been recently 
reanalyzed using a CK2 bona fide substrates collection (533 phosphosites), generating the 
IceLogo (Colaert et al., 2009) shown in Figure 11. It is a graphical representation of the 
different aminoacidic preference at each position in CK2 substrates compared to the total 
human phosphoproteome. From this analysis (Salvi et al., 2009; Salvi et al., 2010) it is 
immediately evident that CK2 displays a preference for acidic residues at all positions 
considered (from n−7 to n+7) with particular emphasis at position n+3 where D or E are 
present in about 71% of total sites, 77% considering the sequences S/TxxD/E/S, and n+1 
where D or E are present in about 50% of total sites, while only 17% of CK2 
phosphosites lack acidic residue at both positions. Basic residues are instead discarded at 
all positions, consistent with their role as negative determinants. It is important to note 
that P is also negatively selected at all positions; in particular, P+1, an essential 
requirement of Pro-directed kinases, has the most negative effect, as already known from 
experiments of peptide phosphorylation (Meggio et al., 2003). 
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Figure 11. CK2 substrate specificity. IceLogo of bona fide CK2 substrates (upper part of the 
figure) versus human Ser/Thr phosphoproteome (lower part). 555 nonredundant sites of CK2 
have been considered from PhosphositePlus (www.phosphositeplus.org) (from Pinna, 2012). 
 
CK2 b subunit has an important role in modulating substrate selectivity. It has been 
demonstrated that for some CK2 substrates, including DNA topoisomerase II, Nopp140, 
FAF-1, p53, and eiF2b (reviewed in Cozza et al., 2010), CK2 b represents a docking 
platform influencing the access of the catalytic site for substrate binding. In the case of 
protein HIV-REV60 (Marin et al., 2000) and the translation factor eiF2b (Salvi et al., 
2006), which are both in vivo substrates, phosphorylation by CK2 occurs only when b 
subunit is present. On the contrary, another in vivo substrate, calmodulin, is 
phosphorylated by the CK2a alone, while b subunit dramatically inhibits the reaction, 
except in the presence of polybasic regulators (Meggio et al., 1992). For these reasons, a 
subdivision of CK2 specific substrates has been proposed (Figure 12): class I substrates, 
are phosphorylated with the same efficiency by both CK2 tetramer and α alone, class II 
substrates are phosphorylated only by monomeric CK2 (and by the holoenzyme only in 
the presence of polylysine or polybasic peptides), and class III substrates are 
phosphorylated only in the presence of CK2 b (Pinna, 2002).  
It is important to observe that the effect of the b subunit on these particular substrates is 
not mediated by turning on or off the catalytic activity, which is constitutively ‘on’, but 
by allowing specific interactions with the protein substrates (Pinna, 2002). Since the a 
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catalytic subunit alone and the holoenzyme affect different substrates, it could be 
predicted that, if a balance exists in vivo between the two forms, this could represent a 
mechanism for a fine control of the cellular events governed by CK2. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.Comparison between the mechanism of activation of PKA (Protein kinase A), CDKs (cyclin-
dependent kinases) and CK2. For PKA, whose heterotetrameric structure is similar to that of CK2, the 
binding of cyclic AMP to the inactive tetrameric form leads to the release of the free active catalytic 
subunits. In the case of CDKs, the isolated catalytic subunits are inactive until their heterodimeric binding 
to the cognate cyclin and the phosphorylation of the activation loop. aCK2 is constitutively active and this 
is due to the unique interaction between the activation loop and its N-terminal segment and the association 
with bCK2 whose presence indeed influences the substrate specificity, summarized in the three classes: 
class I substrates phosphorylated with the same efficiency by both CK2 forms, class II substrates 
phosphorylated only by monomeric CK2 and by the holoenzyme only in the presence of polylysine or 
polybasic peptides and class III substrates phosphorylated only in the presence of bCK2( from Pinna, 
2002). 
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PHYSIOPATOGICAL ROLE OF CK2 
 
CK2 is highly pleiotropic and more than 300 substrates have been identified so far, 
many of them also in vivo (Meggio and Pinna, 2003). This underlies the massive 
involvement of CK2 in many cellular processes. However, the CK2 recognized 
global function, its  pro-survival and anti-apoptotic action, will be described in the 
following paragraph. 
ROLE OF CK2 IN CELL SURVIVAL AND APOPTOSIS 
 
CK2 phosphorylates a huge number of substrates related to cell life/death, thus the 
mechanisms by which it controls survival/proliferation and blocks apoptosis are 
complex. CK2 is essential for cell viability, as reported by various authors (Glover 
et al., 1998; Kikkawa et al., 1992). Observations from experiments performed in 
yeast indicated that the catalytic activity of CK2, just not only the presence of the 
protein, is required for viability (Birnbaum and Glover, 1991; Glover et al., 1998). 
In mammal cells, recent and multiple studies  always suggest the absolute 
requirement of a and/or a’ for cell viability (Vilk et al., 1999; Xu et al., 1999; 
Ahmed et al., 2001; Ruzzene et al., 2002), and a deep connection between CK2 
down-regulation and apoptosis has been disclosed. The mechanisms exploited by 
CK2 in preventing apoptosis are multiple. One is represented by the 
phosphorylation of proteins which are substrates of caspases, the proteases activated 
in response to apoptotic stimuli. It has been demonstrated that several caspases 
substrates, when phosphorylated by CK2, are protected from cleavage. The most 
important examples are Bid, which is a pro-apoptotic member of Bcl-2 family 
(Desagher et al., 2001), Max, which is the partner of the c-Myc proto-oncogene 
product (Krippner-Heidenreich et al., 2001), hematopoietic lineage cell-specific 
protein 1 (HS1) (Ruzzene et al., 2002), Presenilin-2 (Walter et al., 1999), Connexin 
45.6 (Yin et at. 2001), PTEN (Torres et al., 2003) and caspase 9 (McDonnell et al., 
2008). Caspases themselves have been found to be phosphorylated by CK2 and thus 
protected from activatory cleavage. Clear examples are caspase-9 (McDonnell et 
al., 2008) and caspase-2 (Turowec et al., 2013). 
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Figure 13. CK2 regulates the cleavage of caspase targets (A) Consensus sequences for caspases 
and for CK2 are illustrated. Acidic residues within these recognition sequences are highlighted in 
pink. Caspase cleavage sites are indicated with arrows. Residues phosphorylated by CK2 are boxed 
in green. (B) Specific examples of proteins whose phosphorylation by CK2 has been shown to inhibit 
caspase-mediated cleavage. Acidic residues, CK2 phosphorylation sites and caspase cleavage sites 
are highlighted as in (A). CK1 phosphorylation site that may act co-operatively with the CK2 
phosphorylation site in Bid is highlighted in yellow. Note that Bid is cleaved at aspartic acid, 
whereas Max and connexin 45.6 are both cleaved at glutamic acid. The cleavage site in HS1 has not 
yet been determined. The specific caspase affected for each protein is indicated (from Litchfield et 
al., 2003). 
 
Indeed, it has been noticed that a strong similarity between the recognition sequence 
for degradation by caspases and the consensus motif for phosphorylation by CK2 
exists (Litchfield et al., 2010) (Figure 13). Furthermore, CK2 is also involved in the 
control of caspase effectors, such as ARC (apoptosis repressor with caspase 
recruitment domain), whose phosphorylation by CK2 inhibits caspase 8 activation 
(Li et al., 2002) (Figure 14). Moreover the up-regulation of survivin (member of the 
inhibitors of apoptosis proteins, IAP) occurs in response to increased level of CK2 
(Tapia et al., 2006). We can conclude that the effects of CK2 on caspase machinery 
are multiple, with the global result that, when CK2 level/activity are high, caspase-
mediate degradation is counteracted. 
 
 
 
24 
 
 
 
 
 
 
 
 
 
 
 
 
                                                             
Figure 14.  Role of CK2 in the regulation of apoptosis. (A) Under survival conditions, CK2 
phosphorylates proteins such as ARC and Bid. When phosphorylated by CK2, ARC is targeted to 
mitochondria, where it inhibits caspase 8. Bid is resistant to cleavage by caspase 8 when it is 
phosphorylated by CK2. (B) Under apoptotic conditions and/or when CK2 is compromised, CK2 
phosphorylation sites on proteins such as Bid and ARC are not phosphorylated. Under these 
conditions, ARC is not targeted to mitochondria and does not inhibit caspase 8. In the absence of 
phosphorylation, Bid is susceptible to cleavage by caspase 8. The subsequent translocation of Bid to 
the mitochondria is followed by release of cytochrome c (Cyt. c) that results in the amplication of 
caspase activation. (from Litchfield et al. 2003). 
 
CK2 cooperates with other anti-apoptotic pathways and processes such as 
PI3K/Akt(PKB), NF-κB and Wnt pathways, and DNA repair, all involved in 
sustaining cell survival. A brief description of how CK2 regulates these signalling 
pathways will be presented below and schematically illustrated in Figure 15: 
- NF-kB: as summarized by Dominguez and coauthors (Dominguez et al., 
2009), CK2 acts at multiple levels on NF-kB signaling pathway, which is 
essential for development but also related to oncogenesis, in the case of 
untimely activation. NF-kB is normally retained in cytosol, bound to its 
inhibitor IkB, which prevents NF-kB nuclear translocation. Once 
phosphorylated by IKK, IkB undergoes proteolytic degradation, releasing 
NF-kB, which translocates to the nucleus, where functions as transcription 
factor for anti-apoptotic and pro-proliferative genes. CK2 regulates IKK, 
whose expression is induced by CK2 (Eddy et al., 2005), and directly 
phosphorylates IkB, promoting an alternative degradation signal 
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(McElhinny et al., 1996). Moreover, CK2, phosphorylating b-arrestin, a 
suppressor of NF-kB, prevents NF-kB association to IkB (Luan et al., 2005). 
Finally, CK2 also phosphorylates the p65 subunit of NF-kB, thus increasing 
NF-kB transactivation potential (Wang et al., 2000). 
- Wnt/b-catenin: this proliferation signal is essential for embryonic 
development but is often up-regulated in cancer.  It is supported by CK2 
from several fronts: CK2 directly phosphorylates b-catenin (Song et al., 
2003) protecting it from proteasome degradation, at opposite to GSK3 
which instead phosphorylates b-catenin and promotes its 
ubiquitination/degradation (Yost et al., 1996). Other Wnt signaling players 
are CK2 targets, such as dishevelled (Dvl), whose phosphorylation is 
important to maintain a high protein level (Song et al., 2000) but also to 
allow its CK1-dependent phosphorylation (Bernatik et al., 2011). Moreover, 
LEF-1, a Wnt dependent DNA-binding protein, upon CK2 dependent 
phosphorylation, stimulates binding of b-catenin/LEF-1 complexes to Wnt-
target genes (Wang and Jones, 2006). 
- PI3K/Akt: CK2 operates as a multisite up-regulator in this pathway, again 
acting at different levels. The first step is represented by the tumor 
suppressor PTEN, the phosphatase which, dephosphorylating PIP3 
(phosphatidylinositol 3,4,5 trisphosphate),  maintain the PI3K/Akt signaling 
down-regulated. CK2 phosphorylates PTEN, enhancing its stability (Torres 
and Pulido, 2001) but reducing its activity (Arevalo and Rodriguez-Tebar, 
2006) leading, as final effect, to Akt activation. PTEN level in many cancer 
cells has been demonstrated to be very low; on the contrary, in many 
primary T-ALL cells its amount is higher than in normal T-cell precursors, 
but interestingly, its phosphatase activity is reduced due to a high expression 
of CK2 (Silva et al., 2008). Moreover, neprisylin (NEP) has been reported 
to be a CK2 substrate; it interacts directly with PTEN, and its CK2-
dependent phosphorylation has been demonstrated to prevent its inhibitory 
action on PTEN (Siepmann et al., 2010). The second level of CK2 
intervention on this pathway involved directly Akt, whose CK2 dependent 
phosphorylation on Ser129 induces its up-regulation (Di Maira et al., 2005). 
An indirect effect of this CK2-mediated phosphorylation has also been 
26 
 
documented since it maintains high level of phospho-Thr308, one of the two 
canonical phosphorylation sites on Akt, ensuring a stable association 
between Akt and the chaperone protein Hsp90, known to protect phospho-
Thr308 from dephosphorylation (Di Maira et al., 2009). The final result of 
all of these interventions of CK2 on the PI3K/Akt pathway is a global up-
regulation of the pro-survival functions of Akt on its multiple downstream 
effectors, such as the ș-catenin/survivin signaling (Ponce et al., 2011). In 
this context, survivin is under the control of ș-catenin, but its CK2 
dependent phosphorylation (Barrett et al., 2011) is crucial for its anti-
apoptotic and mitotic roles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. CK2-dependent multisite regulation of NF-κB (A), β-catenin (B) and PI3K/Akt (C) 
signaling. A negative effect (−) is indicated by a dot-arrow, and means inhibition or increased 
degradation, while a positive effect (+), indicated by a normal arrow, means enhanced stability 
and/or activity. Circles, in blue, denote kinases located in “vertical pathways”, downstream from 
extra-cellular signals, while the CK2 “lateral role” is highlighted by the yellow rectangle (from 
Pinna and Ruzzene 2010). 
 
Collectively, it is evident how CK2 acts at different levels, assuming multiple and 
overlapping roles in promoting cell survival and preventing apoptosis: this 
iscertainly related to its oncogenic potential. 
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CK2 ROLE AS A “LATERAL PLAYER” 
As schematized in Figure 20, CK2 behaves in an atypical way respect to the other 
protein kinases, in the signaling cascades where it is involved. It is important to 
stress that CK2 is a constitutively active enzyme and mechanisms able to switch on 
or off its activity do not exist. Indeed, CK2 can be seen as a “later player” of many 
survival pathways (Ruzzene and Pinna, 2010). Generally, a cell gets a signal from 
the outside environment and the information is delivered to the nucleus through a 
hyerarchical mechanism in a figurative vertical direction; from this point of view, 
CK2 acts as a “horizontal” player, acting at different levels of the signaling cascade, 
hitting, at the same moment, multiple actors of the pathway. CK2 is always 
available and ready to act in the cell, but it better performs its functions only when 
the activation of a pathway occurs offering new substrates, now available for 
phosphorylation. Thus, a signal that stimulates a cellular response of growth, 
proliferation, and survival will be potentiated by the intervention of CK2, while a 
death message will be counteracted. 
 
 
CK2 INVOLVEMENT IN THE REGULATION OF 
CHAPERONE MACHINERY  
 
CK2 phosphorylates two important members of chaperone machinery, namely 
Hsp90 and Cdc37. Hsp90 is one of a major chaperone molecules required for the 
folding and maintenance of many proteins. Several observations sustain the 
connections between CK2 and Hsp90. CK2 was initially co-purified with a 90-kDa 
substrate that was later identified as Hsp90 (Meggio et al., 1985; Dougherty et 
al.,1987), and it co-immunoprecipitates with Hsp90 from cell lysates (Miyata and 
Yahara, 1995). CK2 phosphorylates both a and b isoforms of Hsp90 in vitro and in 
vivo, and this phosphorylation may influence Hsp90 and its clients activity (Szyszka 
et al., 1989). Hsp90 forms two major chaperone complexes: one is specific for the 
steroid hormone receptors and in this case the co-chaperone of the immunophilin 
family FKBP52 is present; the other is specific for the folding of signaling protein 
kinases, and include the co-chaperone Cdc37 (Miyata et al., 2009). Besides Hsp90, 
both co-chaperones are phosphorylated by CK2 (Cox et al., 2007; Miyata et al., 
1997). In particular, Cdc37 is phosphorylated by CK2 at Ser13, and this 
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phosphorylation is essential for its stabilization and activation of many signaling 
protein kinases (Miyata et al., 2009). It has also been proposed that CK2 is itself a 
Cdc37 client kinase (Kimura et al., 1997; Bandhakavi et al., 2003) and that a 
positive feedback loop can occur between the two proteins in promoting the folding 
of multiple client kinases (Miyata et al., 2009).The chaperone systems have very 
important functions in controlling different signaling pathways. It is therefore 
evident that by affecting co-chaperones, and Cdc37 in particular, the CK2 action is 
greatly amplified, allowing the targeting of a huge number of proteins, including 
kinases and their downstream substrates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Connections between CK2 and Cdc37 protein. CK2 and Cdc37 constitute a positive 
feedback loop that results in promoting multiple client protein kinases in yeast and in vertebrates. 
CK2-dependent phosphorylation is essential for the role of Cdc37 in maintaining Hsp90-Cdc37-
kinase heterocomplexes and thus the physiological function of multiple client protein kinases. In the 
picture many other Cdc37-dependent signaling client kinases are omitted for simplicity (from 
Miyata, 2009). 
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ROLE OF CK2 IN CANCER 
 
The involvement of CK2 in cancer is well documented and a huge number of 
observations have confirmed its role in the sustaining malignant transformation. 
Indeed, CK2 level and activity have been found to be invariably higher in a wide 
variety of tumors respect to normal cells (Tawfic et al., 2001; Unger et al., 2004; 
Trembley et al., 2009). Despite the abnormally high CK2 level found in the 
majority of cancer cells, CK2 is neither the cause nor the consequence of neoplastic 
transformation but rather it may well reflects the tendency of the tumor to 
preferentially settle in those cells where CK2 is higher, regardless of the genetic 
accidents responsible of transformation (Ruzzene et al., 2011). As schematically 
shown in Figure 21, a high level of CK2 promotes neoplastic growth by means of 
several modes of action: the transforming potential of many oncogenes is increased 
by CK2 (Seldin and Leder, 1995; Channavajhala and Seldin, 2002); CK2 stabilizes 
most of the onco-kinases in their active conformation phosphorylating the co-
chaperon Cdc37 (Miyata and Nishida, 2004); CK2 blocks the efficacy of antitumor 
drugs, i.e. imatinib (Mishra et al., 2007) and melphalan (Piazza et al., 2006); CK2 
sustains neovascularization (Ljubimov, et al., 2004); CK2 contributes to the multi-
drug resistance phenotype (Di Maira et al., 2007) and, most generally, CK2 creates 
a large number of pro-survival and anti-apoptotic signals. Persistence of growth 
signals, escape of apoptosis and sustainment of angiogenesis are fundamental 
events which together lead to malignant growth (Figure 17). Thus, it is conceivable 
that CK2 reaches a critical threshold and it may become a cancer driver creating an 
environment particularly susceptible to the development of tumor phenotype. As a 
possible consequence, the higher the CK2 level is, the worse the grading of the 
malignancy will be (Unger et al., 2004).  
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Figure 17. Effects promoted by abnormally high CK2 levels (from Ruzzene and Pinna, 2010)  
 
ADDICTION TO CK2  
The essential role demonstrated by CK2 in embryonic development and growth 
(Lou et al., 2008; Landesman-Bollag et al., 2011) underlines how CK2 pro-survival 
and pro-proliferation functions are fundamental for viability of all cells. However, 
recent evidences have indicated that, although CK2 is necessary for the entire 
organism, it is “more necessary” for some cells than for others (Ruzzene and Pinna, 
2010). It has been suggested that this reliance of cells on CK2 could represent an 
example of ‘‘non-oncogene addiction’’ (Solimini et al., 2007), a term coined to 
denote situations where the tumor phenotype displays an overdue reliance on 
abnormally high level of proteins which are not subjected to genetic alterations as 
oncogenes are, but nevertheless generate a cellular environment which is 
particularly favorable to neoplasia. In a given population of normal cells, where the 
concentration of CK2 is variable, few cells will have a level of CK2 significantly 
higher than average, but this will not be critical to trigger a malignant phenotype. 
However, if an oncogenic mutation of one or more genes occurs, these cells are 
more resistant to apoptosis and are able to survive better, and will be gradually 
selected, becoming at the end the majority of the neoplastic tissue, since they are in 
some way ‘‘predisposed’’ to malignant transformation more than cells where CK2 
level is normal (this concept is illustrated in Figure 18) (Ruzzene et al., 2011). This 
goes in parallel with the fact that such ‘‘oncophilic’’ cells are more sensitive to 
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CK2 inhibitors and die for apoptosis when this powerful tool for tumor survival has 
been removed (see below).  
The causes leading to CK2 accumulation in malignant cells are still obscure. 
Mutations have never been found, thus, excluding genetic alteration, and usually the 
over-expression of CK2 in malignant cells is not accompanied by a proportional 
increase of mRNA (Tawfic et al., 2001; Di Maira et al., 2007). Several hypothesis 
have been proposed (Ruzzene et al., 2011) looking for causes correlated to 
epigenetic events. Enhanced translation could be possibly due to altered micro-
RNAs regulation; an alternative mechanism could be represented by defective 
degradation of CK2, through down-regulation of proteolytic pathways, and/or 
hyper-protection of the CK2 molecule by the chaperone machinery, whose 
efficiency is largely dependent on CK2 (Miyata et al., 2009) but which in turn 
could also prevent a regular CK2 protein turnover.  
 
 
 
 
 
 
 
 
Figure 18.  Non-oncogene addiction by CK2. Schematic representation of the mechanism by which 
cells with abnormally high CK2 are selected by malignancy, accounting for the phenomenon of 
‘‘non-oncogene addiction’’ (from Ruzzene et al., 2011). 
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CK2 AS AN ECTOKINASE 
CK2 is present in all cell compartments. Early immunocytochemical studies showed 
that it is mostly detected in the cytoplasm and in the nucleus, but it is also 
associated to cellular membranes and organelles. In proliferating cells CK2 
phosphorylates and alters the activity of a number of regulatory nuclear proteins, 
among them, DNA topoisomerase II (Escargueil et al., 2000). Pools of cytoplasmic 
CK2 shuttling from the cytosol to the nucleus and/or viceversa in response to 
various stimuli such as cellular stress (Yamane et al., 2005) and cell growth and 
apoptosis (Guo et al., 2001), have been well described.  
Moreover, CK2 has been also found on the external side of the cellular membrane 
where, acting as ectokinase, can phosphorylate extracellular proteins and external 
domains of membrane proteins. Originally it was found (Kubler et al., 2002) that 
incubation of HeLa cells with CK2 model substrates, such as casein or phosvitin, 
resulted in the release of the enzyme activity into the medium. Later on, several 
physiological extracellular proteins have been identified as substrates of the CK2 
ectokinase activity; one is vitronectin whose phosphorylation has been suggested to 
regulate the adhesion of cells to the extracellular matrix (Seger et al., 2001; 
Stepanova et al., 2002). More recently, it has been shown that CK2 phosphorylates 
the C9 component of the complement and it has been suggested that this 
phosphorylation might control cell lysis caused by this complement protein 
(Bohana and Kashtan, 2005). Another recent example of an extracellular protein 
domain phosphorylated by ecto-CK2 is the collagen XVII receptor. The 
phosphorylation may inhibit its degradation catalyzed by metalloproteases (Zimina 
et al., 2007). However, studies on CK2 functions as ectokinase are still 
inconclusive, and many questions remain unanswered; moreover the mechanism by 
which CK2 is transported to the external surface of the cellular membrane is 
unknown. It is worth to note that phosphorylation of extracellular membrane 
proteins may have a role in the regulation of cell adhesion and cell migration, and 
this could be involved in the development/sustainment of metastasis. Therefore, a 
better understanding of the CK2 functions as ectokinase would be crucial also from 
a medical point of view. In this context, preliminary data will be presented in 
Chapter 2 of this thesis, where a CK2 not cell-permeable inhibitor, developed in our 
laboratory, has been exploited to selectively block ecto-CK2 kinase activity. 
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INHIBITION OF  
PROTEIN KINASE CK2 
 
WHY AND HOW TO TARGET PROTEIN KINASE 
CK2? 
 
CK2 is a constitutively active enzyme known for several years, but the 
understanding of its role inside the cell has been particularly difficult. Specific 
inhibitors, able to selectively and potently block CK2 activity, can be very useful in 
this context.  Therefore, a huge number of chemical compounds able to inhibit CK2 
activity have been developed to this purpose. There could be multiple reasons to 
developed CK2 inhibitors with therapeutic implications. First of all, CK2 is 
considered a potential drug target for cancer therapy. In fact, as described in 
paragraph 3.3, its amount and activity are elevated in various cancers (Guerra and 
Issinger, 2008), it suppresses apoptosis and strongly promotes cell survival and 
proliferation (Pinna and Ruzzene, 2010), and it reinforces the multi-drug resistant 
phenotype (Di Maira et al., 2007). Therefore, it is considered a key player in the 
development of global favorable conditions for tumorigenesis, and all these 
observations support the rationale of inhibiting CK2 as a potential successful 
strategy for cancer therapy. Moreover, CK2 is not only correlated to cancer, but 
also implicated in viral and infective diseases, and several viral proteins essential 
for virus life cycle are among CK2 substrates (Meggio and Pinna, 2003). Thus, 
CK2 inhibitors with anti-viral and anti-infectious properties could be potentially 
interesting. Moreover, new roles for CK2 have been recently discovered in the 
molecular pathology of different neurodegenerative disorders, such as Alzheimer, 
Parkinson and amyotrophic lateral sclerosis (Perez et al., 2011). Thus, CK2 can be 
considered a potential new target for the treatment of these diseases. CK2 is also 
reported to play an important role in many vascular system diseases, such as 
atherosclerosis (Harvey et al., 2007), laminar shear stress (Widder et al., 2007), and 
hypoxia (Hubert et al., 2006), and it has also been recently connected to 
angiogenesis and related diseases (Ljubimov et al., 2004). Finally it has been 
disclosed a possible functional link between CK2 and cystic fibrosis pathogenesis 
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(Pagano et al., 2010; Venerando et al., 2011). In this context, it is important to 
underline that a large number of CK2 inhibitors have shown a good correlation 
between the in vitro efficacy toward the kinase and the capacity to induce apoptosis 
in different tumor cell lines. A great impulse to the development of inhibitors comes 
from the resolution of CK2 crystal structure: the first one was maize a subunit 
(Niefind et al., 1998), and then several other structures have been solved, allowing 
structure-based approach for developing CK2 inhibitors. Different molecular 
modeling techniques have been used to propose and analyze the essential 
pharmacophoric features for CK2 binding, and significant results have been 
obtained by molecular docking, a computational technique whose goal is the 
detection of the lowest free energy conformation of an inhibitor inside the protein 
active pocket, and the evaluation of the different chemical/physical interactions 
(Kitchen et al., 2004) 22 crystal structures of CK2 kinase domains in complex with 
different ATP-competitive inhibitors are available on the Protein Data Bank (PDB) 
(Berman et al., 2002). The compounds so far available for CK2 inhibition are 
usually small and hydrophobic molecules, very heterogeneous in structure.  
Most CK2 inhibitors act as ATP-competitive molecules. Although the ATP binding 
site is highly conserved in all kinases, in the case of CK2 it presents peculiar 
features, and in particular it is much smaller if compared with the majority of the 
other kinases, thus representing the rational for the selectivity of CK2 inhibitors. In 
detail, the pharmacophoric features for an inhibitory activity toward CK2 include an 
hydrophobic/aromatic moiety in the center of the molecule. This is essential and 
present in all the best CK2 inhibitors; in fact many apolar bulky aminoacids are 
present in the CK2 ATP-binding pocket, such as Met163, Ile66, and Ile174 (Niefind 
et al., 1998).It is worth to note that the latter two residues are unique of CK2, being 
replaced by alanine or other small residues in almost all the other kinases. This 
aspect explains the CK2 specific inhibition by relatively small molecules 
(Battistutta et al., 2001), and also the fact that CK2 has a very low responsiveness 
to staurosporine (Meggio et al., 1995), an inhibitor of almost all the other kinases, 
composed of a large molecular mass, unable to access to the small active site of 
CK2.  
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SELECTIVITY OF CK2 INHIBITORS 
The selectivity of the most promising CK2 inhibitors has been tested in vitro 
evaluating their activity against a panel of different protein kinases. The first 
compounds were assayed towards 25/50 kinases (Pagano et al., 2007; Sarno et al., 
2003; Sandholt et al., 2009) but recently larger panels (up to 200) are used (Pagano 
et al., 2008; Battistutta et al., 2011). From these studies, it has turned out that the 
selectivity for CK2 is usually high, but that other kinases are also often inhibited by 
CK2 inhibitors, such as DYRK1A, DYRK3, the members of the PIM family, 
HIPK2, ERK8, PKD, and in some cases also GSK3b and CDK2 (Pagano et al., 
2008b). In some cases, the selectivity that was initially considered very high was 
revaluated by screening the same compound toward a large panel of kinases 
(Pagano et al., 2008); for example TBB, still widely used as a CK2 specific 
inhibitor, turned out to be much less selective than other compounds such as 
quinalizarin (Cozza et al., 2009) or CX-4945 (Battistutta et al., 2011). Interestingly, 
the kinases targeted by CK2 inhibitors are not randomly distributed throughout the 
kinome, but tend to belong to the same subset of enzymes. This suggests that 
important analogies in the ATP-binding sites of these kinases are present; for these 
reasons, it is possible to exploit the available huge repertoire of CK2 inhibitors as a 
source for the development of inhibitors that selectively blocks one or few other 
kinases beside CK2, for the so-called multi-target strategy. An example is provided 
by the serine/threonine kinases of the Pim family, which control both apoptosis and 
cellular metabolism and are believed to be potential targets for the treatment of 
various human diseases including cancer and ischemic diseases (Amaravadi et al., 
2005). From these considerations, it is evident that a compound simultaneously 
blocking both CK2 and PIM activity could represent an interesting drug candidate 
(Cozza et al., 2014). Sometimes the incidental inhibition of other kinases by a CK2-
directed compound has been exploited to developed new selective inhibitors. This is 
the case of TBID, the first specific HIPK2 inhibitor, developed in our laboratory by 
chemical modification of the tetrabromo-benzimidazole scaffold, initially studied 
for CK2 inhibition, and now established as a selective HIPK2 inhibitor, as it will be 
described in Chapter 4 of Results. 
The strategy applied to obtained specific CK2 inhibitors as is based on the 
optimization of the interactions with the hydrophobic residues of the ATP-binding 
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pocket (Val45, Val53, Lys68, Val95, Phe113, Val116, and Met163) and in 
particular with the peculiar Ile66 and Ile174. However, the peculiarity of the CK2 
ATP-binding pocket is not only due to the small size and the hydrophobic nature, 
but also to its electrostatic properties (Cozza et al., 2010). Indeed, only PoloLike 
Kinase 1 (PLK1) shows charge distribution of the ATP pocket similar to that of 
CK2, while, interestingly, PIM1 and PIM2, often targeted by CK2 inhibitors, are 
quite different in this respect, suggesting a way to improve selectivity. 
A further enhancement of the specificity toward CK2 is expected from a new 
strategy, represented by the so-called “bi-functional” compounds that are designed 
to bind simultaneously to the ATP and the phosphoracceptor site of CK2. This 
approach will be described in details in the Results (see Chapter 2). 
 
 
POTENCY OF CK2 INHIBITORS 
Beside the Ki, a common manner to define the potency of a kinase inhibitor is IC50, 
which represents the concentration of the compound required to inhibit 50% of the 
kinase activity, many CK2 inhibitors display an IC50 in the nanomolar range. The 
most potent CK2 inhibitors have been studied have been co-crystallized in  complex 
with the kinase and have shown common features: they all presents high 
hydrophobicity and thus are readily transferred from the aqueous phase to the 
hydrophobic active site; they have excellent shape complementarity with the small 
active site of CK2 (to maximize van der Waals contacts) and, most importantly, 
they are able to simultaneously establish electrostatic interaction and hydrogen 
bonds both with the hinge region and/or with the phosphate binding region.Crystal 
structures of very potent compounds indicate that, to reach efficacy in the very low 
nanomolar range, inhibitors must target both the hinge region and the positive area 
with polar interactions. The best characterized CK2 inhibitor carrying all these 
features is CX-4945 which displays an IC50 of 2 nM towards CK2a (Battistutta et 
al., 2011); a very strong binding to the enzyme, with a Kd <1 nM has been 
confirmed by crystallographic studies (Battistutta et al., 2011). This compound will 
be described in details in the next paragraph and in Chapter 1 of the Results section. 
A different issue is represented by the potency of an inhibitor when it is used in 
biologic systems (in cells or even in animal). Considerations on this usage will be 
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done in the last paragraph of this Chapter. Here it is worth to mention that a 
frequently used parameter to give information on the potency of CK2 inhibitor in 
cells is its DC50 (concentration of the compound required to induce 50% of cell 
death). Since CK2 down-regulation is expected to produce cell death (at least in 
cancer cells), the efficacy of the inhibitor is proportional to the DC50. Usually DC50 
is significantly higher than IC50 (up two order magnitude), for reasons that will be 
described in last paragraph. 
 
 
CLASSIFICATION OF CK2 INHIBITORS 
Many inhibitors directed to several protein kinases have been developed until now 
and different strategies have been exploited, to target the ATP-binding site or an 
allosteric pocket. As far as CK2 inhibitors are concerned, research started in the 80s 
searching for ATP-competitive small molecules very potent and selective for this 
kinase. Although at that time it was not known, this was particularly successfully 
due to by the CK2 peculiar ATP-binding pocket of CK2, which, as already 
described, is smaller respect to the other kinases, and is able to use either ATP or 
GTP as phosphate donor.  
We can roughly distinguish CK2 inhibitors between a large group of ATP-
competitive inhibitors and a smaller group of compound able to target different 
domains of the kinase. In the following section a brief description is presented of all 
CK2 inhibitor families known so far with special refer to their selectivity, 
mechanism of action and potency in cells. 
 
ATP-COMPETITIVE CK2 INHIBITORS 
The majority of CK2 inhibitors are ATP-competitive compounds. Their mechanism 
of action is based on the binding to the active conformation of the enzyme, in the 
position normally occupied by an ATP (or GTP) molecule, thus affecting the global 
structure of the protein only marginally. Perturbations have been observed at the 
level of the phosphate-anchor loop in the complexes of quinalizarin with the maize 
and human enzymes (Cozza et al., 2009; Papinutto et al., 2012). In this context it is 
important to underline that fundamental apolar interactions occur between CK2 and 
CK2 inhibitors. In fact, for these compounds, the energetic contribution for the 
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binding is given by hydrophobic forces, in particular hydrophobic interactions and 
van der Waals contacts, which take place on the hydrophobic surface of the CK2 
binding site. The residues involved are Leu85, Val95, Leu111, Phe113, and Ile174 
that constitute the hydrophobic region I; Val53, Ile66, Val116 and Met163 that 
constitute the adenine region; and Val45 and Tyr115 for the hydrophobic region II 
(see Figure 19) 
 
 
 
 
 
 
 
 
 
 
Figure 13. Main structural features of the CK2α ATP-binding site shown in two different 
orientations . The active site is occupied by the CX-4945 inhibitor (cyan), belonging to the class of 
carboxyl acid derivatives CK2 inhibitors. Residues of the three hydrophobic regions common to the 
“kinase pharmacophore” are shown in yellow (hydrophobic region I, in the deepest part of the 
cavity), in orange (hydrophobic region II, at the entrance of the cavity), and in magenta (adenine 
region). Other important elements of the CK2α pharmacophore are the hinge region (dark red) and 
the area with a positive electrostatic potential. These two regions are the main polar anchoring 
points for CK2 inhibitors (from Pinna, 2012). 
 
Val66 and Ile174 are bulky residues not present in the majority of other kinases, 
reducing the space available in the CK2 molecule for ATP and inhibitors. This is an 
important point to be considered when an ATP-competitive CK2 inhibitor has to be 
designed. For instance, the active site of CDK2, another kinase belonging to CMGC 
group, is larger than in CK2 for the presence of Ala31 instead of Ile66 and of 
Ala144 instead of Ile174. As a consequence, the inhibitor TBB (4,5,6,7-tetrabromo-
1-benzotriazole) binds differently to the two proteins, showing a remarkable 
selectivity for CK2 (De  Moliner et al., 2003). Inhibition data on CK2 α mutants 
confirmed the importance of Ile66 and Ile174; in the case of the single mutants 
Ile174Ala or Val66Ala and for the double mutant Ile174Ala/Val66Ala, the TBB 
IC50 increases from 0.50 to 1.74, and 13.0 to 12.5 μM, respectively (Sarno et al., 
2005). A reduced sensitivity of these mutants is observed toward several other CK2 
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inhibitors. Moreover, the smaller size of the CK2 a active site prevents the action of 
staurosporine, a promiscuous protein kinase inhibitor, against which CK2 has a 
striking modest sensitivity due to the large size of the molecule (Meggio et al., 
1995).  
Another important peculiarity for the binding of ATP-competitive CK2 inhibitors is 
the presence of a positively charged region located in CK2 a between the 
hydrophobic region I and the salt bridge between Lys68 and Glu81 (see Figure 20). 
The electrostatic interaction with this area greatly contributes to the different 
orientation of the ligands in the active site of CK2. Some examples are available, 
regarding TBB, its benzoimidazole analog TBI and the carboxyl acid CX-4945, and 
they will be discussed in the respective sections.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20.Three important water molecules reside in the positive area near Lys68. W1 is strongly 
anchored to the Lys68 side chain and to the Trp176 backbone amide nitrogen, and it is conserved in 
all CK2 structures, so it can be considered a “constitutive” component of the kinase. W2 is present 
in many structures but is displaced by inhibitors strongly interacting with W1 and Lys68, typically 
harboring a carboxylic function. W3 is present only in few complexes with small inhibitors such as 
TBI, a benzoimidazole derivate, shown in the figure. Note the two halogen bonds (dashed lines) 
between TBI bromines and carbonyls of Glu114 and Val116 from the hinge region (from Pinna , 
2012). 
 
Polyhalogenated Benzimidazole and Benzotriazole derivates 
Benzoimidazole derivates constitutes the first and the most abundant family of 
inhibitors developed to target protein kinase CK2. Many of these compounds have 
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been crystalized in complex with CK2 and structural data revealed that hydrophobic 
and van der Waals interactions are necessary for the binding to the kinase. 
Moreover, the presence and the nature of halogen atoms are fundamental for the 
inhibitory activity and potency. The first ATP-competitive CK2 inhibitor of this 
family was 5,6-dichloro-1-(-D-ribofuranosyl)benzimidazole (DRB), developed as a 
nucleoside analogue, which had an IC50 of 23 mM. Authors reported (Lonn et 
al.,1987; Dobrowolska et al., 1991) that this molecule shows high cytotoxicity and 
is able to block also topoisomerase and RNA synthesis. Starting from this 
compound many others derivatives were designed and tested, looking for a better 
IC50 and a higher selectivity towards CK2. Among them, TBB (4,5,6,7-
tetrabromobenzotriazole), a largely employed CK2 inhibitor, has shown an IC50 of 
0.16 mM and a good selectivity on a panel of 30 protein kinases (Sarno et al., 2001). 
Moreover, when tested on a larger panel, it was found to inhibit several others PKs 
beside CK2 (Pagano et al., 2008). TBB, as many other derivatives, presents four 
bromine atoms on the benzene ring, that are responsible for the hydrophobic 
interactions with bulky side chains inside the ATP binding site (Val 66 and Ile 174), 
and for a network of halogen bonds with the hinge region. The replacement of 
bromine atoms with chlorine and fluorine, that are less bulky, or their reduction in 
number, severely impairs the inhibitory efficiency. A class of benzimidazole 
derivatives with iodines atoms, bulkier than bromines, on the benzene ring was 
synthetized and they displayed IC50 values generally much lower than the 
brominated analogs. In particular 4,5,6,7-tetraiodo-1H-benzimidazole (K88), 
4,5,6,7-tetraiodo-2-methyl-1H-benzimidazole, (K92), 2-ethyl-4,5,6,7-tetraiodo-1H-
benzimidazole, (K93), and 2-[(4,5,6,7-tetraiodo-1H-benzimidazol-2-
yl)amino]ethanol (K100), show Ki values around 20 nM (Gianoncelli et al., 2009). 
More recently, a novel group of DRB-derived inhibitors of protein kinase CK2 has 
been described where methyl or ethyl substitutions at benzene ring have been 
introduced (Makowska et al., 2011); they shows a high activity in the micromolar 
range, the best one being compound 40 (IC50 = 0.16 mM) shown in Figure 21. 
Benzofurane derivatives 
Recently, a new class of benzofurane CK2 inhibitors, similar to the benzoimidazole 
derivatives, has been considered. Among these benzofurane molecules, four novel 
compounds with an IC50 from the micromolar to the nanomolar range have been 
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identified. In particular, TF compound (6,7-dichloro-1,4-dihydro-8-hydroxy-4-
[(4methylphenylamino) methylen]dibenzo[b,d]furan-3(2H)-one) has been 
demonstrated to markedly inhibit recombinant CK2 (IC50 = 29 nM, Ki =15 nM), 
and to be cell permeable. Moreover, a screen of TF compound against a panel of 61 
human kinases, shows that seven of them (Aurora A, KDR/VEGFR2, SGK1, 
FLT4/VEGFR3, PIM1, PKD2, LCK) are sensitive to the inhibitor (inhibited >70%) 
(Gotz et al., 2012). 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Schematic representation of the most active polialogenated benzoimidazole and 
benzofurane derivatives as inhibitors of CK2 (from Cozza et al., 2013). 
 
Natural derived CK2 inhibitors 
 
The progenitor of another class of ATP-competitive CK2 inhibitors is the natural 
anthraquinone emodin (Figure 22) identified from Rheum palmatum, displaying 
anti-inflammatory and anti-tumor properties (Sarno et al., 2002). Its Ki for CK2 is 
1.5 mM, but it inhibits several other kinases (Sarno et al., 2002). Starting from 
emodin, structure based improvements have been done leading to 1,8-dihydroxy-4- 
nitroanthraquinone (MNA), 1,8-dihydroxy-4-nitro-xanthen-9-one (MNX), and 1,4-
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diamino-5,8-dihydroxy-anthraquin-one (MNY) (De Moliner et al., 2003). 
Interestingly these compounds very similar in structure, except for a nitro-group, 
exert different effects toward monomeric CK2, while their activity on tetrameric 
CK2 is very similar.  
The most potent and selective anthraquinone inhibitor of CK2 is 1,2,5,8-
tetrahydroxy-anthraquinone (quinalizarin) (Figure 22). It displays a Ki value of 60 
nM for CK2 and at 1 mM concentration (inhibiting 93% of CK2 activity) none of 
the other 75 kinases tested is affected. Cell treatment experiments have revealed 
that quinalizarin is cell-permeable, able to inhibit more than 50% of endogenous 
CK2 activity at 5mM (Cozza et al., 2009). Other compounds belonging to this class 
are based on fluorenone scaffold as FL12 (2,7-dihydroxy-3,6-dinitrofluoren-9-one) 
which displays an IC50 of 1 mM, and benzonaphtones, like THN, a tetra-hydroxy-
benzonaphtone (Ki of 0.68 mM) (Figure 22) (Sarno et al., 2002; Meggio et 
al.,2004). 
Flavonoids, a class of polyphenolic compounds, are present in fruit, stems, flowers, 
roots, vegetables, wine and tea; they are very important for plants, being responsible 
of flowers pigmentation. Very common in the human diet, they play an important 
role as scavengers of oxygen-derived free radicals, and have been shown to exert 
anti-microbial, anti-inflammatory and anti-cancer activities (Middleton et al., 
1998). Several flavonoids have been related to inhibition of CK2; among them 
fisetin (3,3',4',7-tetrahydroxy-flavone), quercetin (3,3',4',5,7 penta-hydroxy-
flavone), apigenin (4',5,7-tri-hydroxy-flavone) and myrecitin (3,3',4',5,5',7-
hexahydroxy-flavone), whose IC50 are reported in Figure 22 (Sarno et al., 2002). 
Their selectivity is usually poor, although systematic analysis has not been done. 
Recently the flavonol scaffold has being optimized leading to new derivates with 
IC50 in the nanomolar ranges (FLC21, IC50 = 40 nM, FLC26, IC50=9 nM) (Golub et 
al., 2011). 
Another class of CK2-targeting natural compounds, largely distributed in plants (in 
particular Apiaceae and Rutaceae) is represented by coumarins, important for plant 
protection against other organisms and wounds.  It has been reported that many 
polyhydroxylated coumarins possess anticancer properties (Lacy et al., 2004; 
Kawase et al., 2003). About 60 cumarines derivatives have been synthetized as 
CK2 inhibitors; the most active compounds are 3,8-dibromo-7-hydroxy-4-
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methylchromen-2-one (DBC) and the 8-hydroxy-4-methyl-9-
nitrobenzo(g)chromen-2-one (NBC) (Figure 22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Schematic representation of anthraquinone, xanthenone, fluorenone and cumarin 
derivatives, inhibitors of CK2 (from Cozza et al., 2013). 
 
Another natural CK2 inhibitor is ellagic acid, whose structure corresponds to two 
fused coumarins.  Ellagic acid has been demonstrated to be a very potent CK2 
inhibitor, able to interact simultaneously with the phosphate binding region and 
with the hinge region (Cozza et al., 2006) and it is reported to have antineoplastic 
and antioxidant properties (Cozza et al., 2011). An optimization of ellagic acid 
scaffold was also performed (Cozza et al., 2006). From this analysis, urolithin A 
moiety was suggested as a new scaffold linking ellagic acid and coumarin 
analogues. After structural optimization, a novel potent urolithin derivative has 
been identified as CK2 inhibitor: 4-bromo-3,8-dihydroxy-benzo[c] chromen-6-one 
(compound 21, Ki = 7 nM, Figure 22). 
Resorufin is another natural compound recently described as CK2 inhibitor (Figure 
15). Its crystal structure in complex with human CK2 shows a direct interaction of 
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the compound with the phosphate binding site and, at the same time, with the 
carboxyl group of Val 116 in the hinge region, but its potency in cells is modest 
(Sandholt et al., 2009). 
 
Carboxyl acid derivatives 
 
This class of ATP-competitive CK2 inhibitors includes different compounds which 
share the presence of a carboxyl group in their scaffolds. The first compound of this 
group was produced by Novartis, the indoloquinazoline IQA (5-oxo-5,6- 
dihydroindolo-(1,2-a) quinazolin-7-yl acetic acid, also known as CGP029482). It 
displays an IC50 of 0.39 mM and a quite good specificity (Sarno et al., 2003). From 
structural analysis it was possible to highlight the importance of the interaction 
between the carboxyl function of the inhibitor and Lys68 of CK2 a (Sarno et al., 
2003). 
Another member of this group is the tetrabromocinnamic acid (TBCA), derived 
from the fusion between the tetrabromominated benzene ring of TBB and the 
carboxyl function of IQA. Also in this case an electrostatic interaction with Lys68 
occurs, as well as hydrophobic interactions in the adenine binding region (Pagano et 
al., 2007). TBCA was successfully used in in vivo study (Yao et al., 2012). TBCA 
derivatives were obtained, such as the benzoic acid derivative 3,4,5-
tribromobenzoic acid (compound 26, IC50 = 0.64 mM) and TID46 (2-(4,5,6,7-
tetraiodo-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propanoic acid) with a IC50 of 
0.15 mM (Golub et al., 2008) (Figure 23). 
Another family of compounds belonging to the carboxyl acid group is represented 
by the 2,6-disubstituted pyrazines, whose best member is compound 1a which 
shows an IC50 of 30 nM, and a remarkable selectivity against CK2a’ (IC50 = 7 nM) 
(Suzuki et al., 2008). 
A new class of 3-carboxy-4(1H)-quinolones derivatives has been developed, with 
four compounds with IC50 lower than 2 mM; in particular compound 7 (5,6,8-
trichloro-4-oxo-1,4-dihydroqui noline-3-carboxylic acid) shows an IC50 of 0.3 mM 
against CK2 and a good selectivity (Golub et al., 2006) (Figure 23). 
From TBCA scaffold, two novel carboxylated CK2 inhibitors have been produced. 
The first molecule is (E)-3-(3-stibonophenyl) prop-2-enoic acid (denoted as 
compound 10 in Figure 23) (IC50 = 0.15 mM against CK2), the second one is 
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compound 35 (2,3,4,5-tetrabromo-6-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-benzoic 
acid) (IC50 = 0.08 mM) (Prudent et al., 2008). However these compounds have poor 
specificity, since they affect also other signaling pathways, such as Bax-Bcl-X(L) 
(Tan et al., 2003). 
Another family of CK2 inhibitors belonging to this group presents a phenyl-azole 
scaffold (Hou et al., 2012). In particular compound 10 shows an IC50 against CK2a 
and a’ of 32 and 46 nM respectively.  The thiazole ring has been shown to interact 
with the hinge region (Val116, Glu114) and the carboxylic function with Lys68. It 
has been also assayed on cell lines, showing an IC50 in the low micromolar range 
(Hou et al., 2012). 
Finally, the most interesting compounds of this class include pyridoquinoline 
derivatives. CX-4945 (5-(3-Chloro-phenylamino)-benzo[c][2,6]naphthyridine-8 
carboxylicacid) (Figure 23 and 24), the first CK2 inhibitor in clinical trials 
developed by Cylene Pharmaceuticals, belongs to this group. CX-4945 displays an 
IC50 of 2 nM for CK2a (Chua et al., 2008) and the selectivity profile against a panel 
of over 145 protein kinases shows significant preference for CK2, being all the 
other kinases unaffected or inhibited with higher IC50, such as DAPK3 (IC50 = 17 
nM), FLT3 (IC50 = 35 nM), HIPK3 (IC50 = 45 nM), PIM1 (IC50 = 46 nM), 
CDK1/cyclin B (IC50 = 56 nM) and DYRK2 (IC50 = 91 nM).  
Derivatives of CX-4945 (CX-5011 and CX-5279) able to inhibit CK2 with similar 
potency (IC50 of 9 nM and of 3 nM respectively) were recently published (Pierre et 
al., 2011). Consistent with their mechanism of action, all the CX compounds bind 
in the ATP active site of CK2 creating multiple hydrophobic interactions with the 
binding cavity. Moreover, the carboxylic group, present in all three compounds, 
penetrates into the deepest part of the active site making interactions with a 
conserved water molecule and Lys68, thus accounting for the crucial role of this 
negatively charged group in conferring high potency to this class of inhibitors. The 
presence of a pyrimidine in CX-5011 and in CX-5279 instead of a pyridine (as in 
CX-4945) confers higher specificity to these compounds in panels of 102 and/or 
235 kinases, with the highest selectivity ever reported for CK2 inhibitors 
(Battistutta et al., 2011).  Since these compounds were specifically used to obtain 
the results presents in this thesis, a more detailed description of them will be given 
in the Introduction of Chapter 1 of the Result Section. 
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Figure  23.  Example of carboxyl acid derivatives as inhibitors of CK2 (from Cozza et al., 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Inhibitor CX-4945 bound to the CK2 active site. CX-4945 is able to establish polar 
interactions with the two possible anchoring sites present in the CK2 ATP binding pocket, i.e., the N-
terminal portion of the hinge region (Val116 backbone) and the positive area in the deepest part of 
the cavity (W1 and Lys68)(from Pinna, 2012). 
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NON ATP-COMPETITIVE CK2 INHIBITORS 
 
A rational strategy to inhibit a kinase would be by modeling compounds competing 
with the protein kinase phosphoacceptor substrate site instead of the phosphodonor 
site: in fact while ATP is the phosphodonor substrate used by all the kinases, 
phosphoacceptor substrates are largely variable, and molecules competing with its 
binding would ensure higher specificity.  
Besides compounds able to compete with the ATP, or peptide substrates, allosteric 
compounds can be considered, which bind to the kinase not at the catalytic site, but 
at a different site which interfere with the catalytic activity. An alternative site for 
the binding of a non-competitive inhibitor, correspond to the interface between CK2 
a and CK2b subunits, as suggested by structural information. In particular, a 
segment of the CK2b subunit forms a b hairpin loop which is situated deep inside 
an hydrophobic groove present in CK2a (Niefind et al., 2001). The identification of 
this new “druggable” site, suggested the design of compounds able to disrupt or 
prevent the CK2a/CK2b assembly as a strategy to regulate CK2 activity. One of the 
oldest ATP-competitive CK2 inhibitor, DRB, can be considered also an inhibitor of 
this type. In fact, it has been found to bind not only to the ATP-binding site 
(competitive inhibition constant 29.2 mM), but also an external hydrophobic cavity 
(“secondary or allosteric binding site”), which is the main anchoring point between 
a and  b subunit in the holoenzyme formation, so interfering with the assembly of 
the tetrameric a2b2 structure. As expected this binding shows a non-competitive 
inhibitory effect on CK2 activity (non-competitive inhibition constant 39.7 mM) 
(Raaf et al., 2008). Recently, another non-ATP-competitive class of inhibitors has 
been proposed, comprising the podophyllotoxine indolo derivatives. Also these 
small cyclic peptides block the interaction between the CK2 subunits, disrupting 
CK2 tetrameric architecture, and modulating CK2 substrate specificity (Laudet et 
al., 2008). W16 (IC50 = 20mM) was indicated as an allosteric inhibitor devoid of 
ATP competitive action and able to selectively disrupt the CK2 a/b assembly 
(Laudet et al., 2008).  
A different and promising strategy for the development of allosteric CK2 inhibitors 
derives from CFTR (fibrosis cystic transmembrane regulator), whose fragment with 
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Phe508 deletion, peculiar of the fibrosis cystic pathology (CFTRDF508) seems to 
interfere with CK2 activity by an allosteric mechanism (Pagano et al., 2010). This 
is not fully understood, yet, but, interestingly, inhibition occurs only of isolated 
CK2 a catalytic activity, and not in the case of CK2 a2b2 holoenzyme, which is 
instead up-regulated. Since these CFTR-derived inhibitors are peptides, they are 
probably not easy permeable to cell membranes, but they have physiological 
relevance in the case of CFTR pathology, whose fragments formed from this 
channel might in vivo regulate CK2 activity.  
A completely different approach for CK2 inhibition is provided by a cyclic peptide 
inhibitor, CIGB-300 (also known as P15-Tat), introduced by Perea and colleagues 
(Perea et al., 2008) which also entered clinical trials. It has been designed to target 
CK2 substrates instead of the kinase but its mechanism of action is still unclear. 
More detailed information of this peptide and the biochemical and cellular data 
obtained with it will be presented in Chapter 3 of Results section. 
 
 
BI-SUBSTRATE CK2 INHIBITORS 
 
A new family of CK2 inhibitors is that of the so-called bi-substrate compounds. 
These molecules have an ATP-competitive portion and a substrate mimetic tail by 
which they compete with the target protein; they therefore interfere with both the 
ATP and the protein substrate simultaneously. The greater advantage would be an 
extremely high specificity. The most potent inhibitor of CK2 belonging to this 
family is ARC-1504, which shows a remarkably good IC50 (1.8 nM); however, its 
interference with the phosphoacceptor binding site is not fully understood (Enkvist 
et al., 2012). 
In our laboratory, a class of bi-substrate compounds derived from 
tetrabromoimidazole has been recently developed and they have been used in the 
experiments presented in this thesis. Therefore, they will be described in details in 
Chapter 2 of the Results section. 
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In Vivo VERSUS In Vitro INHIBITORY ACTIVITY 

To be useful in biological studies and to be considered as potential pharmacological 
tools, inhibitors must be cell permeable and active towards their targets inside the 
cell. 
Most of the CK2 inhibitors presented in this chapter are small hydrophobic 
molecules, without any particular problem in crossing cellular membranes. Indeed, 
for many of them the action in cells has been confirmed. This can be easily done by 
analyzing the effects on cell viability, since, as already anticipated, the reduction of 
CK2 activity is usually associated to the induction of apoptosis. Moreover, the 
endogenous CK2 activity can be measured in treated cells by means of in vitro 
assays towards CK2-specific peptides, or by analyzing the phosphorylation level of 
known CK2 endogenous substrates in western blot experiments with phospho-
specific antibodies (Ruzzene et al., 2010). Of course, the concentrations required in 
cells are usually much higher (up to two orders magnitude) than in vitro (see 
recommendation in Davies et al., 2000). This is probably due to the sequestration of 
lipophilic compounds by cellular structures and, in the case of ATP-competitive 
inhibitors, to the fact that they have to cope with a very high ATP concentration (in 
the mM range) inside the cell. 
An important aspect that dictates the choice of an inhibitor to be used in cells is of 
course its specificity and the absence of side effects not related to the inhibition of 
CK2, such as targeting of different cellular structures. 
All together these considerations allow to identify those inhibitors that are 
convenient for in vivo studies. TBB was one of the first compounds tested in cells 
(Ruzzene et al., 2002), it is very effective and quite specific (Sarno et al., 2001), 
and, also because it is commercially available, it is still one of the most widely used 
CK2 inhibitor. However, as already mentioned, its selectivity has been revaluated 
(Pagano et al., 2008) and it turned out that it is not the best choice for in vivo 
investigations. 
On the other side, some inhibitors are not sufficiently stable in water, so their 
addition to the aqueous cellular medium can produce too low concentrations; this is 
the case of IQA (Sarno et al., 2005). In other cases the availability in the organism 
is not optimal, and this should be considered, especially when animal treatments are 
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planned; for example, ellagic acid is not able to cross the intestinal barrier and it is 
converted to urolithin (Seeram et al., 2006). 
Several examples of usage of CK2 inhibitors in vivo are available. The first 
employment of a CK2 inhibitor in animal model was presented by Ljubimov and 
colleagues showing that CK2 inhibition prevented retinal neovascularization in a 
mouse model of oxygen-induced retinopathy (Ljubimov et al., 2004). Another 
pioneering study of CK2 inhibitor administration to animals employed TBB and 
DRB in several pain models (Li et al., 2005), while brain injections of TBCA 
allowed to disclose a relationship between CK2 inhibition and superoxide anion 
production (Kim et al., 2009). However, the majority of the studies have been 
performed to demonstrate the efficacy of CK2 inhibition in murine xenograft cancer 
models. They were initially performed with TBB or its derivatives (Manni et al., 
2012; Sass et al., 2011) or with different class of compounds such as ellipticine 
derivatives (Prudent et al., 2010), or hematein (Hung et al., 2013), but a great 
impulse to this field came from the discovery, and later the commercialization, of 
CX-4945 (Pierre et al., 2011). Many reports have shown the efficacy of this 
compound in reducing tumor sizes, mostly in murine xenograft models (Zheng et 
al., 2013).  
At present, quinalizarin (Cozza et al., 2009) and the CX-compounds (CX-4945, 
CX-5011 and CX-5279) (Pierre et al., 2011) are the CK2 inhibitors with the highest 
selectivity and demonstrated effectiveness in cells. In particular, the effects of CX-
4945 and CX-5011 in cells will be extensively described in Chapter 1 of Results.   
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HOW DRUGGABLE IS CK2? 
As already mentioned, CK2 is involved in several diseases, such as cancer and 
neurodegenerative disorders, and can be therefore considered a potential drug 
target. Several potent, selective, and cell-permeable CK2 inhibitors are available as 
described above, and they could represent good from a therapeutic point of view. 
However, CK2 is an essential kinase for cell viability, involved in many 
physiological processes, with hundreds substrates; this raises the question if it is 
really an effective drug target for therapeutic intervention, and for many years 
research did not considered convenient the investiments on this field. However, 
later it turned out that CK2 amount is much higher in tumor than in normal cells, 
and that it is involved in many of the processes associated to malignant 
transformation. Recently, the hypothesis of the addiction to CK2 of cancer cells has 
been proposed (Ruzzene and Pinna, 2010) as an example of "non-oncogene 
addiction" on abnormally high CK2 level (Ruzzene and Pinna, 2010). In this view, 
CK2 is able to generate an environment favorable to neoplasia consistent with its 
global antiapoptotic and prosurvival role, and tumor cells develop a reliance on 
particularly high level of CK2. CK2 is therefore not a real “promoter” of 
malignancy, but a “driver” of it, being able to support several other biological 
alterations, truly responsible of the malignancy. The hypothesis of this higher 
reliance of cancer cells to CK2 compared to normal cells is supported by several 
experimental data showing how tumor cells are more susceptible to apoptosis 
induced by CK2 inhibitors than their normal counterpart (Kim et al., 2007; Piazza 
et al., 2006; Silva et al., 2008). In particular, Slaton and colleagues (2004) have 
reported that, in xenograft models, inhibition of CK2 activity by siRNA and 
antisense vectors is able to induce apoptosis in cancer cells with no or small effects 
on normal cells. All these results have allowed the beginning of animal treatments 
with CK2 inhibitors and also of clinical trials of experimentation in humans. In 
particular, encouraging data from Phase I clinical trial of CX-4945 have been 
reported in different kinds of cancer (Siddiqui-Jain et al., 2011); the compound has 
demonstrated favorable safety, and pharmacokinetic and pharmacodynamics 
characteristics.  
A new strategy, based on multitarget drugs, is presently under investigation, 
looking for additive synergistic effects between different drugs. This approach 
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should be successful to target a particular disease, improving antitumor activity and 
also overcoming drug-resistance. Good examples are already available for kinases 
different from CK2; among them Sorafenib and Sunitinib, approved by FDA, which 
target the vascular endothelial growth factor receptor, the platelet-derived growth 
factor receptor, the FMS-like tyrosine kinase 3 (FLT-3), and the stem cell factor 
receptor (c-Kit). Targeting CK2 would be particularly convenient because of its 
extreme pleiotropicity: by reducing its activity, especially high in cancer cells, other 
survival pathways, which are typically and specifically up-regulated in different 
type of cancers will be also affected. 
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MULTI DRUG RESISTANCE 
 
Drug resistance is a phenomenon by which human tumors acquire resistance to a 
certain drug and often also to many other compounds, different in structure and 
mode of action; for this reason it is usually defined as multi-drug resistance, or 
MDR, and it results in a decreased drug activity. It is defined as primary resistance, 
if present prior to drug exposure, or as acquired resistance, if it appears during or 
after the course of treatment. In both cases this event critically limits treatment 
outcomes, and it is one of the major reasons for the failure of cancer therapy.  
But where do resistant cells come from? The development of human cancers is a 
complex multistage process involving accumulation of both genetic and epigenetic 
alterations over time (Caulin and Maley, 2011). As a consequence, a single tumor is 
composed of heterogeneous cells with distinct genetic fingerprints (Heppner, 1978, 
Marusyk and Polyak, 2010, Michor and Polyak, 2010). As the tumor progresses, 
some cells undergo genetic alterations, with selection of those having a superior 
growth advantage in a given context. The innate heterogeneity has relevance in 
cancer resistance. Since cancer cell selection obeys the Darwinian law of evolution, 
under therapeutic pressure, those populations that are most adaptive or resistant to 
treatment will be selected. These clones will then dominate and populate the tumor 
rendering, it highly resistant to a given therapy (Figure 24) (Breivik et al., 2005; 
Crespi and Summers, 2005; Lichtenstein et al., 2005; Monceviciute-Eringiene et 
al., 2005; Greaves et al., 2007).  
At a cellular level, there are multiple active mechanisms of resistance, such as 
increased activity of efflux pumps, i.e. ATP-dependent transporters; reduced drug 
influx; activation of mechanisms that repair drug-induced DNA damage; 
deficiencies in apoptotic signaling pathways. Alteration in drug efflux mechanisms 
is one of the most frequent causes of MDR; in fact, transporters pump anticancer 
agents out of the intracellular environment into the extracellular matrix, thereby 
preventing the agents from reaching their minimally effective intracellular 
concentrations (Perez et al., 2009). 
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Figure 24. Development of cancer resistance. While most tumors initially respond to the given 
therapy, the majority will relapse following treatment, and in some cases resistance even predates 
clinical intervention. Cells can develop resistance by at least two mechanisms: (A) presence of 
multiple initial clones some of which emerge as dominant after treatment. These subpopulations 
possess stem-like characteristics and/or use their interactions with the surrounding 
microenvironment to enter into a dormant state, thus surviving the insult of therapy; (B) acquisition 
of alterations within the cancer cells per se. In all cases, the surviving population is less likely to 
respond to any further therapy and will be responsible for the minimal residual disease and cancer 
relapse (from Zahreddine and Borden, 2013). 
 
 
Among the 48 known ATP binding cassette (ABC) human transporter proteins, at 
least three members can be involved in developing cancer chemoresistance 
(Gottesman et al., 2002; Gottesmanetal et al., 2002). They are the P-glycoprotein 
(P-gp, MDR1 gene product), the multidrug-resistance-associated protein 1 (MRP1), 
and the mitoxantrone resistance protein (MXR; also known as breast cancer 
resistance protein (BCRP) or placenta ABC protein (ABC-P)). P-gp pump functions 
as an efflux pump with a broad specificity for hydrophobic anti-cancer drugs such 
as vinblastine, doxorubicin, vincristine, and taxol, and therefore its increased 
expression has been correlated with resistance to these compounds (Gottesmanetal 
et al., 2002). Studies conducted in 31 breast cancer clinical speciments 
demonstrated that overexpression of P-gp was associated with 3-fold increased risk 
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of failure to respond to chemotherapy and its expression was found to increase after 
chemotherapy exposure (Trock et al., 1997). MRP1 instead transports negatively 
charged natural drugs and drugs modified by the conjugation of glutathione (GSH), 
glucuronic acid or sulfate (Jedlitschky et al., 1996; Hipfner et al., 1999; Konig et 
al., 1999; Borst et al., 2000). MXR altered expression has been correlated with 
resistance to topoisomerase I inhibitors, anthracyclines, and mitoxantrone 
(Gottesman et al., 2002).  
As already mentioned a drug transporter can recognize to resistance structurally 
different compounds, thus the therapeutic employment of a certain drug could 
influence the efficacy of many other compounds. For this reason, new strategies to 
overcome this problem are being proposed, such as the usage of drugs that are not 
recognized by transporters and therefore evade efflux, efflux inhibitors, drugs that 
are selectively lethal to P-gp expressing cells (Hall et al., 2009; Nobili et al., 2012).  
Drug inactivation can also play an important role in the development of resistance. 
These mechanisms include, for example, conjugation of the drug to glutathione 
(GSH), a powerful anti-oxidant that protects the cells against the damaging effects 
of reactive oxygen species. GSH conjugation to platinum drugs, such as oxaliplatin 
and cisplatin used in the treatment of various types of cancers, transforms them in 
optimal substrates for ABC transporters which enhance drug efflux (Ishikawa and 
Ali-Osman, 1993). Furthermore, the binding of platinum drugs, particularly 
cisplatin, to metallothionein (MT), a small cysteine-rich protein, is another mode of 
drug inactivation (Kasahara et al., 1991). Interestingly, cancer cells can develop 
resistance through decreased drug activation mechanism  for those agents that need 
of metabolic activation to show their cytotoxic effects. This occurs via the 
downregulation or mutation of enzymes involved in this metabolic pathway. 
Although MDR mechanisms are well-characterized, agents targeted against 
multidrug resistance have produced poor results. Recent observations have 
highlighted that MDR phenotype of some cancer cells is by no means the result of a 
single gene aberration. Since it is recognized that multiple genetic defects, such as 
DNA mutations, translocations, truncations, deletions, or duplications, are present 
in cancer cells, the role of drug-induced epigenetic aberrations such as histone 
posttranslational modifications, DNA hypermethylation, and subsequent gene 
silencing is of increasing importance. Epigenetic changes can occur rapidly upon 
chemotherapy exposure. 
56 
 
Other mechanisms by which cancerous cells circumvent the effects of targeted 
inhibitor drugs have also been proposed, including amplification of alternative 
oncogenes or inactivation of alternative survival pathways (le Coutre et al. 2000). 
In some cases, targeting of one protein alone can become ineffective because 
another parallel pathway sustains tumor survival, resulting in the development of a 
lethal relationship between these two networks (Tucker and Fields, 2003). Thus, the 
loss/inactivation of one of these genes would be supported by the other pathway 
and, for the most effective treatment one would need to target both pathways 
(Nijman et al., 2011). 
Intrinsic or acquired resistance can occur also towards biologic agents, such as 
trastuzumab (Valabrega et al., 2007) and hormonal therapies (Musgrove and 
Sutherland, 2009), not only through the specific pathways that underlie their 
respective mechanisms of action, but also through redundancy and cross-talk  with 
other pathways that finally result in treatment failure (Leary et al., 2010). 
 
Strategies to Overcome Drug Resistance 
Mechanisms of intrinsic drug resistance and the acquisition of resistance during the 
course of malignant progression are strongly influenced by the tumorigenic 
pathways. Both genetic and epigenetic changes are dynamic events which work 
together for the maintenance of the malignant “homeostasis”. Many attempts to 
overcome mechanisms of resistance to cytotoxic, hormonal, and biologic agents 
have failed. Some approaches have evaluated concomitant administration of agents 
that mislead resistance, but have product limited satisfactory results for therapy 
(Fracasso et al., 2000, Pusztai et al., 2005). More recently, the incorporation of 
mTOR inhibitors or demethylation agents has had some success in preclinical and 
clinical studies (Nahta and O’Regan, 2010; Baselga et al., 2012; Bachelot et al., 
2012). It is common for patients with resistant tumors to receive additional 
chemotherapy agents that demonstrate somewhat different mechanisms of action 
and/or biochemical structures respect to the canonical therapy for a given tumor 
type. These combinations may also show synergism with good efficacy on tumor 
progression since they impact on multiple intracellular escape pathways essential 
for tumor cell growth and survival. In recent years, an ever-growing group of 
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cytotoxic drugs with different mechanism of action has been considered in 
combination treatment strategies. 
CK2 AND MDR 
CK2 is dramatically involved in the sustainment of malignant transformation, and 
also involved in the MDR phenotype. It has been reported that CK2 phosphorylates 
P-gp (Glavy et al., 1997). Matsumoto and co-workers (1999) have also highlighted 
that in a MDR cell lines, overexpressing P-gp, CK2 is also overexpressed at the 
mRNA level. Moreover, in a study conducted in our laboratory some years ago, it 
has been demonstrated that CK2 catalytic subunit is overexpressed in a MDR cell 
line compared to the non-MDR counterpart, and this contributes to the maintenance 
of the resistant phenotype, as demonstrated by the effects of selective down-
regulation of CK2 activity, either pharmacologically or through siRNA technique 
(Di Maira, 2007). Moreover, CK2 positively controls the P-gp activity, since the 
accumulation of its substrate doxorubicine in P-gp expressing cells is increased in 
cell treated with CK2 inhibitors (Di Maira et al., 2007). Recently, it has been 
reported that the activity of another efflux pump, MRP1, is regulated by the 
phosphorylation at its Thr249 by CK2 (Stolarczyk et al., 2012). Therefore CK2 
inhibition has been found to induce a higher accumulation of drugs in cells 
overexpressing these transporter proteins.  
It is worth to note that CK2 overexpression is not an absolute requirement for the 
MDR phenotype, since several examples have been reported where its level is very 
similar in resistant cells and their apoptosis-sensitive counterparts (Di Maira et al., 
2007; Borgo et al., 2013). However, CK2 inhibition has always been found to 
induce apoptosis in resistant cells, regardless of its overexpression; in several cases, 
interestingly, a synergistic effect has been also observed between CK2 inhibitors 
and conventional drugs, such as melphalan (Piazza et al., 2006), vinblastine (Di 
Maira et al., 2007) and imatinib (Borgo et al., 2013). In this thesis, we will present 
an additional example of synergism between antitumor drugs and a new and 
prominent CK2 inhibition, CX-4945. 
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MATERIAL AND METHODS 
 
MATERIALS 
Proteins  
Recombinant human CK2a, a2b2 and GST-p53 were purified and kindly provided 
by Dr. Andrea Venerando (University of Padova, Italy). Native CK2 was purified 
from rat liver in our laboratory (Meggio et al., 1981). Recombinant His-B23 was 
from AbCam. Total casein and a-casein were from Sigma. 
Peptides 
The CK2 peptide substrates CK2-tide (RRRADDSDDDDD), eiF2b-tide 
(MSGDEMIFDPTMSKKKKKKKKP) and HIPK2-tide (NKRRRSPTPPE) were 
synthetized and kindly provided by Dr. Oriano Marin (University of Padova, Italy).  
 
Inhibitors 
CK2 inhibitors 
CX-4945 (5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxyliucacid) 
and CX-5011 (5-(3-ethynylphenylamino)pyrimido[4,5-c]quinoline-8-
carboxylicacid) were synthetized and kindly provided by Cylene Pharmaceuticals 
(San Diego, USA). Stock solutions were made in dimethylsulfoxide (DMSO) and 
stored at -20°C.  
K137 and K137-E4 was synthesized and kindly provided by Prof. Giuseppe Zagotto 
(University of Padova, Italy). Stock solutions were made in dimethylsulfoxide 
(DMSO) and stored at -20°C. 
CRIBI-300 and peptide derivatives (listed in Table 1, Chapter 3) were syntetized 
and kindly provided by Prof.O.Marin and Michele Sandre (University of Padova, 
Italy). Stock solutions were made in sterile water and aliquots were stored at -20°C. 
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HIPK2 inhibitors 
TBID (4,5,6,7-tetrabromo-2-(1H-imidazol-2-yl)isoindoline-1,3-dione) was 
synthesized and kindly provided by Prof. Conrad Kunick (University of 
Braunschweig, Germany). Stock solution was made in DMSO and stored at -20°C. 
 
Others 
Staurosporine, Vinblastine and Doxorubicin were from Sigma. 
Antibodies 
CK2α-subunit antisera were raised in rabbit against the sequence of the human 
protein at C-terminus [376–391] (Sarno et al., 1996), total Akt, total Cdc37, LAMP 
and S6 antibodies were from Santa Cruz Biotechnology, β-actin and a-tubulin 
antibodies were from Sigma, PARP antibody was from Roche, caspase-3, total p53 
and p53Sp46 were from Cell Signaling Technology, CK2b and HIPK2 antibodies 
were from Epitomic; B23 antiboby was from Invitrogen, P-gp monoclonal 
antibodies were from Calbiochem, Akt Sp129 phospho-specific antibodies were 
raised in rabbit and purified in our laboratory (Di Maira et al., 2005); Cdc37 Sp13 
phospho-specific antibodies were from Abcam; secondary antibodies towards rabbit 
and mouse IgG, conjugated to horse radish peroxidase, were from PerkinElmer. 
Oligonucleotides 
CK2a specific siGENOME SMARTpool siRNAs and aspecific siRNA 
siCONTROL riscfree#1 were from Dharmacon (Lafayette, CO, USA). CK2b 
siRNA (sense, 5’-GCCAUGGUGAAGCUCUACUdTdT-3’; antisense, 5’-
AGUAGAGCUUCACCAUGGCdTdT-3’) were from Dharmacon. Transfecting 
reagent INTERFER in was from Polyplus-transfection SA (Illkirch, France). 
Cell lines 
For these thesis the following cell lines were used: human T lymphoblastoid CEM 
cells (normally sensitive, S-CEM, and their MDR variant, R-CEM, selected with 
0.1 µg/ml vinblastine, Vbl (Di Maira et al., 2007)); human osteosarcoma U2OS 
cells (normal sensitive, S-U2OS, and their MDR variant, R-U2OS (Cenni et al., 
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2004)); human ovarian carcinoma 2008 cells (normally sensitive, S-2008, and their 
cisplatin-resistant variant, R-2008 (Marzano et al., 2007)); acute promyelocytic 
leukemia HL60 cells; acute T lymphoblastic  Jurkat cells; human hepatocellular 
liver carcinoma HepG2 cells; human cervix adenocarcinoma HeLa cells; human 
embryonic kidney HEK-239T cells; human lung CCD34Lu cells; chronic myeloid 
leukemia (CML) LAMA84 (le Coutre et al., 2000), KCL22 (Redaelli et al., 2010), 
and K562 (Redaelli et al., 2010) cells, in their sensitive (S) or resistant (R) to 
Imatinib, kindly supplied by Dr. C. Gambacorti-Passerini (University of Milano-
Bicocca, Milano). 
 
METHODS 
Cell culture and treatments 
Cells were cultured in an atmosphere containing 5% CO2; CEM, LAMA84, K562, 
KCL22 and HL60 cell lines were maintained in suspension in RPMI 1640 medium 
(Sigma), U2OS, 2008, HepG2, HeLa, HEK293-T and CCD34LU cell lines were 
adherent cells maintained in D-MEM medium (Sigma); both media were 
supplemented with 10% (v/v) fetal calf serum (FCS), 2 mM L-glutamine, 100 U/ml 
penicillin, and 100 µg/ml streptomycin. Cell treatments with inhibitors were 
performed in the culture medium at 3x10
6
 cells/ml for cells that grow in suspension, 
and about 70% of confluence for adherent cells, but with 1% FCS, where not 
differently indicated. Control cells were treated with equal amounts of the inhibitor 
solvent.  
Cell viability 
Cell viability was detected by means of MTT (3-(4,5-dimethylthiazol-2-yl)-3,5-
diphenyltriazoliumbromide) reagent, a tetrazolium salt that is metabolized by 
mithochondrial dehydrogenases and produces a violet precipitate (formazan) in 
viable cells. For cell viability experiments, cell treatments were performed in 96-
well plates at a density of 10
5
 cells/100 µl for cells in suspension; 2x10
4
 adherent 
cells were seeded in 96-well plates in 100 ml medium, and left to adhere for one 
night before treatment. Cells were incubated for variable times under the conditions 
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indicated in the figure legends. 1 h before the end of the incubation, 10 µl of MTT 
solution (5 mg/ml in PBS) was added to each well. Incubations were stopped by 
addition of 20 µl of lysis solution at pH 4.7, containing 20% (w/v) SDS, 50% (v/v) 
N,N-dimethylformamide, 2% (v/v) acetic acid and 25mM HCl. Plates were read for 
OD at λ590 nm, in a Titertek Multiskan Plus plate reader (Flow Laboratories). DC50 
(concentrations inducing 50% of cell death) values were calculated with Prism 4.0c 
software (GraphPad Software). 
Combined treatments 
Drug interactions were assessed by treating cells with increasing concentrations of 
two different compounds, at fixed concentration ratio, indicated in the figure 
legends. The combination index (CI) (Giovannetti et al., 2007), was calculated with 
the software Calcusyn (Biosoft); CI<1, CI = 1, and CI>1 indicate synergistic, 
additive and antagonistic effects, respectively.  
Doxorubicin accumulation measurement 
About 100000 CEM cells were seeded in 96-well plates and treated with 25 µM 
doxorubicin for 30 min. CK2 inhibitors, where present, were added 30 min before 
doxorubicin.  After washing with phosphate-buffered saline, cells were lysed in the 
lysis buffer described above, supplemented with 1% (w/v) SDS. Doxorubicin 
content was determined fluorimetrically, by reading the plate at λexc.485 nm, 
λem.590 nm with Titertek Multiskan Plus plate reader (Flow Laboratories).  
Apoptosis assay 
Apoptosis was evaluated by detecting the cleavage of the caspase substrate PARP 
or the activation of pro-caspase 3 by WB. Apoptosis quantitative determination was 
performed by means of the Cell Detection Elisa kit (Roche), based on the 
quantification of nucleosomes present in the cytosol of the apoptotic cells, by 
measuring the absorbance at λ405–λ490, following the manufacturer's instructions. 
About 10 000 cells were used for each determination. Alternatively, DNA-laddering 
was performed starting from 10
7 
cells, in the presence or absence of CK2 inhibitors. 
Cells were washed with PBS and pelleted by centrifugation. Pellets were 
resuspended in 1.5 mL of lysis buffer containing  10 mM Tris-HCl, pH 7.5, 400 
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mM NaCl, 2 mM EDTA, pH 8.2, 0.7% SDS and Proteinase K (2 mg/mL) and 
incubated overnight at 37°C. Proteins were then precipitated by addition of 0.5 mL 
of 5 M NaCl at room temperature for 1 hour. The precipitated proteins were 
pelleted by centrifugation at 3300 g for 30 minutes. The DNA, present in the 
supernatant, was transferred in a new tube and precipitated with 2.5 volumes of cold 
absolute ethanol and washed in 70% ethanol after centrifugation at 3300 g for 30 
minutes.  The DNA pellet was dissolved in 100 µL of TE buffer containing 0.5 
mg/mL RNase and was allowed to dissolve for 2 hours at 37°C before quantitating. 
After quantification of the DNA content by Nanodrop, 10 µg of DNA per lane was 
separated on 1.7% agarose gel at 60V for 2 hours at 4°C. The staining was 
performed in ethidium bromide (1 µg/mL) for 15 minutes and washed for 30 
minutes in water. 
Cell lysis  
Cells were collected by centrifugation at 1200 rpm for 5min, washed with cold 
PBS, and lysed to obtain a total lysate, by adding an ice-cold buffer consisting of 
20mM Tris-HCl, pH 7.5, 150mM NaCl, 2mM EDTA, 2mM EGTA, 0.5% (v/v) 
Triton X-100, 2mM dithiothreitol (DTT), protease inhibitor cocktail Complete 
(Roche), 10 mM NaF, 1 mM okadaic acid, 1mM Na vanadate. After 30min 
incubation on ice, the lysates were centrifuged at 13200 rpm for 10 min, at 4°C. The 
supernatants contained the cell-soluble fraction, whose protein concentration was 
determined by the Bradford method.  
Western blot analysis 
Equal amounts of proteins were solubilized in Laemmli buffer, loaded on 11% 
SDS-PAGE (Laemmli, 1970), blotted on PVDF membranes (Immobilon-P 
Millipore) in a TE 22 Mini Tank Transfer Unit (GE Healthcare), at 60V  for 75 min, 
using a buffer containing 10 mM CAPS-NaOH (3-(Cyclohexylamino)-1-
propanesulfonic acid pH 10, DTT 3 mM and 1% (v/v) methanol. Dried PVDF 
membranes were then washed with TBS buffer (Tris-HCl 50 mM pH 7.5, NaCl 50 
mM) with 1% (w/v) BSA (Sigma-Aldrich) and then incubated with the indicated 
antibodies diluted in the same buffer. The incubation times were variable, ranging 
from 2h to 16h, at room temperature (< 3h incubation) or at 4°C (longer 
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incubation). Then membranes were incubated with a secondary HRP-conjugated 
antibodies solution for 30 min in the same buffer and then washes three times with 
TBS buffer. Antibodies signals were detected by ECL solution (enhanced 
chemiluminescence, Amersham Biosciences). For the quantitation of the signal, this 
solution was left in contact with membrane for a time ranging from 2 sec to 4 min; a 
Kodak Image Station 4400MM PRO was used for detenction and the analysis was 
performed with the Kodak 1D Image software. 
 
Immunoprecipitation assays  
Immunoprecipitation was performed incubating 100-200 mg of proteins from total 
cell lysates over night at 4°C, with the specific antibody for the interested protein or 
with an aspecific antibody as a negative control, in gently rocking . Then, protein 
A-Sepharose (Sigma-Aldrich) is added for 40 min at 4°C. Immunoprecipitates were 
washed twice with 50 mM Tris-HCl pH 7.5 and once with 5 mM Tris-HCl pH 7.5 
and used for phosphorylation assays. 
Immunofluorescences 
About 200000 cells were seeded on glass cover-slips and allowed to adhere 
overnight.  Cells were washed with warm PBS,  fixed with 4% (w/v) 
paraformaldehyde (Sigma) for 20 minutes at room temperature, permeabilized with 
0.1% Triton X-100 in PBS for 10 min at 4°C, and incubated with the primary 
antibody anti-CK2 (1:50) from a time variable ranging from 2h at room temperature 
to overnight at 4°C. After 3 times washes with PBS, cells were incubated with 
Alexa Fluor 633 goat anti-rabbit IgG secondary with PBS, cells were incubated 
with the secondary antibody. Alexa Fluor 633 conjugated goat anti-rabbit IgG (Life 
Science) was used at 1:400 dilution, FITC conjugated secondary antibody (Dako) 
was used at 1:50 dilution for 1 hour at 37°C in the dark. Nuclei were stained with 
Hoechst 33342 (1:10000; Sigma) for 10 min at room temperature in the dark. The 
coverslips were mounted with fluoromount solution (Sigma) and the 
immunofluorescence images were acquired with LEICA TCS SP5 confocal 
microscope equipped with HCX PL APO lambda blue 63x1.4 oil immersion 
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objective. Argon laser emitting at 488 nm (for detection of LAMP1) and a HeNe 
laser emitting at 633 nm (for detection of CK2) were used. LAS IF software was 
used for image processing. 
CK2 ACTIVITY ASSAYS 
Activity assay of purified CK2 
Recombinant CK2 a2b2 (40ng), recombinant CK2a (10-50ng) or native CK2 (0.005 
U) were incubated with peptides or protein substrates in the presence of 50 mM 
Tris-HCl pH 7.5, 10 mM MgCl2, 10 mM [γ-
33
P] ATP (1000-2000 c.p.m/pmol) and 
0.1 M NaCl, in a total volume of 20 ml. When CK2 a was used, NaCl was omitted. 
Substrates concentrations were: CK2-tide 0.1mM, eiF2b 0.1mM, a-casein 0.5mg, 
total casein 0.5mg, p53 0.5 mg and calmodulin 2mg. When CK2 a2b2 and a activities 
were compared, the same units were added (0.01), where 1 unit is defined as the 
amount of enzyme which catalyzed the introduction of 1nmol of Pi to CK2-tide/min 
under the experimental conditions. Incubation was carried out at 30°C for 10 min. 
Reaction of peptide phosphorylation were stopped by sample absorption on 
phospho-cellulose paper. Papers were washed three times with 75 mM phosphoric 
acid and counted in a scintillation counter (Perkin Elmer). 
In the case of protein substrates reactions were stopped by the addition of Laemmli 
buffer (Laemmli, 1970) and proteins were separated in SDS-PAGE, stained with 
Coomassie blue and analyzed by digital autoradiography (CyclonePlus Storage 
Phosphor System, PerkinElmer). 
 
CK2 activity assay in cell lysates 
0.5-2 mg of proteins from cell lysate were incubated in the presence of 50 mM Tris-
HCl pH 7.5, 10 mM MgCl2, 10 mM [γ-
33
P] ATP (1000-2000 c.p.m/pmol) and 0.1 M 
NaCl, with 0.1mM CK2-tide in a total volume of 20 ml. Incubation was carried out 
at 30°C for 10 min and stopped by sample absorption on phospho-cellulose P81 
paper. Papers were washed three times with 75 mM phosphoric acid and counted in 
a scintillation counter. Control samples were performed in the absence of CK2-tide; 
they always turned out to display an activity lower than 5% of the same samples 
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incubated with CK2-tide. Phosphorylation of endogenous proteins was performed 
on 5 µg of lysate proteins under the same conditions for 20 min, but without the 
addition of the peptide substrate. The reactions were stopped by the addition of 
Laemmli buffer and the proteins were analyzed by SDS/PAGE/WB and digital 
autoradiography (CyclonePlus Storage Phosphor System, PerkinElmer). 
CK2 ectokinase activity assay (from Kubler et al., 1989) 
For cells growing in adhesion, 100000-200000 cells were used, seeded in a 96 well 
plate 24 h before the assay; for cells growing in suspension, 50000 cells were used 
and pelleted in steril tubes. Cells were washed three times with an isotonic buffer 
containing 70 mM NaCl, 30 mM Tris-HCl pH 7.5, 5 mM MgCl2, 5 mM KHPO4, 
0.5 mM EDTA and 75 mM glucose and then preincubated with 50ml of the same 
buffer for 3 min at 37°C. Reactions started when a mixture containing ATP to a 
final concentration of 10 mM, [γ-
33
P] ATP (10000-20000 cpm/pmol) and the CK2-
specific peptide for a final concentration of 1mM, was added in each well for total 
volume of 56.6ml. Samples incubated with the same mixture but without the peptide 
substrate were used to check non-specific phosphorylation. Controls of CK2-tide 
phosphorylation activity in cell supernatant were performed under the same 
condition using 50ml of the cellular medium, in a total incubation volume of 56.6 
ml. Plates or tubes were incubated at 37 ° C, with gentle shacking (130-150 rpm) for 
variable times. Then 20ul of the phosphorylation mixture are spotted on 
phosphocellulose paper and analyzed as described for purified CK2 at different 
times. 
Cellular HIPK2 activity assay 
Cellular HIPK2 activity was assayed on HIPK2 immunoprecipitation from 350 mg 
of total lysate proteins deriving from HepG2 cells, with 2.5 ml anti-HIPK2 or an 
aspecific antibody, as negative control (for detailes see above Immunoprecipitation 
assay) Immunoprecipitated HIPK2 activity was measured towards the specific 
peptide substrate NKRRRSPTPPE at 1.6 mM final concentration using a 
radioactive mixture composed of 50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 10 mM 
[γ-
33
P] ATP (1000-2000 c.p.m/pmol) and 0.1 M NaCl, for 10 min at 30 °C. Peptide 
radioactivity was measured after sample spotting on phospho-cellulose paper, 
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washing and scintillation counting, while the amount of HIPK2 immunoprecipitated 
was evaluated by WB. 
RNA interference assay 
LAMA84 (1.5 × 10
6
) were transfected with 40 nM CK2 α specific siGENOME 
SMARTpool siRNAs or 30nM CK2 b siRNA (see above), or 40nM aspecific 
siRNA siCONTROL riscfree#1 as control, using the transfecting reagent 
INTERFER in (Polyplus-transfection SA, Illkirch, France), according to the 
manufacturer's recommendations. Transfection was performed for 72 h in RPM1 
supplemented with 10% (v/v) fetal calf serum (FCS), 2 mM L-glutamine, 100 U/ml 
penicillin, and 100 µg/ml streptomycin. 
Statistical analysis 
All experiments were performed at least 3 times, each time in duplicate; graphs and 
statistical analysis were performed with Prism 4.0c software (GraphPad Software). 
Peptide Synthesis 
The peptides used for this work, provided by Prof. O. Marin, were synthesized by 
solid-phase technique with a multiple peptide synthesizer on a p-benzyloxybenzyl 
alcohol resin using the fluoren-9-ylmethoxycarbonyl (Fmoc) strategy (Marin et 
al., 1994). In case of cyclic peptides, cyclization was achieved by oxidizing the 
two cysteines of the purified peptide (0.1 mg/ml) in 100mM NH4HCO3 buffer (pH 
8.2) for 72 hours. The formation of disulphide bridges and each peptide mass were 
verified by mass spectrometry analysis performed by Michele Sandre (University of 
Padova). 
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INTRODUCTION 
 
As largely presented in the Introduction of this thesis, CK2 has a central role in 
multiple pathways that support cancer, and it is generally overexpressed in cancer 
compared to the healthy cells. Therefore the development of selective CK2 
inhibitors has emerged as an attractive approach for the treatment of cancers. 
Indeed, a compound, CX-4945, has been recently developed by Cylene 
Pharmaceuticals and entered human clinical trials. 
CX-4945 is a potent and selective ATP-competitive CK2 inhibitor with a Mw of 
350 (chemical structure in Figure 1) (Pierre et al., 2011). It has shown the same 
inhibitory efficacy toward both isoforms of the CK2 catalytic subunits, CK2a and 
CK2a’, with IC50 values close to 1 nM (Siddiqui-Jain et al., 2010) (see Table 1). 
The crystal structure of CK2a in complex with CX-4945 has been solved, and 
reveals that there are two major polar interactions in the ATP pocket: one hydrogen 
bound to Val116 amide in the hinge region and the salt-bridge with Lys68 (Figure 
1). The removal of one of these interactions causes a dramatic decrease in the 
inhibitor affinity (Pierre et al., 2011).  
 
 
 
 
 
 
 
 
Table 1. IC50 determinations for CX-4945 against selected kinases from the 238-kinase selectivity 
panel (from Siddiqui-Jain et al., 2010). 
 
CX4945 is very specific for CK2: when it was tested at 0.5mM, a concentration 
500-fold greater than the IC50 for CK2a, on a panel of 238 kinases, only 7 of them 
were inhibited more than 90%.  
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Figure 1. Schematic representation of CX-4945 binding model in ATP pocket of CK2. Binding 
resulted from interactions with hydrophobic residues (not shown), a ionic bridge with positively 
charged Lys68, and hydrogen bonding with the hinge Val116 amide (from Pierre et al. 2011). 
 
CX-4945 has been also demonstrated to inhibit pro-survival and angiogenic 
signaling in cancer cell lines and it is active against a broad range of cancer cell 
types, including breast, lung, and prostate cancers, where CK2 is usually 
overexpressed (Siddiqui-Jain et al., 2010; Pierre et al., 2011). 
The molecular mechanism by which CX-4945 acts in cells is essentially represented 
by the inhibition of CK2. This in turn affects several signaling pathways where 
CK2 is involved, as demonstrated in different in cell studies. For example, its 
effects has been checked on PI3K/Akt signaling, cell cycle arrest, and induction of 
apoptosis (Siddiqui-Jain et al., 2010 and Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Schematic mode of action of CX-4945. CX-4945 inhibits the phosphorylation of PI3K/AKT 
and p21/p27 and transcriptional activation of HIF1α in the nucleus. These effects might influence 
cancer survival, angiogenesis, and pro inflammatory cytokine production (from Kim J. and S.H. 
Kim, 2012). 
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CX-4945 induces a reduced phosphorylation of Akt on Ser129, the direct CK2 
phosphorylation site on Akt kinase, and a subsequent reduction in the canonical 
regulatory sites of Akt (Thr308 and Ser473). In addition, in cells treated with CX-
4945, a decreased phosphorylation of the cell cycle inhibitor protein p21 at Thr145 
is observed, and G2/M or G1 cell cycle arrest occurs. In parallel, an apoptotic 
response with the induction of caspase-3/7 activity in CX-4945–treated cancer cells 
is observed. In different studies, CX-4945 was used to induce apoptosis not as a 
single agent, but in combination with other anti-tumor drugs, after showing 
interesting synergistic effects (Quotti-Tubi et al, 2013; Buontempo et al., 2013; 
Manni et al., 2013). 
After in vitro and in cells experiments, CX-4945 has been tested in murine 
xenograft models (Buontempo et al., 2013; Zheng et al., 2013; Siddiqui-Jain et al., 
2012). In these studies, CX-4945 exhibited dose-dependent antitumor activity with 
86% tumor growth inhibition at the highest dose level; it was well tolerated at all 
doses as indicated by minimal changes in body weight (Figure 3). CX-4945 has also 
been found to exert an anti-angiogenic activity (Siddiqui-Jain et al., 2010), as 
expected considering the demonstrated role of CK2 in angiogenesis and 
vascularization (Ljubimov et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Antitumor efficacy of CX-4945 delivered orally, twice-a-day in PC3 prostate cancer 
xenograft model (from Pierre et al., 2011.) 
 
The promising results obtained in animal studies concerning safety, 
pharmacokinetics, and efficacy studies have led to the current clinical evaluation of 
CX-4945 for the treatment of cancer. The human experimentation started with 
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Cylene Pharmaceuticals, on relapsed or refractory multiple myeloma, breast cancer, 
advanced solid tumors and Castleman's Disease (www.clinicaltrials.gov). 
Encouraging preliminary results were reported (Pierre et al., 2011) and the 
compound successfully reached the end of phase I of clinical trials. At present, 
Cylene Pharmaceuticals is no more active, and CX-4945 experimentation has been 
transferred to a new company Senhwa Biosciences (www.senhwabiosciences.com). 
Another molecule belonging to the class of ATP-competitive inhibitors of CK2 the 
CX-4945 analog CX-5011, is very potent (IC50 for CK2a of 2.3 nM) and selective 
(Battistutta, et al., 2011). It has also been used in cellular assays, such as prostate 
cancer cells, where it is able to decrease endogenous CK2 activity (Pierre et al., 
2011). Studies in mouse model of formalin-induced pain have demonstrated that 
this compound induces a dose-dependent reduction of pain and its possible anti-
inflammatory action has been suggested (Pierre et al., 2011).  
The development of CX-4945 and its advancement into clinical trials has allowed, 
for the first time, the therapeutic targeting of CK2 with an ATP-competitive 
inhibitor for the treatment of cancer. However, this promising compound has never 
been tested in apoptosis-resistant cells. My research in this field has been prompted 
by this observation, as presented in the following paragraphs. 
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AIM OF THE STUDY 
 
CK2 is deeply connected to the resistance to apoptosis, and evidences of its 
intervention in the MDR phenomenon have already been reported (Di Maira et al., 
2007); moreover, several inhibitors have been proposed as a useful tool to 
overcome drug resistance (Di Maira et al., 2007). However, no study has been 
performed in drug-resistance cells with the only one CK2 inhibitor already in 
clinical trials, CX-4945. This part of the work was performed to assess if CX-4945 
and its analog CX-5011 are able to induce apoptosis in drug-resistant cells. We 
therefore exploited different cell lines available in the apoptosis normally sensitive 
form (S) and in a variant resistant to apoptosis (R). In this pairs of cell lines, we 
analyzed if CX-4945 and CX-5011 are able to induce a reduction of CK2 
endogenous activity, and if concomitantly cell viability is affected by apoptosis 
induction. Moreover, we wanted to assess if CX-4945 is able to increase the amount 
of drug retained inside in cells overexpressing an efflux pump, such as P-gp, which 
extrudes drugs outside from the cell, and if a consequent sensitization to the drug 
occurs. For this purpose we planned experiments of combined treatment with CX 
and conventional anti-tumor drugs.  
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RESULTS 
 
For this study, several cancer cell lines have been exploited, available in the 
apoptosis sensitive (S) and resistant (R) variants. In particular we used: CEM 
(human T lymphoblastoid cells, S and the MDR variant R), U2OS (human 
osteosarcoma cells, S and the MDR variant R), 2008 (human ovarian carcinoma 
cells, S and R, resistant to cisplatin), and three pairs of chronic myeloid leukemia 
cells (CML), LAMA84, KCL22 and K562, whose R variants are resistant to 
imatinib. As reported in the Figure 4 A, R-CEM and R-U2OS cells express P-gp 
pump and are therefore considered MDR (multi-drug resistant) lines, while the R 
variant of 2008 cells and CML cells do not express Pg-P and are resistant toward 
specific drugs, CisPt in the case of R-2008, and imatinib in the case of CML; their 
resistance mechanisms are still largely unknown. CML is related to the expression 
of the chimeric fusion protein Bcr-Abl, which represents a hyperactive state of the 
Abl tyrosin kinase. Bcr-Abl is the target of imatinib, the first-choice drug for this 
pathology, and resistance to imatinib is sometimes due to Bcr-Abl mutations.  
However, in the CML cell lines used in this work, no mutation are reported in Bcr-
Abl; while in the case of R-LAMA84, the fusion protein is overexpressed compared 
to S-LAMA84 (Figure 4 B). 
 
 
 
 
 
 
 
 
Figure 4. P-gp and Bcr-Abl expression. A.10 mg of proteins from total lysates of the indicated cells 
were loaded onto an SDS-PAGE, blotted and analyzed by WB with anti-P-gp or anti-b actin (from 
Zanin et al. 2012). B. 30 mg of proteins from total lysates of the indicated cells were loaded onto an 
SDS-PAGE, blotted and analyzed by WB with anti-Bcr-Abl (from Borgo at al., 2013). 
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EFFECTS OF CX-4945 AND CX-5011 ON CK2 ACTIVITY IN S 
AND R CELLS  
To verify that CX compounds are able to inhibit CK2 both in sensitive cells and 
resistant counterparts, we firstly measured CK2 activity in cells treated with 
increasing concentrations of CX-4945 and CX-5011 for different times. To this 
purpose we exploited in vitro assays of endogenous CK2 present in total lysates and 
western blot analysis of specific phosphorylation sites of CK2 substrates.                            
The in vitro assays were performed by testing the activity of endogenous CK2 
present in total lysates, measured towards a CK2 specific synthetic peptide: as 
shown in Figure 5 cell treatment with CX-4945 promptly inhibit CK2 in S and R 
cells, with similar efficacy, without affecting CK2 amount (Figure 6). For the 
evaluation of the phosphorylation state of CK2 intracellular substrates, phospho-
specific antibodies were used directed to Ser129 of Akt and Ser13 of the co-
chaperone protein Cdc37, which are two known key targets of CK2. In all cases, 
CK2 activity toward peptide is reduced more than 50% at submicromolar 
concentrations of CX-4945, and this data correlates with the reduction of phospho-
Ser129Akt and phosphor-Ser13Cdc37. As shown in Figure 5 CK2 activity is almost 
totally reduced after only 6 h treatment with CX-4945, indicating that these 
compounds acts very rapidly on CK2; longer treatment times produce only a 
minimal increase of the inhibition degree. Interestingly, a marked 
dephosphorylation of Ser129Akt occurs after 6 h treatment at very low 
concentrations (0.5mM CX-4945), while a slower reduction of phosphorylation on 
Cdc37 Sp13 is observed, indicating that this CK2 site is more resistant to 
dephosphoryation, which is clear appreciable only after higher concentrations and 
longer times. It is worth to note that, as evident in Figure 6 and previously reported 
(Di Maira et al., 2007) CK2 amount significantly differs in S and R CEM cell. 
Consequently, the level of phosphorylation of the analyzed sites Ser129Akt and 
Ser13Cdc37 in untreated cells are higher in R than in S cell, especially considering 
that the amount of both proteins is instead higher in S cells. 
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Figure 5. CK2 activity in CX-4945-treated cells. CK2 activity was measured towards a synthetic 
specific peptide. 1–2 mg of proteins from total lysates of the indicated cells were incubated with the 
peptide and a radioactive phosphorylation mixture (see Materials and Methods). Activity is reported 
as percentage of that found in vehicle-treated control cells. Mean ±  SE values of four independent 
experiments are shown (from Zanin et al., 2012). 
 
 
 
 
83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  6. CK2 activity in CX-4945-treated cells. 10 µg of total proteins were analyzed with the 
indicated antibodies; actin was used to normalize the loading. Representative WB of three 
independent experiments are shown (from Zanin et al., 2012). 
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Similar data are observable in total lysates from cells treated with increasing 
concentration of CX-5011 and for different times (not shown and Figure 7 for 24h 
treatment in CEM cells).  
 
 
 
 
 
 
 
Figure 7. CK2 activity in CX-5011-treated cells. S-CEM and R-CEM cells were treated for 24 h 
with different concentrations of CX-5011. Cell lysates were analyzed for the activity of CK2 towards 
a synthetic specific peptide (on the left), or by WB with the indicated antibodies (on the right, 
separate development for S- and R-CEM cells). See details in the legend of Figure 5 (from Zanin et 
al., 2012). 
 
To further confirm CK2 inhibition, we analyzed the radioactive phosphorylation of 
endogenous proteins from total lysates derived from cell treated with CX-4945 or 
CX-5011 or vehicle. As Figure 8 shows, the phosphorylation level of some protein 
bands is lower in treated than in untreated cells. The effect is already evident when 
cells were treated with 1mM CX-4945 and CX-5011, which almost totally reduces 
the radioactivity incorporated in several bands, similar to what observed when the 
compounds are added in vitro. Even with this approach, we observed a very similar 
inhibition by CX4945 and CX-5011 in S and R cells. To exclude a non-specific 
effect, cells were treated with staurosporine at concentrations that inhibit the 
majority of protein kinases but no CK2 (Meggio et al., 1995). Staurosporine, at the 
concentration used (1mM), induces a degree of cell death similarly to that observed 
with CX inhibitors (not shown), but is uneffective on endogenous protein 
phosphorylation. This confirms the specificity of CX-4945 and CX-5011 on CK2, 
and indicates that under the used conditions, CK2 is the major kinase responsible 
for the observed phosphorylated bands, as expected for such a pleiotropic and 
constitutively active enzyme.  
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Figure 8. Protein phosphorylation in lysates from cells treated with CX-4945, CX-5011, or 
staurosporine. S-CEM (upper panel) or R-CEM (lower panel) were treated with the indicated 
concentrations of the CX inhibitors or staurosporine for 16 h, and then lysed. 5mg of total proteins 
were incubated with a radioactive phosphorylation mixture, resolved by SDS-PAGE plus blotting, 
and analyzed by digital autoradiography and WB for actin, as loading control. Asterisk * denotes 
samples where the inhibitors were added in vitro during the phosphorylation assay. Representative 
results of five independent experiments are shown (from Zanin et al., 2012). 
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EFFECTS OF CX-4945 AND CX-5011 ON CELL VIABILITY IN 
S AND R CELLS  
Then we moved to verify if CK2 inhibition by CX compounds induces cell death, as 
expected whenever this anti-apoptotic and pro-survival kinase is inhibited. For this 
purpose, we treated cells with increasing concentrations of CX-4945 and CX-5011 
for 24 or 48 hours and we evaluated cell viability by the MTT method.  
In Figure 9, 10, 11 and 12 some of the most representative results are reported, 
obtained under different experimental conditions and treatments times. We found 
that the U2OS and 2008 cell R variants show a very similar response to CX-4945 
than the corresponding S variants (Figure 9 and 10). In the case of CEM cells, the R 
variant shows a slightly lower sensitivity to CX-4945 when the treatment were 
performed in the presence of only 1% (v/v) fetal calf serum (FCS) (Figure 11). 
However the effect is quite similar if cells are treated in the presence of a higher 
(10%) FCS concentration (Figure 11, lower panel). Also in the case of CX-5011 a 
similar effect on cell viability is observed in sensitive and resistant cells. An 
immediate outcome of these results, and in particular of those obtained with R-
CEM and S-U2OS that express high level of the P-gp pump, is that both CK2 
inhibitors are not P-gp substrates and can be used to induce cell death also in MDR 
cells. Figure 12 instead shows the effects of CX-4945 and CX-5011 on the viability 
of three CML S and R cell lines. All the R variants of these cells are resistant to 
imatinib (the well-known Bcr-Abl inhibitor used for CML treatment), although for 
different and only partially understood reasons. In all cases, we found that the CX 
inhibitors induce cell death in R cells to a very similar or even higher degree than in 
S cells. This finding has suggested the usage of CX inhibitors to sensitize these 
resistant cells to the effect of imatinib, as it was later successfully demonstrated 
(Borgo et al., 2013). All the results on cell viability of the different lines analyzed 
are summarized in Table 2, where the DC50 (concentration required to induce 50% 
cell death respect to vehicle-treated cells) are reported. All values have been 
calculated from the results obtained at 48 h, shown in Figure 9, 10, and 12, excpect 
the values reported for CEM cells in the presence of 10% FCS, that are obtained by 
the 24h-treatment experiment (Figure 11). It is evident that in all cases the DC50 
values are very similar in the R variant compared to the respective S counterpart. As 
anticipated, R-CEM, which seem less sensitive than S-CEM when 1% of FCS is 
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present, respond instead very well in the presence of 10% FCS. The reason of this 
result is presently unknown (see Discussion).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Cell viability of CX-4945 and CX-5011 treated U2OS cells. Cells were incubated with 
increasing concentrations of the CX compounds; the FCS concentration in the medium and the 
treatment time are indicated on each graph. Cell viability was assessed by the MTT method, 
assigning 100% value to the vehicle-treated control cells. Mean ± SE values of at least four 
independent experiments are reported (from Zanin et al., 2012). 
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Figure 10. Cell viability of CX-4945 and CX-5011 treated 2008 cells. See legend of Figure 9 for 
details (from Zanin et al., 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Cell viability of CX-4945 and CX-5011 treated CEM cells. See legend of Figure 9 for 
details (from Zanin et al., 2012). 
CX-5011 CX-4945
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Figure 12. Cell viability of CX-4945 and CX-5011 treated Imatinib-resistant cells. See legend of 
Figure 9 for details (from Zanin et al., 2012). 
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Table 2.  DC50 of CX-4945 and CX-5011. The values, calculated from 48 h MTT assays reported in 
Figures 9, 10, 11 and 12 (except for CEM* = 24 h treatment), are the mean of 4–6 independent 
experiments ±  Standard Deviation. FCS concentration (v/v) during the treatment is also indicated. 
 
APOPTOSIS OCCURES IN CELLS TREATED WITH CX-4945 
AND CX-5011 
The next step was to check if cell death induced by CX-4945 and CX-5011 in 
different cell lines was due to apoptosis. To this purpose we used two approaches: 
the evaluation of nucleosomes formation in the cell cytosol of treated cell 
(measured by a commercial kit), and the analysis of the caspase-dependent cleavage 
of PARP (detected by WB of total cell lysates). Figure 13 A shows that in CEM 
cells apoptosis-dependent release of nucleosome in the cytosol occurs in response to 
the treatment, in a dose-dependent manner, and with a similar efficacy in S and R 
cells. The results were confirmed by the finding of PARP cleavage, as shown in 
Figure 13 B also for U2OS cells, indicating that caspase activation has been caused. 
Similar results were obtained in all the cell lines analyzed (data not shown). 
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Figure 13. Apoptosis induction by CX-4945 and CX-5011. A. Apoptosis was assessed by evaluation 
of nucleosomes present in the cytosol, using the Cell Detection Elisa kit (Roche), after 8 h of CEM 
cell treatment as indicated. Nucleosome enrichment was calculated from the ratio between the signal 
in treated and untreated cells; reported values are the means ± SE of four independent experiments. 
B. Caspase-dependent PARP cleavage was analyzed by WB on 10 µg proteins of lysate from CEM 
or U2OS cells treated as indicated. Actin WB was used as loading control. Representatives WB of 
three independent experiments are shown. f.l. PARP: full length PARP (from Zanin et al., 2012). 
A 
B 
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EFFECTS ON CEM CELL VIABILITY OF COMBINED 
TREATMENT WITH VINBLASTINE AND CX-4945  
Since we have demonstrated that CX-4945 is not recognized by the P-gp pump, and 
considering that P-gp has been previously demonstrated to be regulated by CK2 
(Glavy et al., 1997; Di Maira et al., 2007), we then tested if CX-4945 is also able to 
sensitize MDR cells to other conventional chemotherapeutic drugs. We focused on 
R-CEM cells (a line selected for the resistance to vinblastine (Di Maira et al., 
2007)) and performed combined treatments with vinblastine and CX-4945, looking 
for a synergistic effect in inducing cell death. As shown in Figure 13 the effect of 
vinblastine is significantly higher if it is administered in combination with CX-4945 
even at very low concentration; it can be calculated that DC50 for vinblastine 
changes from 39.4 to 6.2 mg/ml. We calculated also the combination index (CI), a 
parameter which gives information on the possibility that two compounds exert a 
synergistic, additive or antagonistic effect, assuming values of <1, =1 or >1, 
respectively (Giovannetti et al., 2004). We found that CI for CX-4945 plus 
vinblastine in R-CEM is indeed 0.66±0.04 confirming a synergistic effect. 
Curiously, a synergistic effect occurs also in S-CEM occurs when Vbl and CX-4945 
are administered together, with a CI = 0.70±0.08 (Figure 13, upper panel). The 
reason of this synergism is not obvious (see Discussion), since S-CEM cells do not 
express significative level of P-gp (see Figure 4), but in any case confirm that the 
simultaneous administration of the CK2 inhibitors in combining treatment can be 
applied to significantly reduce the lower doses of conventional drugs. 
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Figure 13. Effect of combined treatment with CX compounds and chemotherapeutic drugs. S-
CEM and R-CEM viability was assessed by the MTT method after 24 h treatment with increasing 
concentrations of both CX-4945 and Vbl, administrated alone or in combination, at fixed ratio (1 
µM CX-4945 : 0.8 µg/ml Vbl for S-CEM, 1 µM CX-4945 : 2 µg/ml Vbl for R-CEM, due to their 
different sensitivity to Vbl). Viability (mean values ± SE of four experiments) was plotted as function 
of Vbl concentrations (left panels), or CX-4945 concentrations (right panels) (from Zanin et al., 
2012). 
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EFFECTS OF CX-4945 ON THE ACCUMULATION OF 
CHEMOTHERAPEUTIC DRUGS INSIDE RESISTANT CELLS 
The synergistic effect observed in experiments of combined treatment with CX-
4945 and vinblastine prompted us to check whether conventional drugs accumulate 
more abundantly inside resistant cells after CX-4945 treatment. To this purpose we 
exploited the fluorescence of doxorubicin and measured its uptake in CEM cells 
pre-treated with CX-4945, compared to untreated cells (Figure 14). We found that 
CK2 inhibitor markedly increases the amount of drug retained inside R-CEM cells 
in a dose dependent manner, while in S-CEM this effect is not observed. 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Effect of CX-4945 on doxorubicin accumulation. CEM cells were preincubated for 30 
min with vehicle (Contr) or CX-4945 at the indicated concentrations, then further incubated for 30 
min with 25 µM doxorubicin, whose amount, detected fluorimetrically as described in Materials and 
Methods, is reported as percentage of the value found in control S-CEM (mean ± SE of three 
independent experiments) (from Zanin et al., 2012). 
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EFFECT OF COMBINED TREATMENT WITH CX-4945 AND 
CX-5011 
Curiously, we found a synergistic effect between the two CX-compounds when 
simultaneously administered. As shown in Figure 15, the effect on cell viability of 
combining CX-4945 and CX-5011 concentration is higher than that observed with 
the individual inhibitors in CEM and U2OS cells, both S and R variants. 
Interestingly, when we performed the same combined treatments with CX 
compounds in non-tumor cell lines, such as 293T (human embryonic kidney cells) 
and CCD34LU (human neonatal lung fibroblasts) we did not observed any 
synergistic effect (Figure 15, right panel). We therefore hypothesized that the 
synergistic combination is a peculiarity of the cancer cells; conjectures can be done 
about the possibility of the two compounds have different and complementary side 
effects, or inhibit different CK2 pool, such as those located in specific subcellular 
compartments (see Discussion).  
 
Figure 15.  Effect of combined treatment with CX-4945 and CX-5011. Cell viability was assessed 
by the MTT method after treatment of the indicated cell lines with CX-4945, CX-5011 or both 
(CX+CX), as indicated (in blue sensitive tumor cells, in orange resistant tumor cells, in yellow non 
tumor cells). Mean ± SE values of at least three independent experiments are reported. 
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DISCUSSION 
As widely presented in the general Introduction of this thesis, CK2 overexpression 
in cancer cells is important in tumorigenesis, and we have previously hypothesized 
that a high level of CK2 ensure a survival advantage under the pressure represented 
by treatment with pro-apoptotic drugs (Ruzzene at al., 2011). CK2 is thus expected 
to play a major role in the apoptosis resistant phenotype, as also suggested by 
previous studies (Di Maira et al., 2007; Di Maira et al., 2008). Here we focused on 
CX-4945 (the first ATP-competitve CK2 inhibitor that has entered clinical trials) 
and on its analog CX-5011 since there were no previous evidences of their efficacy 
in apoptosis resistant cells. 
In this work we demonstrate that the CX inhibitors are able to overcome apoptosis 
resistance, since they show similar efficacy in resistant cells (R) and their normally 
sensitive counterparts (S), in a panel of cell lines displaying different mechanism of 
apoptosis-resistance: R-2008 cells are resistant to cisplatinum; R-LAMA84, R-
KCL22 and R-K562 are resistant to imatinib, while R-CEM and R-U2OS are MDR 
cells, expressing the P-gp pump.  
The first outcome of our data is that CK2 inhibition by CX compounds has a 
general effect on resistant cells, by reducing the efficacy of cellular equipment to 
escape apoptosis. Secondly, we can also conclude that these inhibitors are not 
recognized by the Pgp, since their effects are detectable in cells expressing this 
MDR pump.  
In the case of CEM cells we observed that CX compounds are slightly less effective 
in the MDR resistant than in the sensitive lines. However, the differences between 
the two variants are detectable on cell viability and not on endogenous CK2 
inhibition which is very similar in S and R-CEM (see Figure 5). Moreover the 
difference on cell viability is abrogated when assays are performed in the presence 
of 10% instead of 1% FCS (Figure 11). Although we do not know the exact reason 
of the results observed at different concentration of FCS used during treatments, our 
interpretation is that, at quite critical conditions (such as 1% FCS), the antiapoptotic 
machinery of R-CEM is more effective than that of S-CEM in protecting cells from 
the stress represented by CK2 inhibition; on the contrary, if cells are maintained in 
healthy conditions (10% FCS), the two cell variants are equally equipped to 
counteract apoptosis. In any case, these findings suggest that any observed 
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difference is not due to extrusion of the inhibitors by the P-gp, as also confirmed by 
the results obtained with other Pgp-expressing cells (compare S-U2OS and R-
U2OS, Figure 9). As far as U2OS cells is concerned, CX compounds, especially 
CX-5011, seem to be less effective on this type of cancer cells than with the other 
cell lines (compare Figure 9 with Figures 10, 11 and 12); at the moment we have no 
explanations, however they are not related to the MDR phenomenon, being the 
response very similar in the S and R variants of this cell line. 
Another observation from our results is that the CX compounds efficacy is 
independent of the level of CK2 expression. In fact previous data obtained in our 
laboratory demonstrated that R-CEM display a higher level of the CK2 catalytic 
subunit compared to S-CEM (Di Maira et al., 2007) and this is also confirmed by 
the results shown in Figure 6, where we can appreciate that the phosphorylation 
state of CK2-dependent sites (particularly of Ser129 Akt) in R-CEM is higher than 
in S-CEM. Interestingly, despite the different endogenous CK2 activity, the degree 
of inhibition induced by CX-4945 and CX-5011 is very similar in S- and R-CEM 
cells (Figure 5).  
While our results obviously confirmed that CK2 inhibition leads to apoptosis, an 
interesting observation emerging from these data is that cell death is appreciable 
only when the degree of CK2 inhibition induced by the CX compounds is 
sufficiently high to ensure the dephosphorylation of major substrates. In fact we 
found that, while the endogenous CK2 activity towards the specific peptide 
substrate is already reduced more than 50% in cell treated with 0.5 mM inhibitors 
(see for example 24 h treatment in CEM cells, Figure 5), significantly higher 
concentrations are required to induce 50% of cell death (see Figure 10). If we 
considere the phosphorylation state of endogenous CK2 substrates analyzed by 
phospho-specific antibodies, we notice that while Ser129 Akt is promptly reduced, 
Cdc37 Sp13 phosphorylation is much more stable. This observation may be ideally 
extended to the multitude of CK2 substrates, imaging that each one has its own 
susceptibility to CK2 inhibition that will mainly depend on the turnover of its 
phosphorylation state; since this is obviously the result of the balance between 
kinase and phosphatase activity, there will be variability depending on cell type and 
conditions. We therefore presume that the dephosphorylation of one or few specific 
CK2 substrates is required before cell death occurs, or, alternatively, that only when 
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a massive dephosphorylation of all CK2 substrates occurs, cell death is observed, 
whose degree, therefore, does not necessarily correlate with the decrease of CK2 
catalytic activity.  
Another important result from our data has demonstrated that CX-4945 is able to 
sensitize resistant cells to conventional chemotherapeutic drugs. It has already been 
reported that CX-4945 augments the anti-tumor efficacy of gemcitabine and 
cisplatin on ovarian cancers (Siddiqui-Jain et al., 2012). Additionally, CX-4945 
appears to enhance the efficacy of inhibitors which disrupt BCR-mediated signaling 
pathways as well as fludarabine in primary CLL cells (Prins et al., 2013). It is also 
reported that the combination between CX-4945 and erlotinib (Bliesath et al., 
2012), an EGF-receptor inhibitor, produce cell death by reducing PI3K-Akt-mTOR 
pathway, with the final complete abrogation of Akt phosphorylation. Moreover, a 
parallel study conducted in our laboratory (Borgo et al., 2013) has disclosed a 
synergistic effect between imatinib (the first choice drug for CML patients) and 
CX-4945 in imatinib-resistant cell lines. Our data extend the drug-combination 
experiments to MDR cells, showing that R-CEM are six fold more sensitive to Vbl 
when simultaneously treated with sub-lethal doses of CX-4945, compared to cells 
treated with Vbl alone. Interestingly, we also observed accumulation of doxorubicin 
in R-CEM (Figure 14), after treatment with CX-4945; this effect is probably due to 
the positive effect that the blockage of CK2 exerts on P-gp. As expected, the drug 
accumulation is unaffected by CX-4945 in S-CEM, not expressing P-gp. However, 
the synergistic effect between CX-4945 and the conventional anticancer drug is 
instead observable also in S-CEM (Figure 13), suggesting that additional 
mechanisms of increased cell death, other than the effect on the P-gp pump, are 
induced by the combined treatment.  
Surprisingly we found a synergistic effect between CX-4945 and CX-5011; this was 
observed when the two compounds were simultaneously administered to both S and 
R cells, but was not evident in non-tumor cells (Figure 15). At the moment we have 
no explanation for these results but different speculations can be done. The first 
obvious hypothesis is that, despite their high specificity (Battistutta et al., 2011), the 
two compounds hit different and complementary kinases, beside CK2. If these 
alternative targets are typical and/or expressed only in cancer cells, this would 
account for the tumor specific effect that we observed. Another possibility is that 
the two CX compounds, due to their differences in structure, are able to reach 
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different subcellular localization; in this case, the combined treatment would target 
additional pools of CK2, for a more complete inhibition than in the case of 
individual administration. However, preliminary experiments of cell fractionation 
have shown that CK2 localizes in different cell compartments, is similarly inhibited 
by CX-4945 and CX-5011 (not shown), although more experiments will be required 
to completely exclude this hypothesis. At present, we can only suggest that, 
independently of its reason, the combined treatment with CX-4945 and CX-5011 is 
an additional strategy that can be considered.  
In summary, our results show that CX-4945 and CX-5011 are internalized in 
resistant cells, inhibit endogenous CK2, and, alone or in combination with other 
drugs, induce significant cell death, suggesting that they can be considered as a 
valid therapeutic strategy also in case of pharmacological resistance.  
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INTRODUCTION 
 
In order to obtain CK2 inhibitors as more specific as possible, it was decided to in silico 
develop (Dr. G. Cozza) a new class of compounds capable to inhibit CK2 by 
simultaneously bind to the ATP and peptide substrate sites. For this purpose, suitable 
modifications have been introduced on an ATP-competitive molecule. The chosen 
inhibitor was K137 (chemical formula in Table 1), whose structure is very similar to 
that of TBB, presenting, however a benzimidazole ring instead of TBB benzotriazole 
scaffold; the carbon atom at position 2 of K137 benzimidazole is functionalized with a 
diamino propyl chain, whose N-terminal is suitable for a peptide derivatization. K137, 
indeed, was derivatized by linking its amino terminal group to a short peptide chain 
composed by three or four aspartic/glutamic acids (Prof. G. Zagotto, Padova). Since 
CK2 is an acidophilic kinase, recognizing serine or threonine surrounded by acidic 
residues, the compounds designed should be capable to bind both CK2 substrate site 
thorough their acidic peptide sequence, and the ATP site through their tetrabromo-
benzimidazole portion. They are therefore called “bi-functional” or “bi-substrate” 
inhibitors. 
The compounds obtained are listed in Table 1. The in vitro analysis on recombinant 
CK2, demonstrates that the molecular design of bifunctional inhibitor was successful, 
being the introduction of the acidic chain very effective in reducing the IC50 for CK2, 
compared to K137 (Table 2, Dr. G. Cozza, University of Padova, personal 
communication). The most effective compound is K137-E4, which presents a tail of 
four glutamic acid residues. The inhibition curve of recombinant CK2, assayed towards 
a synthetic peptide substrate, is reported in Figure 1 in comparison with the parental 
compound K137: it is evident that K137-E4 (IC50=0.025mM) is about five-fold more 
efficient in inhibiting CK2 than K137 (IC50=0.13mM). Two other compounds listed in 
Table 1, denoted as K137-D4 and K137-E3, are able to inhibit CK2 with an efficacy 
higher than that of K137. Interestingly, the oligo-glutamic or aspartic moieties alone, 
lacking of the ATP-mimetic part, are inefficient in inhibiting CK2 up to 40mM, 
denoting a dramatic synergism between the two components of the bi-functional 
compounds (see Table 1). 
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Compound Formula 
IC50 for recombinant 
CK2 (μM) 
 
K137 
 
 
 
 
 
0.13 
 
K137-D3 
 
 
0.033 
 
K137-D4 
 
 
0.035 
 
K137-E4 
 
 
0.025 
 
AS-D3 
 
 
>40 
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AS-E4 
 
 
>40 
 
AS-D4 
 
 
>40 
 
Table 1. Chemical structure, name and IC50 of K137-E4 and other potential bifunctional CK2 
inhibitors (from Dr. G. Cozza). 
 
Once established that the bi-functional inhibitors are able of potently inhibiting CK2, 
the selectivity of the most promising one, K137-E4, was evaluated, by testing its effect 
at 1mM concentration on a panel of 140 kinases. The results obtained (not shown) 
suggest that K137-E4 is a very selective inhibitor of CK2, with the activity of most 
other kinases left unchanged; only one kinase, ERK8 was inhibited more than 70%. 
Interestingly, K137-E4 was found ineffective also towards those kinases which are 
inhibited by K137 such as HIPK2 and PIM kinase (Dr. G. Cozza, personal 
communication) (Table 2).  
 
Table 2. IC50 (µM) values of K137, bi-functional inhibitors and oligo-glutamyl or aspartyl moieties 
towards CK2 and other  kinases (from Dr.G.Cozza). 
Compound CK2 PLK2 CK1δ HIPK2 PIM1 Aurora-A 
K137 0.13 39 5.7 0.34 0.25 >40 
K137-D3 0.033 2.34 34 >40 >40 >40 
K137-D4 0.035 3.76 21 >40 >40 >40 
K137-E4 0.025 0.400 16 >40 >40 >40 
AS-D3 >40 >40 >40 >40 >40 >40 
AS-E4 >40 >40 >40 >40 >40 >40 
AS-D4 >40 >40 >40 >40 >40 >40 
106 
 
 
 
 
 
 
 
Figure 1. Inhibition curve of K137 and K137-E4 on the activity of recombinant CK2 holoenzyme 
measured against a CK2-specific synthetic peptide (from Dr. G. Cozza). Values ± SEM of three 
independents experiments are reported. 
 
In summary, this new approach to develop CK2 specific inhibitors resulted successful 
as judged from in vitro studies. However, no data were available for their employment 
in cells.  
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AIM OF THE STUDY 
 
In this work we focused on a the CK2 inhibitor K137-E4 belonging to the new class of 
CK2 inhibitors of the so called bi-functional inhibitors, able to bind to both the 
phosphate donor (ATP) site and the phosphate acceptor (protein) site of CK2. The 
compound was designed and developed in our laboratory with the final goal to obtain a 
highly potent and specific inhibitor of CK2. K137-E4 was indeed found to meet the 
expectations, but its inhibitory activity was assayed only toward recombinant CK2, 
using synthetic peptides as substrates. Therefore, the first aim of this work was to check 
whether K137-E4 is also able to inhibit native CK2 (not only the enzyme purified as a 
recombinant protein) and to reduce the phosphorylation state of cellular substrates, 
besides model peptides. Secondly, we wanted to verify if K137-E4 is cell-permeable 
and produces the effects expected when endocellular CK2 is blocked, apoptosis in 
particular. In case K137-E4 is not able to cross plasma membrane, an additional aim of 
this work is the investigation on its possible employment to CK2 ectokinase (CK2 
present at the external side of the cell) and on the cellular effects of this inhibition. 
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RESULTS 
  
EFFECTS OF K137-E4 ON THE ACTIVITY OF NATIVE CK2  
 
Since K137-E4 has been shown to be a potent inhibitor of recombinant CK2, we started 
to check if it has the same efficacy also toward cellular CK2, evaluating its activity on 
its cellular substrates. For this purpose, we exploited cellular lysates as source of 
endogenous CK2 and substrates, and we performed in vitro phosphorylation assays in 
the presence of increasing concentrations of K137-E4. For the analysis, we used also the 
canonical ATP-competitive CK2 inhibitors CX-4945 and K137; this compounds had 
been added as a control, in order to distinguish the CK2-dependent protein bands from 
all the phosphorylated proteins that can be separated by SDS-PAGE/blot and detected 
by autoradiography. As shown in Figure 2 K137-E4 induces a marked decrease in the 
phosphorylation state of a large number of protein bands, in a dose-dependent manner, 
and particularly above all at the highest concentration used (5mM). The same bands are 
also affected by other CK2 inhibitors and can be therefore considered as CK2 
substrates; they are highlighted by arrows in Figure 2. Interestingly, in accordance with 
the higher inhibition capacity of K137-E4 compared to K137 towards recombinant 
CK2, we also found a stronger effect of K137-E4 on endogenous CK2 as judged by the 
more marked reduction of band phosphorylation when K137-E4 is added (for example 
compared lane 4 and 7 of Figure 2 where 1mM K137-E4 and K137 were present, 
respectively). 
It can be concluded that the inhibition properties of K137-E4 observed in vitro toward 
recombinant CK2 can be extended to cellular CK2. However, it can be noted that the 
effective concentrations are higher in assays exploiting cellular extracts. As it will be 
discussed, this is expectable, due to the sequestration of the compounds by the huge 
amount of cellular components cellular components present in these kinds of assays. 
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Figure 2. Effects of K137-E4 on the CK2-dependent protein phosphorylation in cell lysates. 5 mg of 
proteins from total lysate (HepG2 cells), were incubated with a radioactive phosphorylation mixture (see 
“Methods” for details) and CX-4945, K137-E4 and K137 as indicated. Proteins were separated by SDS-
PAGE, blotted and analyzed by autoradiograph. CTL=control (cells where no inhibitor was added).WB 
towards b-actin was used as loading control. Arrows indicate protein bands whose phosphorylation is 
reduced by the well-known CK2 inhibitors CX-4945 and K137. Three different experiments were 
performed and a representative result is shown.  
 
 
EFFECTS OF K137-E4 ON CELL VIABILITY  
 
The next step of our work was to analyze the effects of K137-E4 on cell viability, as an 
indicator of its ability to inhibit CK2 inside the cell. For this purpose we performed 
MTT assay to verify if K137-E4 provokes cell death when administered in intact cells. 
We treated Jurkat cells (human leukemia T lymphocytes) for 24 h with increasing 
concentrations of K137-E4 and in parallel with the canonical CK2 inhibitors, CX4945 
and K137, as controls of cell death induced by CK2 inhibitors. As reported from the 
Figure 3, while CX4945 and K137 provoke a 50% of cell death at low concentrations 
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(lower than 5 mM), K137-E4 does not induce appreciable effects on cell viability. This 
result is the first indication that K137-E4 is not permeable to the plasma membrane and 
is not able to reach endocellular CK2. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Cell viability of Jurkat cells treated with K137-E4, K137 and CX-4945. Cells were incubated 
for 24 h with increasing concentrations of K137-E4, K137 and CX-4945. Cell viability was assessed by 
the MTT method, and is reported as % of viable cells compared to the vehicle-treated cells. Values ± 
SEM of three independents experiments are reported. 
 
To confirm this result, we performed WB analysis of total cell lysates from treated cells, 
and we analyzed the cleavage of PARP protein, known to occur in apoptotic cells. 
Figure 4 shows that, differently to CX-4945, which induces apoptosis (for a detailed 
description of CX-4945 cellular effects see Chapter 1 of Results), K137-E4 even at very 
high concentration has no effect on PARP protein. 
 
 
 
 
 
 
 
 
Figure 4. Analysis of apoptotic effects in  Jurkat cells treated with K137-E4 or CX-4945. Apoptosis was 
assesed  by PARP cleavage  analyzed by WB on 10mg lysate proteins from Jurkat cells treated with K137-
E4 100mM for 24 h. Treatments with CX-4945 2mM was performed as control of cell permeable CK2 
inhibitor. a-tubulin was used as loading control. Representatives WB of three independent experiments 
are shown. f.l. PARP: full length PARP. 
f.l. PARP 
a-tubulin 
cleaved PARP 
CX-4945 
K137-E4 - - + 
- + - 
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a-tubulin 
Akt Sp129 
Akt tot 
CX-4945  
K137-E4  - - + 
- + - 
 
EFFECTS OF K137-E4 ON CK2 ENDOCELLULAR ACTIVITY  
 
To be completely sure that the absence of effect of K137-E4 on cell viability was due to 
its incapacity to reach endocellular CK2, we analyzed the phosphorylation state of the 
CK2 intracellular substrates by WB of total lysates. In particular, we checked Sp129 of 
Akt (Di Maira et al., 2007) and Sp125 of B23 (Louvet et al., 2006) (not shown) and we 
found that their phosphorylation was not prevented by cell treatment with K137-E4 (as 
shown by CX-4945 treatments) (Figure 5). Similarly CK2 endogenous activity from cell 
lysates, measured towards a CK2 specific peptide, is not altered (not shown). 
 
 
 
 
 
 
 
 
 
 
Figure 5. CK2 activity in K137-E4 or CX-4945-treated cells. 10mg of total proteins from Jurkat cells 
treated with CX-4945 2mM or K137-E4 100mM for 24 h were analyzed with the indicated antibodies;a-
tubulin was used as loading control. Representative WB of three independent experiments are shown. 
 
 
EFFECTS OF A K137-E4 MODIFIED COMPOUND ON CELL 
VIABILITY 
 
Once we demonstrated that K137-E4 is not cell permeable, we thought that a chemical 
modification able to increase its hydrophobicity could enhance its capability to 
permeate through the plasma membrane. Our collaborating chemical synthesis group 
(Prof. G. Zagotto, Padova) produced a compound corresponding to K137-E4 with all 
carboxylic groups esterified by a methyl group; this compound was denoted as K137-
E4Me, whose structure is illustrated in Figure 6. 
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Figure 6. Chemical structure of K137-E4Me (from Dr.G.Cozza). 
We performed cell treatments in Jurkat cells with increasing concentration of the 
compound for 24 h and 48 h and cell viability was tested with the MTT method (Figure 
7). K137-E4Me used at a concentration of 100 mM, leads to about 40% of cell death in 
24 h and little more (50%) in 48 h. Moreover K137-E4Me has a significantly lower 
efficacy than K137 and CX-4945 (Figure 7). This could be due to a still very modest 
cell permeability, despite the chemical modification, or to a loss in efficacy towards 
CK2. To discriminate between the two hypothesis, in vitro kinase assays were 
performed with recombinant CK2 and a peptide substrate which showed that K137-
E4Me IC50 is 40-fold higher than that of K137-E4 (Dr. G. Cozza, personal 
communication). We therefore concluded that a different strategy needs to be applied, 
since the charged groups are essential for the binding to the CK2 substrate binding site 
(see Discussion). 
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Figure 7. Effects of K137-E4Me on cell viability. Jurkat cells were incubated for 24 h (upper panel) or 
48 h (lower panel) with increasing concentrations of K137-E4Me, K137-E4, K137 and CX-4945. Cell 
viability was assessed by the MTT method, and is reported as % of viable cells compared to the vehicle-
treated cells. Values ± SEM of three independents experiments are reported. 
 
EFFECTS OF K137-E4 ON CK2 ECTOKINASE 
As described above, K137-E4 needs to be optimized for its usage in cells. However, 
actually, it could be useful for studies concerning CK2 ectokinase activity. In fact, CK2 
can be exposed outside the plasma membrane of the cells (as described in the general 
24h 
48h 
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Introduction), even if its roles are only partially known. Despite other cell permeable 
inhibitors that could block both CK2 ectokinase activity and endocellular CK2 activity 
K137-E4 is a very specific and powerful tool that can be exploited to selectivity inhibit 
only CK2 ectokinase and analyze the consequent effects. 
Firstly, we analyzed the correct conditions to measure CK2 ectokinase activity in cell, 
performing phosphorylation kinase assays in several cell lines. We exploited non tumor 
cell (HEK-293T), and tumor cell (Jurkat and HeLa) lines. We measured CK2 ectokinase 
toward a CK2 specific peptide substrate at different times. The activity was measured 
on the cellular pellet and in the supernatant medium, after cell centrifugation. This was 
necessary to assess if contamination occurred from endocellular CK2 due to cell lysis. 
As reported in Figure 8, we found the conditions in which was detectable in intact cells 
and was instead very low in cell supernatant. Moreover, CK2 ectokinase activity was 
essentially due to the peptide phosphorylation (being the blanks without peptide very 
low), and it was roughly linear respect to the incubation times (Figure 8). We had 
therefore correct conditions to study the possible inhibition of CK2 ectokinase by K137-
E4, and its effect.  
The assays were initially performed on HeLa and HEK-293T, which both grow in 
adhesion on cell plate. Data obtained from these cell lines have shown a poor inhibitory 
effect of K137-E4 towards CK2 ectokinase (not shown). However, when the assays 
were repeated on HEK-293T keeping them in suspension, K137-E4 was found to exert 
a good inhibitory effect on the CK2, (Figure 9). The same study was then performed in 
Jurkat cells, which grow in suspension, and also in this case K137-E4 effectively 
inhibits CK2 ectokinase (Figure 9). We do not know the exact reason for the lack of 
effect of K137-E4 on adherent cells, although a reduced accessibility of the inhibitor 
can be speculated (see Discussion). However, from this studies performed on cells in 
suspension, we can concluded that K137-E4 inhibits CK2 ectokinase activity. 
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Figure 8. CK2 ectokinase activity in different cell lines. CK2 activity was measure in the presence (+) or 
in the absence (-) of the synthetic peptide CK2-tide (1mM) for the indicated times. Intact cells (as 
indicated), in isotonic buffer or supernatant, after 1000g cell centrifugation, were assayed. Cell 
preparation and conditions are detailed in the Methods section. Values ± SEM of four independents 
experiments are reported. 
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Figure 9. Effects of K137-E4 on CK2 ectokinase activity.CK2 activity towards the synthetic peptide CK-
tide (1mM) was measured in intact HEK-293T (left) and Jurkat (right) cells for 30 min at 37°C, under 
conditions described in the Methods section. K137-E4 was added at the indicated concentrations before 
the adding of  the radioactive mixture. CTL=control (cells incubated without the addiction of K137-E4). 
Values ± SEM of three independents experiments are reported. 
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DISCUSSION AND PERSPECTIVES 
In this study, we evaluated the possibility to use the CK2 inhibitor K137-E4 to inhibit 
cellular CK2.  This compound, belonging to the new class of bi-functional inhibitors of 
CK2, had been tested only towards recombinant CK2. Here we show that it is able to 
block also the activity of native CK2, measured in cell lysate towards endogenous 
protein substrates (Figure 2). A precise IC50 of its efficacy in these conditions has not 
been determined, however, from our results we can suppose that it is significantly 
higher than that found with recombinant CK2 (0.025mM). In fact, in Figure 2 it is 
evident that the phosphorylation of most CK2-dependent bands is significantly reduced 
only by 1 mM K137-E4. However, this is somehow expectable and often observed, 
since in this kind of assay a lot of lipophilic molecules and cellular structures are 
present which can trap/mask the inhibitor and reduce its effective concentration. Indeed, 
we can also do the same considerations for the canonical ATP-competitive inhibitor 
K137, whose effect in the experiment of Figure 2 is lower than that expected from its 
IC50 for recombinant CK2. We can therefore conclude that the efficacy of K137-E4 is 
higher than that of K137 both towards recombinant and native CK2.  
The approach described above exploited cellular CK2 and relative substrates, but it was 
performed in vitro, by adding K137-E4 during the phosphorylation assay. On the 
contrary, when we tried to perform treatments of intact cells with K137-E4, we did not 
observe any appreciable effect: both cell viability and CK2 activity were unchanged 
(Figure 3, 4 and 5), allowing us to suppose that the compound is unable to cross plasma 
membrane. This is not surprising, considering that the chain of four Glu present in 
K137-E4 confers a negative charge and a partial hydrophilic nature to the molecule. For 
this reason, we tried to improve its hydrophobicity by methylating all the carboxyl 
groups. The resulting compound, K137-E4Me, produced modest effects in cells (Figure 
7), most probably due to the loss of efficacy towards CK2 (not shown). Indeed, the 
structure of K137-E4 had been modeled to optimally fit to the peptide-binding site of 
CK2, which recognizes acidic residues in the vicinity of the target aminoacid. 
Therefore, a compound completely devoid of negative charges is unlikely to have high 
affinity for CK2. On this basis, future work will be necessary, to produce molecules still 
effective on CK2 but less charged than K137-E4. A possibility that we considered is a 
partial, instead of total, esterification of carboxyl group. Alternatively, different 
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techniques for cell delivery can be experimented, such as the conjugation of K137-E4 to 
the cell-penetrating HIV-derived Tat peptide (Holm et al., 2006). In any case, the final 
goal will be a cell-permeable molecule which inhibits CK2 not only powerfully but also 
with high selectivity, the first reason for which these kind of inhibitors is under 
investigation. 
At present, we have demonstrated that K137-E4 can be used as a not cell permeable 
inhibitor for studies related to CK2 ectokinase. In fact, this form of CK2 has been 
known for several years (Kubler et al., 1989); a few studies have been reported, and 
some of its substrates have been identified as well (Stepanova et al., 2002; Bohana-
Kashtan et al., 2005), but a precise role for a CK2 activity at the external side of the cell 
has not been determined yet. We reasoned that the employment of a classical inhibitor 
risks to fail in giving information, being able to enter cells and block also endocellular 
CK2 activity; in turn, the total absence of K137-E4 activity inside the cells can be 
particularly useful. We first found out the conditions for a reliable measurement of ecto-
CK2 activity in intact cells, then we determined that K137-E4 is able to significantly 
inhibit it, with more than 80% inhibition already at 1 mM (Figure 9). Surprisingly, we 
found that the inhibitory efficacy is much more evident if cells are kept in suspension, 
instead of adherent to the plates (not shown). We speculated that the surface reachable 
by the compound is probably higher in “round” suspended cells. We also tried to 
compared the efficacy of canonical ATP-competitive inhibitors in adhesion and in 
suspension cell cultures; however, their effects seem quite similar in the two conditions 
(not shown), suggesting that their entrance in cells makes negligible the availability of 
access surface. Future studies will be required to better understand this point. 
From our ecto-CK2 studies, we have some preliminary but interesting results; in 
particular, since we found that K137-E4 effectively inhibits ecto-CK2 (Figure 9) but 
does not induce any effect on cell viability (Figure 7), we can suggest that ecto-CK2, at 
variance with endo-CK2, is not required for cell survival. This should be related to ecto-
CK2 amount found in our cell models: the activity is well evident in tumor and non-
tumor cells, and no significant differences are appreciable, although a correct 
comparison, normalized to cell surface and/or obtained by comparing cells from the 
same kind of tissue, has not been done yet. Our feeling is that, while tumor cells rely on 
endocellular CK2 for their survival and indeed express a higher amount of it compared 
to their normal counterpart, the CK2 ectokinase activity is not related to cancer cell 
survival and is probably not more expressed than in normal cells. 
119 
 
 
 
 
 
 
 
 
 
 
PEPTIDES TARGETING  
CK2 SUBSTRATES:  
EFFECTS IN VITRO AND IN CELL 
 
 
 
 
 
 
 
 
 
 
 
120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
121 
 
INTRODUCTION 
Several approaches have been tested so far to directly inhibit protein kinase CK2, as 
largely described elsewhere in this thesis. However, some years ago, a research 
group from Havana introduced a new approach to target CK2, based on the 
development of a peptide interfering with the CK2 phosphorylation site on its 
substrates rather than hitting the enzyme per se (Perea et al., 2004). This peptide, 
formerly termed as P15, was originally identified by screening a random cyclic 
peptide phage library using the human papillomavirus (HPV-16) E7 acidic domain 
as target (Perea et al., 2004), and in fact in vitro experiments showed that P15 
peptide abrogated the phosphorylation of E7-GST protein by CK2 (Figure 1).  
 
 
 
 
 
 
 
Figure 1. CK2 acidic domain binders abrogate the phosphorylation of HPV-16 E7 in vitro. The 
recombinant HPV16 E7-GST was expressed and further purified on Glutathione Sepharose beads. 
Ten micrograms of HPV-16 E7-GST were preincubated 1 hour at 37°C with the selected peptide-
presenting phages. The gel was blue stained. Levels of the 32P-HPV16 E7-GST protein were 
normalized with respect to levels of the Coomassie-stained HPV-16 E7-GST (from Perea et al., 
2004). 
Later, the antitumor properties of the P15 peptide were examined; for this purpose 
modifications on the peptide were introduced. In particular, two cysteine residues 
were added at the C- and N-terminus to permit the formation of a sulfide bridge and 
generate a cyclic P15, expected to be more resistant to cellular protease action. 
Moreover, the cyclic P15 sequence was fused to the cell penetrating peptide Tat 
(48-60) (GRKKRRQRRRRPPQ) that has been extensively used for delivering 
peptide cargoes within cells (Wadia and Dowdy, 2005). Its effect of cargoes 
internalization is due to its aminoacidic composition; its positive charge, due to the 
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presence of arginine and lysine residues, allows the initial electrostatic interaction 
with polyanionic glycosaminoglycan present on the extracellular membrane 
(Ziegler and Seelig, 2004). Different mechanisms for Tat-cargoes internalization 
have been reported, such as clatrin-dependent endocytosis (Richard et al.,, 2005), 
caveolin-dependent endocytosis (Ferrari et al., 2003) or macropinocytosis (Kaplan 
et al., 2005). Once inside the cell, Tat peptide conveys its cargoes to the nucleus, 
where it translocates passing through nuclear pores (Hauber et al., 1989; Truant and 
Cullen, 1999).   
The structure of P15-Tat molecule, now known as CIGB-300 (Perea et al., 2008), is 
the following: 
                
GRKKRRQRRRPPQ-β-Ala-                           
 
 
Proteomic studies have also been performed and different set of proteins up- and 
down-regulated by the peptide have been found (Rodríguez-Ulloa et al., 2010). 
Moreover “pull-down” experiments were carried out to determine if the peptide was 
bound to CK2 substrates; among other target proteins, a predominance of the 
nucleophosmin/B23 was found. This is a nucleolar protein phosphorylated by CK2 
at Ser125; it has a chaperone activity, regulated by phosphorylation, according to 
the model proposed in (Szebeni et al., 2003) and illustrated in Figure 2. 
Interestingly, 13 structural ribosomal proteins from the small subunit and one from 
the large subunit were also identified as CIGB-300 targets (Perera et al., 2009).  
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Figure 2. A model for the plausible involvement of phosphorylation of B23 protein in its 
molecular chaperone activity. Under the macromolecular crowding conditions of the nucleolus 
proteins would have a tendency to form aggregates when partially unfolded. B23 protein could 
recognize and bind to an exposed surface of the protein and temporarily remove it from the 
aggregation pathway. Refolding of the substrate protein could be accomplished either in the 
complex or after its release. Phosphorylation of the complex by casein kinase II (abundant in the 
nucleolus) would reduce the affinity of B23 for a substrate and promote dissociation of the complex. 
After release of substrate, a phosphoprotein phosphatase (PPase) could dephosphorylate protein 
B23. The latter step would restore the affinity of B23 for partially unfolded substrates and allow it to 
participate in additional cycles of binding and release of substrates (from Szebeni et al., 2003). 
 
After preliminary in vitro studies, CIGB-300 was employed in cells and reported to 
induce apoptosis in different tumor lines (Perea et al., 2008). Moreover, it was 
applied in vivo and found effective in different cancer model. Intratumoral 
administration of CIGB-300 led to a significant reduction or complete inhibition of 
tumor growth in murine xenografts models, compared with the groups treated both 
with PBS and with a negative control peptide (Figure 3). Interestingly, the 
differences between CIGB-300 and the control groups were maintained after 
cessation of treatment and until the end of the analysis (Perea et al., 2008). 
Moreover, systemic administrations of CIGB-300 in xenograft mice also inhibited 
the tumor growth (Perera et al., 2008). Finally, to investigate the safety and 
tolerability of the CIGB-300 a clinical trial has started: the compound is so far 
reported to be safe, well tolerated and able to produce signs of clinical benefit, with 
a significant lesion reduction in 19.3% of the cases (Perera et al., 2008; Solares et 
al., 2009).  
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Figure 3. Systemic administration of CIGB-300 in cancer models. Different doses of CIGB-300 or 
PBS vehicle were systemically administered during 5 consecutive days (represented by arrows) (a) 
and (c) represent the mean of tumor mass volume and the respective standard error from the murine 
TC-1/C57/BL6 and human NCI-H125/nude mice tumor models respectively (from Perera et al., 
2008). 
Regarding the molecular mechanism of CIGB-300 action, based on what reported 
by Perea and co-workers, it is known to impair the phosphorylation of CK2 
substrates, in particular of the nucleolar B23 protein. However, it is no clear if it is 
also a direct CK2 inhibitor, as frequently defined, and if it interacts with CK2 
producing a global impairment of its catalytic activity. To investigate this point and 
to try to understand if CK2 is involved or even directly responsible of the cell death 
observed in CIGB-300 treated cells, in this work we used a new synthetized 
peptide, provide by Prof. O. Marin (Padova), denoted CRIBI-300. Its functional 
domain P15 is identical to the original peptide but a slightly different amino-acidic 
sequence in the Tat peptide is present; moreover, Tat is fused at the C-terminal of 
P15 in CRIBI-300, while in CIGB-300 it was at the N-terminal. The structure of 
CRIBI-300, compared to CIGB-300, and that of several other variants used in this 
study are reported in Table 1. 
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Table 1. Sequences of the CIGB-300 derived peptides used this study, as synthetized and kindly 
provided by Prof. O. Marin (Padova). In the first column, the conventional name used in this thesis 
is reported. Tat sequence in green, P15 in pink, while aminoacid variants are bold and underlined. 
*The sequence between the two cysteines is the scramble sequence used in (Perera et al., 2012). ** 
The sequence between the two cysteines is derived from Hemoglobin subunit Alpha 1[21-30]. 
***CRIBI-300 is conjugated to 5-6 carboxyfluorescein (FAM) and used for immunofluorescence 
assays. The right column denotes linear (L) or cyclic (C) peptides, referring to the P15 sequence. 
 
 
 
CIGB-300 GRKKRRQRRRPPQ-β-Ala-CWMSPRHLGTC C 
CRIBI-300 CWMSPRHLGTC-β-Ala-GYGRKKRRQRRRG-NH2 C 
CRIBI-300LIN CWMSPRHLGTC-β-Ala-GYGRKKRRQRRRG-NH2 L 
P15 CWMSPRHLGTC C 
TAT GYGRKKRRQRRRG-NH2 L 
CRIBI-300 
SCRAMBLE * 
CHPGSTWMRLC-β-Ala-GYGRKKRRQRRRG-NH2 C 
EMO-TAT ** CAGEYGAEALC-β-Ala-GYGRKKRRQRRRG-NH2 C 
CRIBI-300ALA  AWMSPRHLGTA-β-Ala-GYGRKKRRQRRRG-NH2 L 
CRIBI-300C1 AWMSPRHLGTC-β-Ala-GYGRKKRRQRRRG-NH2 L 
CRIBI-300C11 CWMSPRHLGTA-β-Ala-GYGRKKRRQRRRG-NH2 L 
CRIBI-300W CAMSPRHLGTC-β-Ala-GYGRKKRRQRRRG-NH2 L 
CRIBI-300S CWMAPRHLGTC-β-Ala-GYGRKKRRQRRRG-NH2 L 
CRIBI-300P CWMSARHLGTC-β-Ala-GYGRKKRRQRRRG-NH2 L 
CRIBI-300R CWMSPAHLGTC-β-Ala-GYGRKKRRQRRRG-NH2 L 
CRIBI-300L CWMSPRHAGTC-β-Ala-GYGRKKRRQRRRG-NH2 L 
CRIBI-300-FAM*** CWMSPRHLGTC-β-Ala-GYGRKKRRQRRRGK-FAM  C 
PENETRATIN RQIKIWFQNRRMKWKK-NH2 L 
CRIBI-300PEN CWMSPRHLGTC-β-Ala- RQIKIWFQNRRMKWKK-NH2 L 
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AIM OF THE STUDY 
In this study, we wanted to investigate at a molecular level the mechanism of action 
of the compound CIGB-300, recently included in clinical trials in humans. In fact, it 
is frequently reported as a CK2 inhibitor, but the rationale of its design was the 
targeting of CK2 substrate, and not of the kinase itself. Therefore we wanted to 
shed light on a possible direct effect of this compound on CK2 and to understand if 
CK2 is directly involved in mediating the effects in cells and in vivo. To this 
purpose, beside CIGB-300, we exploited a new synthetized CIGB-300 derived 
cyclic peptide, called CRIBI-300, and performed in vitro and in cell experiments, to 
analyzed the effects on CK2 and on different signaling pathways. We also aimed at 
identifying the specific aminoacidic position responsible of the CRIBI-300 activity. 
To this purpose, several single aminoacid modifications were introduced in the 
CRIBI-300 sequence; the resulting peptides were synthetized by Prof, Marin 
(Padova) and provided for the in vitro and in cell analysis. A list of the tested 
peptides and their sequences is presented in Table 1. 
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RESULTS 
CRIBI-300 EFFECTS ON RECOMBINANT CK2 ACTIVITY DEPENDS ON 
THE PEPTIDE SUBSTRATES USED 
To investigate if the CIGB-300 derived CRIBI-300 peptide directly inhibits CK2 
activity, we performed in vitro kinase assays with recombinant CK2 a2b2 in the 
presence of increasing concentrations of CRIBI-300. Two different CK2 peptides 
were used as substrates for the phosphorylation assay. One is the canonical CK2 
substrate peptide, designed on the basis of its consensus (Meggio et al., 1994), and 
here called “CK2-tide” (sequence: RRRADDSDDDDD ); the other  is a peptide 
derived from the CK2 substrate eiF2β (sequence: 
MSGDEMIFDPTMSKKKKKKKKP), here called “eiF2b-tide”, and has the 
peculiarity to be phosphorylated only by the tetrameric CK2 a2b2, and not by the 
monomeric a alone (Salvi et al., 2006). 
Interestingly, the effects of CRIBI-300 on CK2 activity are different with the two 
substrates exploited. In the case of CK2-tide no inhibition was observed: as reported 
in Figure 4, panel A, CK2 activity was unaffected up to 50 mM CRIBI-300. On the 
contrary, in the case of eiF2β-tide, CK2 activity is strongly impaired by CRIBI-300 
in a dose-dependent manner: at 0.5 mM CRIBI-300 we already observe a 40% 
reduction in CK2 activity, and more than 60% at 5mM (Figure 4, panel B). Very 
similar effects were induced by CIGB-300, the original peptide developed by Perea 
and coworkers (Perea et al., 2004) (Figure 4). Therefore, the position of the Tat 
sequence respect to P15 is not relevant, and hereafter we will use CRIBI-300 as our 
reference peptide. 
We also tested other CK2-specific peptide substrates, such as a REV-derived 
peptide (Marin et al., 2000) and a B23-derived peptide, but we did not find any 
significant effects (not shown). Therefore, the only case of CRIBI-300-induced 
inhibition was that of the peptide which strictly requires the presence of CK2 β for 
its phosphorylation. We wondered if the effects of CRIBI-300 on CK2 activity were 
due to the cyclic P15 functional domain or to the Tat sequence (see Table 1). 
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Figure 4. Effects of CRIBI-300 and CIGB-300 on CK2 activity towards peptide substrates. 40ng of 
recombinant CK2a2b2  were incubated at 30°C for 10 min with increasing concentration of CRIBI-
300 (red) and CIGB-300 (black), in the presence of a radioactive phosphorylation mixture and the 
specific CK2-tide substrate (0.1mM)(A) or the eiF2b-tide substrate (0.1mM) (B). Activity is reported 
as % of the control (CK2 incubated in the absence of CRIBI-300), corresponding to 100000±5000 
cpm  in the case of CK2-tide and 110000 ± 7000 cpm in the case of eiF2β-tide, respectively). Values 
± SEM of three independents experiments are reported. 
 
We therefore performed CK2 kinase assays with increasing concentration of P15 
peptide or Tat peptide. As shown in Figure 5 A, we found that they do not affect 
CK2 activity towards the CK2-tide, up to 50 mM, as observed for CRIBI-300. In the 
case of eiF2β-tide, P15 alone do not affect CK2 activity, while Tat peptide is 
slightly inhibitory, with only a 50% reduction of CK2 activity at 50mM (Figure 5 
B). Therefore, as also evident in Figure 5 B, we concluded that the entire CRIBI 
sequence, including P15 and Tat fragment, is necessary for the inhibition of CK2 
activity towards the eiF2β. We also tried the simultaneous addiction of the two 
separated P15 and Tat peptides during the eiF2β-peptide phosphorylation assay, but 
we did not find a synergistic effect compared to the individual additions (not 
shown). We then wondered if the CRIBI-300 effect was due to Tat peptide fused to 
any other cyclic sequence; for this reason, we analyzed the effect of a peptide in 
which Tat sequence has been fused to a completely aminoacidic sequence but with 
the same length of CRIBI-300. The effect of this compound, called EMO-Tat, is 
shown in Figure 5. It has no effect on CK2 activity toward CK2-tide, while the 
inhibition of eiF2β-tide phosphorylation is quite similar to that exerted by Tat alone. 
This suggests that the effects induced by CRIBI-300 are mostly to be attributed to 
the cyclic P15 peptide fused to Tat. We also checked if the Tat sequence can be 
A B 
129 
 
0 1 2 3 4 5
0
25
50
75
100
125
P15
TAT
CRIBI-300
EMO-TAT
[COMPOUND] (mM)
C
K
2
 A
C
T
IV
IT
Y
 O
N
 C
K
2
-T
ID
E
 (
%
 O
F
 C
O
N
T
R
O
L
)
0 10 20 30 40 50 60
0
25
50
75
100
125 P15
TAT
CRIBI-300
EMO-TAT
A
[COMPOUND] (mM)
C
K
2
 A
C
T
IV
IT
Y
 O
N
 C
K
2
-T
ID
E
p
e
p
ti
d
e
 (
%
 O
F
 C
O
N
T
R
O
L
)
substituted by a different peptide with the same cell-penetrating function. A 
compound was therefore synthetized, called CRIBI-300 PEN, composed of the P15 
portion fused to the penetrating sequence (Jones et al., 2005) (see Table 1). Its 
effects were very similar to those of CRIBI-300 (not shown), indicating that the 
sequence to be fused to P15 is not essentially that of Tat, and that probably a quite 
basic sequence is sufficient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
130 
 
0 1 2 3 4 5 6
0
25
50
75
100
125
P15
TAT
CRIBI-300
EMO-TAT
[COMPOUND] (mM)
C
K
2
 A
C
T
IV
IT
Y
 O
N
 e
iF
2
b
-T
ID
E
(%
 O
F
 C
O
N
T
R
O
L
)
0 10 20 30 40 50 60
0
25
50
75
100
125
P15
TAT
CRIBI-300
EMO-TAT
B
[COMPOUND] (mM)
C
K
2
 A
C
T
IV
IT
Y
 O
N
 e
iF
2
b
-T
ID
E
(%
 O
F
 C
O
N
T
R
O
L
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Effects of CRIBI-300 and derivatives on CK2 activity towards peptide substrates. 
Increasing concentrations of P15 (pink), Tat (green), EMO-Tat (blue) and CRIBI-300 (red) were 
used. For details and conditions, see Figure 4. 
 
We then wanted to identify which specific aminoacidic residues of P15 are essential 
for the activity of CRIBI-300. For this purpose we used a panel of sequence-
modified peptides which are listed in Table 1. Firstly we investigated the effects of 
CRIBI-300-ALA, where the two cysteines necessary for P15 cyclization have been 
substituted by two alanines. As shown in Figure 6, it induces much more modest 
effects on eiF2β phosphorylation than CRIBI-300, with only 50% CK2 activity 
reduction at 50 mM. Interestingly, this was not due to the absence of cyclization 
since the compound CRIBI-300 LIN, whose P15 sequence was left unchanged, but 
not induced to cyclization, had more pronounced effects than CRIBI-300 (Figure 7). 
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Moreover, we found that Cys or Trp substitutions on this linear peptide were not 
detrimental for its effect (Figure 7). Its effects are very similar to that observed in 
the case of CRIBI-300. We than investigated the effects of another compound,  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Effects of CRIBI-300 and CRIBI-300 ALA on CK2 activity towards eiF2β substrates. 
Increasing concentrations of CRIBI-300 ALA (yellow) and CRIBI-300 (i red) were used. For details 
and conditions, see Figure 4. 
Surprisingly, when we tested a CRIBI-300 derived peptide containing a P15-
scrambled sequence, where the aminoacidic composition was left unchanged but the 
sequence was completely shuffled, we found a still potent inhibition of eiF2β-tide 
phosphorylation by CK2 (Figure 8). The reasons for this result are presently 
unclear, but we hypothesized that some specific aminoacids need to be present, 
although not in a defined position.  
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Figure 7. Effects of CRIBI-300 and derivatives on CK2 activity towards eiF2β peptide. Increasing 
concentrations of CRIBI-300 (red), CRIBI-300 LIN ( dark red), CRIBI-300 W (brown) and CRIBI-
300 C11 (light blue) were used. For details and conditions, see Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Effects of CRIBI-300 and CRIBI-300 SCRAMBLE on CK2 activity towards eiF2β 
peptide. Increasing concentrations of CRIBI-300 (red) and CRIBI-300 SCRAMBLE (violet) were 
used. For details and conditions, see Figure 4. 
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EFFECTS OF CRIBI-300 ON RECOMBINANT CK2 ACTIVITY 
TOWARDS PROTEIN SUBSTRATES 
The effects of CRIBI-300 peptide and derivatives above describe were observed on 
CK2 activity towards peptides. We then wanted to evaluate the effects on protein 
substrates. The CK2 protein substrates available in the laboratory for in vitro assays 
were a-casein, total casein, p53, and calmodulin. We first checked their 
phosphorylation by CK2 using both the monomeric a and the tetrameric CK2 a2b2. 
As shown in Figure 9, when using 0.01 units of a and a2b2 (measured towards 
CK2-tide, see Methods), we found that, under the chosen conditions, all these 
substrates were better phosphorylated by a than a2b2. Calmodulin, as already 
known (Meggio et al., 1994), was phosphorylated only by a (being a2b2 able to 
recognized it only in the presence of polyamines or polybasic peptides).  
 
 
 
 
 
 
Figure 9. Phosphorylation of a-casein, total casein, p53 and calmodulin by CK2a alone or 
CK2a2b2. CK2a or CK2a2b2 (0.01 U, see Methods) were incubated with 0.5 mg of a-casein, total 
casein, and  p53 or 2mg of calmodulin with a radioactive mixture. Samples were resolved by SDS-
PAGE and the radioactivity was detected by autoradiography. The position of a-casein, total casein, 
p53 and calmodulin are indicated by asterisk. Representative autoradiography of four independent 
experiments is shown.   
Surprisingly, on all these substrates, CRIBI-300 induces an activatory effect on 
their phosphorylation by CK2 holoenzyme: in particular, at least 5-fold increased 
phosphorylation of a-casein, total casein and p53 was observed at 10 mM CRIBI-
300 concentration (Figure 10 A and B). In the case of p53 phosphorylation, 
different CRIBI-300 concentrations were applied, and a slight effect was observed 
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already at 1mM, while no further increase was induced passing from 10 to 100mM 
(Figure 10 B). Also in the case of calmodulin, CRIBI-300 has an activatory effect 
on CK2 holoenzyme. In fact, while its phosphorylation in the control lane is 
negligible, a weak phosphorylation is observed when CRIBI-300 is added at 10 mM 
concentration (Figure 10 C), suggesting that CRIBI-300 mimic a polybasic effector.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Effects of CRIBI-300 on the phosphorylation of a-casein, total casein, p53 and 
calmodulin by CK2a2b2. 40ng of CK2a2b2 were incubated with 0.5 mg of a-casein, total casein and 
p53 or 2mg of calmodulin, with a radioactive mixture, resolved by SDS-PAGE and the radioactivity 
was detected by autoradiography. CRIBI-300 was added at the indicated concentrations before the 
addiction of the radioactive mixture. The position of a-casein, total casein, p53 and calmodulin are 
indicated by arrows. Representative autoradiographies of three independent experiments are shown.   
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When we performed protein phosphorylation with CK2 a catalytic subunit, we do 
not observe any activation induced by CRIBI-300. In fact, as shown in the 
autoradiography of Figure 11, the phosphorylation level of a-casein and total casein 
by CK2 a is unchanged or even inhibited by CRIBI-300. Similar results were 
observed with p53 with higher concentrations (not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Effects of CRIBI-300 on the phosphorylation of a-casein and total casein by CK2a. 
30ng of CK2a  was incubated with 0.5 mg of a-casein and total casein, with a radioactive mixture; 
samples were separated by SDS-PAGE and the radioactivity was detected by autoradiography. 
CRIBI-300 was added at the indicated concentrations before the addiction of the radioactive 
mixture. The position of a-casein and total casein are indicated by arrows. Representative 
autoradiographies of three independent experiments are shown.   
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EFFECTS OF CRIBI-300 ON CK2 AUTOPHOSPHORYLATION 
We then wondered if CRIBI-300 has also a direct effect on recombinant CK2 
autophosphorylation activity, than usually occurs at the level of β subunit, as 
described in the general Introduction. We therefore incubated CK2 holoenzyme 
with a radioactive phosphorylation mixture, without any protein substrate, in the 
presence of increasing concentration of CRIBI-300 (Figure 12). We found that it 
induces a decrease in the autophosphorylation of β subunit, already visible at 1 mM 
concentration, accompanied by concomitant induction of CK2 a 
autophosphorylation. This effect is similar to that induced by polyamines or 
polybasic peptides (Meggio et al., 1994). This evidence, in addition to the effect of 
CRIBI-300 on calmodulin phosphorylation by CK2, suggests that it can behave as a 
polybasic effector. To exclude that this was due to the basic portion of CRIBI-300 
corresponding to the Tat sequence, we performed autophosphorylation assays with 
increasing concentration of Tat peptide not conjugated to P15. However, the results 
demonstrate that it is almost ineffective in inhibiting CK2 β autophosphorylation 
and increasing CK2 a autophosphorylation (Figure 12). We therefore concluded 
that the all sequence of CRIBI-300 is required to produce polybasic-like effects on 
CK2. We also demonstrated that these effects were induced also on native CK2, 
deriving from rat liver, beside recombinant CK2 (Figure 12 B). 
 
 
 
 
 
 
 
Figure 12. Effects of CRIBI-300 on the autophosphorylation of recombinant and native CK2. 
40ng of recombinant CK2a2b2  (A) or 0.05 U of native CK2(B) (see Materials), were incubated  with 
CRIBI-300 or Tat as indicated with the corresponding concentrations in the presence of a 
radioactive mixture, separated by SDS-PAGE and the radioactivity was detected by 
autoradiography, The position of CK2 a autophosphorylation and CK2 b autophosphorytion are 
indicated by # or *, respectively. Representative autoradiographies of four independent experiments 
are shown.   
137 
 
EFFECTS OF CRIBI-300 ON CK2 PHOSPHORYLATION OF 
B23 
Special attention is deserved by the CK2 substrate nucleophosmin/B23, which has 
been demonstrated to be the major target of CIGB-300 (Perea et al., 2008). 
Therefore, also in vitro CRIBI-300 was expected to bind to the phosphorylation site 
of B23 and prevent its phosphorylation by CK2. However, when we performed in 
vitro CK2 kinase assay towards B23, we had difficulties in obtaining reproducing 
results. In fact, with recombinant B23 we never observed inhibition by CRIBI-300 
of the CK2-dependent phosphorylation, which instead was activated (Figure 13A). 
On the contrary, when we performed the CK2 assay on the B23 immunoprecipitated 
from a cell total lysate, we sometimes observed a strong inhibition (as shown in 
Figure 13 B). However, even this effect on immunoprecipitated B23 was poorly 
reproducible. At present we do not known the reasons of these inconsistent results. 
We can hypothesize (see Discussion) that a double effect is produce by CRIBI-300 
in this kind of assay, being it able to bind to both the kinase and the substrate.  
 
 
 
 
 
 
 
 
 
 
Figure 13. Effects of CRIBI-300 on the phosphorylation of B23 by CK2 a2b2. 40ng of CK2 a2b2 
was incubated with 1mg of recombinant B23 (A) or B23 immunoprecipitated from cell lysate as 
described in Methods section (B). CRIBI-300 was added at the indicated concentrations before the 
addiction of the radioactive mixture. The position of B23 and CK2b are highlighted by arrows. WB 
anti-B23 is also shown in (B) as a control of equal amount of B23 immunoprecipitation. 
Representative autoradiographies of three separated experiments are shown.   
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CRIBI-300 LOCALIZATION INSIDE THE CELL 
We then passed to use CRIBI-300 for cell treatments. CRIBI-300 is provided of Tat 
sequence which allows it to enter cell and targets it to the nucleus. It has been 
reported that Tat peptide binds directly to the nucleolar protein B23 (Stauber and 
Pavlaskis, 1998), one of the major targets of CRIBI-300 (Perea et al., 2008). Thus, 
in order to assess the cell permeability and subcellular localization of CRIBI-300, 
we exploited a CRIBI-300 peptide fused to fluorescein dye (CRIBI-300-FAM) and 
performed confocal microscopy immunofluorescence experiments. As evident from 
Figure 14, CRIBI-300 turned out to be cell-permeable, reaching the nucleus in a 
very short time (30 min). Moreover, its accumulation in the nucleolus was also 
observed (Figure 14). 
 
 
 
 
 
 
 
 
Figure 14. CRIBI-300 subcellular localization. R-CEM cells were treated with CRIBI-300-FAM 
(green) at 80mM for 30 min. Cells were then fixed and mounted on coverslip and the images were 
acquired with LEICA TCS SP5 confocal microscope. The figure is a representative picture of three 
independent experiments. The square of the left image is magnified on the right. Arrows indicate the 
nucleolar localization of CRIBI-300.  
 
EFFECTS OF CRIBI-300 ON CK2 CELLULAR ACTIVITY AND 
AMOUNT 
Data described so far show that CRIBI-300 can affect CK2 activity, with different 
effects in dependence of substrate, and it enters cells and localized mainly to the 
nucleolus. Thus, we decided to evaluate the effect of CRIBI-300 on CK2 
endocellular activity. We performed cell treatments with increasing concentrations 
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of CRIBI-300 and for different times, and tested the endocellular CK2 activity in 
treated cells, compared to control cells, exploiting synthetic peptides as CK2 
substrate. We observed a marked dose- and time-dependent reduction of CK2 
activity. This was evident either using CK2-tide (Figure 15) or eiF2β-tide (not 
shown), at variance with what observed in vitro. However, when we checked the 
CK2 amount by Western Blot analysis of cell lysates, we found that it dramatically 
decreases in cell treated with CRIBI-300 even after very short times (Figure 15). 
For example, CK2 activity in S-CEM is strongly reduced after 2 h treatment with 25 
mM CRIBI-300 and it is completely abolished after 2 h with 80 mM CRIBI-300, but 
a parallel decrease of CK2 protein amount is observed. Similar results were 
observed in R-CEM although with a slower time-course.  
 
 
 
 
 
 
 
 
Figure 15. CK2 activity and amount in CRIBI-300-treated cells. S-CEM and R-CEM cells were 
treated for the indicated times and with the indicated concentrations of CRIBI-300. Cell lysates were 
analyzed for the activity of CK2 towards CK2-tide (graphs on the top). Mean ± SE values of four 
independent experiments are shown.  10 µg of total proteins of the same cell lysates was analyzed by 
WB with the indicated antibodies for the amount of CK2 (on the bottom). Representatives WB of 
three independent experiments are shown. CTL=control (cells incubated 2 h in the absence of 
CRIBI-300). 
 
These results were very surprising since CK2 is usually very resistant to proteolysis 
and it is not degraded after cytotoxic stimuli; even when cells are treated with CK2 
canonical inhibitors, a reduction of its amount is never observed, up to 24-48 h (Di 
Maira et al., 2007).  
Experiments in LAMA84 and HL60 cells also confirmed the results (Figure 16); in 
this case, Western Blot analysis was performed by using either an antibody raised 
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against C-terminal or N-terminal CK2, and the results were very similar indicating 
that not only a partial proteolysis of CK2 occurs, but the entire protein is cleavaged. 
Moreover, also CK2 β and the alternative isoform of the catalytic subunit, CK2 a’, 
are reduced in parallel with CK2a (Figure 16). Whatever its causes, the prompt 
decrease in CK2 amount in response to CRIBI-300 treatment indicates that the 
reduction in CK2 activity is not a real inhibition, but simply reflects the amount of 
the active kinase present. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. CK2 activity and amount in CRIBI-300-treated cells. HL60 and LAMA84 cells were 
treated for the indicated times and with the indicated concentrations of CRIBI-300. Cell lysates were 
analyzed for the activity of CK2 towards a synthetic specific peptide (graphs on the top). Mean ±  SE 
values of four independent experiments are shown.  10 µg of total proteins of the same cell lysates 
was analyzed by WB with the indicated antibodies for the amount of CK2 (on the bottom). 
Representatives WB of three independent experiments are shown. CTL=control (cells incubated 2 h 
in the absence of CRIBI-300). 
 
We also tried to evaluate the endocellular CK2 kinase activity by WB analyses of 
its known phosphosites, such as Sp129 Akt. However this approach failed to give 
information, since, beside CK2 decrease, also other protein amounts are reduced 
(see below). Therefore, when we observed that phosphorylation decreased, this was 
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in parallel with the decrease of total protein amount. Figure 17 shows the results 
obtained in R-CEM cells.  
 
 
 
 
 
 
 
Figure 17. CK2 endogenous activity in CRIBI-300 treated cells.10 µg of total proteins were 
analyzed by WB with the indicated antibodies. Representatives WB of three independent experiments 
are shown. CTL=control (cells incubated 2 h in the absence of CRIBI-300). 
 
EFFECTS OF CRIBI-300 ON CELL VIABILITY 
We then move to the cytotoxicity of CRIBI-300 on a panel of human cancer cell 
lines, namely Jurkat, HL-60, LAMA84, HeLa, HepG2, U2OS, S-CEM and their 
resistant variant, R-CEM. We also performed cell treatments in non tumor cells 
such as HEK-293T and CCD34Lu. We found variable sensitivity to CRIBI-300: we 
can distinguish a group of high-sensitive cells, essentially represented by blood 
tumor cells (Jurkat, HL-60, LAMA84, S-CEM and R-CEM), a middle-sensitive 
group corresponding to cells deriving from solid tumor (HeLa, HepG2 and U2OS), 
and a very low-sensitive group corresponding to non tumor cells (HEK-293T and 
CCD34Lu). In Figure 18 A, B and C some of these results are shown. Interestingly, 
we found that CRIBI-300 induces cell death in a similar manner in sensitive and 
resistant CEM cells (Figure 18 A). Table 2 summarizes the effects of CRIBI-300 in 
different lines by showing the DC50 values (concentrations required to induce 50% 
of cell death in 24 h). Also from these values, it emerges the very low response to 
CRIBI-300 of the non tumor cell lines tested. 
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Figure 18. Different sensitivity on cell viability of CRIBI-300-treated cells. Cells were incubated 
with increasing concentrations of the CRIBI-300 for 24 h; cell viability was assessed by the MTT 
method, assigning 100% value to the vehicle-treated control cells. Panels A, B and C correspond to 
cells with similar sensitivity toward CRIBI-300. Mean ± SE values of at least four independent 
experiments are reported. 
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Table 2. DC50 values of CRIBI-300. DC50 values (concentration required to induce 50% of cell 
death in 24 h) were calculated from viability curves in Figure 18, by means of the MTT method (see 
Methods). The values are the mean of 4–6 independent experiments ±  Standard Deviation (SD). 
The next step was to evaluate the effects on cell viability of Tat peptide not 
conjugated to P15. In no cell line we have ever observed any signal of cell death in 
response to Tat (representative example are shown in Figure 19). Similarly, P15 
peptide was ineffective on cell viability (not shown). Thus we concluded that 
similarity to what observed for the effects on CK2 activity, the whole CRIBI-300 
structure, including the cyclic P15 sequence, is necessary to induce cell death. 
 
 
 
 
 
 
Figure 19. Cell viability of Tat peptide-treated cells. Cells were incubated with increasing 
concentrations of the Tat peptide  for 24 h; cell viability was assessed by the MTT method, assigning 
100% value to the vehicle-treated control cells. Mean ± SE values of at least three independent 
experiments are reported. 
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We performed a comparative analysis by assaying cell viability with several 
variants of CRIBI-300 available (see Table 1). First we found that EMO-Tat and 
CRIBI-300-ALA are almost ineffective as observed on the in vitro activity. Then 
we analyzed the effects of peptides presenting a point substitution of a single 
aminoacid in P15 domain, in order to assess which are the aminoacid essential for 
the CRIBI-300 effects. The results shown in Figure 20 and Table 3 for HL60 and 
LAMA84, revealed that some substitutions are indeed more detrimental, such as 
that of the tryptophan, at least in LAMA84 cells. On the contrary, some variants are 
even more effective than the parental peptide, such as those devoid of Ser or Cys of 
P15. 
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Figure 20. Cell viability of LAMA84 and HL60 cells treated with CRIBI-300 and CRIBI-300 
derivatives peptide. LAMA84 (A) and HL60 (B) cells were incubated with increasing concentrations 
of the CRIBI-300 and CRIBI-300 derivatives for 2 h; cell viability was assessed by the MTT method, 
assigning 100% value to the vehicle-treated control cells. The colors assigned to each peptide 
correspond to those in Table 1. Mean ± SE values of at least three independent experiments are 
reported. 
 
 
 
 
 
 
 
 
Table 3. 2 h DC50 of CRIBI-300 and CRIBI-300 derivatives. The values, calculated from 2 h MTT 
assays reported in Figures 20 are the mean of 4 independent experiments ±  Standard Deviation 
(SD). 
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CELL DEATH INDUCED BY CRIBI-300 IS NOT APOPTOSIS 
Once determined that CRIBI-300 induces very fast cell death in tumor cells, we 
wanted to investigate if this is due to apoptosis. For this purpose we exploited 
different techniques; firstly we checked caspase activation and the consequent 
caspase-dependent cleavage of PARP, by analyzing WB of total cell lysates. Figure 
21 shows that PARP is not cleaved in response to CRIBI-300 treatments up to 80 
mM and 12 h. The same applies to pro-caspase-3, which is not degraded and 
activated to caspase-3. This was surprising since CK2 amount and activity 
reduction observed in the same experimental conditions (up to 50% after 2 h 80 mM 
see Figure 16) should correlate with the occurrence of apoptosis. 
 
 
 
 
 
 
 
 
 
Figure 21. Detection of apoptosis in CRIBI-300 treated cells. Cells were treated with 80 mM 
CRIBI-300 for the indicated times and 10 µg of proteins from total lysates were analyzed by WB 
with the indicated antibodies.b-actin was used as loading control. Representatives WB of three 
independent experiments are shown. f.l. PARP: full length PARP. 
 
We also tried to evaluate apoptosis by different methods, such as the detection of 
DNA-laddering (Figure 22) and of nucleosomes release (by a commercial kit) (not 
shown): in no cases we observed apoptotic events. Once excluded apoptotic cell 
death, we hypothesized that CRIBI-300 could induce necrotic death. In support of 
147 
 
this hypothesis, we observed lactate-dehydrogenase (LDH) release in the 
supernatant of treated cells and increase in LHD activity in a time-dependent 
manner after CRIBI-300 treatment (not shown). However, these are preliminary 
data that have to be confirmed and more deeply investigated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Effects of CRIBI-300 on DNA-laddering. 10 µg of extracted DNA from CRIBI-300 
treated S-CEM for the times and concentrations indicated, were separated on a 1.7 % agarose gel as 
described in Methods. Marker:100bp DNA Ladder (Promega) CTL=control (cells incubated in the 
absence of CRIBI-300). 
 
CHANGES IN CK2 SUBCELLUAR LOCALIZATION UPON 
CRIBI-300 TREATMENT 
In order to better understand the events involving CK2 in response to CRIBI-300, 
we decided to investigate if CK2 changes its subcellular localization after CRIBI-
300 cell treatment. We performed confocal microscopy analysis; the 
immunofluorescence images obtained from CEM cells are shown in Figure 23. CK2 
(red) is clearly detectable in the cytoplasm and also in the nucleus in control cells, 
but, interestingly, it moves out from the nucleus after a very short time of treatment 
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(30 min), and it almost completely accumulates in the cytoplasm, with a punctuate 
distribution after 2 h treatment. Again, as observed for the CK2 amount reduction, 
the effects are very similar in S-CEM and R-CEM, but slightly slower in R-CEM 
(Figure 24). Immunofluorence experiments performed in other tumor cell lines 
confirmed this early change in CK2 subcellular localization (see U2OS cells in 
Figure 25).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Effects of CRIBI-300 in CK2 subcellular localization in S-CEM cells. S-CEM cells 
were treated as indicated, then stained with anti-aCK2 (conjugated to Alexa 633) (red); nuclei were 
stained with Hoechst 33258 (blue). Fluorescence images were captured with confocal microscopy. 
Merge images are shown, where CK2 and DNA colocalization gives violet signal. Representative 
images of six independent experiments are shown. 
 
 
CK2 confocal images of cells treated with apoptosis-inducers have never shown 
such a behaviors for CK2 (not shown). This suggests that this punctuated CK2 
pattern is a specific response to CRIBI-300, not related to the cell death events; 
moreover, the CRIBI-300 induced CK2 localization may be related to its 
degradation (see above). Indeed, we hypothesized a possible localization of CK2 at 
level of proteolytic systems, such as lysosomes.  
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Figure 23. Effects of CRIBI-300 in CK2 subcellular localization in R-CEM cells. For details see 
Figure 24. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Effects of CRIBI-300 in CK2 subcellular localization in U2OS cells. For details see 
Figure 24. 
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To check this hypothesis we exploited co-localization confocal images of CK2 and 
LAMP1, a protein used as a lysosomal marker. Images are shown in Figure 26, for 
experiments performed in LAMA84 cells. Firstly they demonstrated that CRIBI-
300 induces the activation of lysosomal system as judged from the strongly 
increased LAMP1 signal. Secondly, they show that CK2 partially co-localized with 
LAMP1 after 2 h CRIBI-300 treatment, confirming our hypothesis.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. CK2 and LAMP1 co-localization. LAMA84 cells were stained with anti-aCK2 
conjugated with Alexa Fluor 633(red) and with anti-LAMP1 conjugated with FITC (green). 
Fluorescence images were captured using confocal microscopy. Merge images are shown, where 
CK2 and LAM1 colocalization gives yellow signal. Representative images of three independent 
experiments are shown. Image in the square is magnified (5-fold) on the right. 
 
CRIBI-300 seems also to affects the nuclear structure of the cells. From in vivo 
time-laps analysis (see Figure 28), DNA signal gradually disappears over time, 
suggesting that possible side effects are triggered by CRIBI-300 in tumor cells after 
very short treatment times.  
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Figure 28. Nuclear changes after CRIBI-300 treatment. LAMA84 cells were stained with Hoechst 
33258 for 15 min at 37°C and maintained in an isotonic buffer for 2h. Flourescence images were 
captured in vivo every 2 min, using confocal microscopy. Representative images experiments are 
shown. 
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EFFECTS OF CRIBI-300 ON PROTEASOMAL AND 
LYSOSOMAL PROTELYTIC SYSTEMS. 
The observation that CK2 amount decreases in cell treated with CRIBI-300, and 
that lysosomal activation seems to occur, as detected by immunofluorescence of 
LAMP1 protein, prompted us to investigate on a possible action of CRIBI-300 on 
proteolytic systems. First, we confirmed the increase in LAMP1 amount by means 
of WB analysis (Figure 29 A): in two different cell lines (LAMA84 and HL60) 
LAMP1 amount is dramatically higher after 2 h treatment with 80 mM CRIBI-300 
than in untreated cells. We also checked the possible involvement of the proteasome 
system, by analyzing the ubiquitination state of cellular proteins by means of an 
antibody recognizing polyubiquitinated proteins, a condition required for the 
recognition and subsequent degradation by proteasome (Andersen et al., 2005). We 
observed an increase of poly-ubiquitinated proteins in a time-dependent manner in 
LAMA84 cells treated with CRIBI-300, with a maximal after 12 h (Figure 29 B). 
The accumulation of ubiquitinated proteins suggests a possible impairment of the 
proteasome activity, whose reason needs further investigation to be understood (see 
Discussion). Furthermore, the decrease of ubiquitinated signal observed at longer 
times (see 24 h in Figure 29 B) might indicate that the blockage of the proteasome 
could be counteracted by the activation of alternative pathways for protein 
degradation which intervene to solve proteasome engulfment. Of course more 
studies will be necessary; however, we have preliminary data that suggest that also 
the catabolic autophagic process is triggered by CRIBI-300. In fact, p62, a protein 
that normally is degraded in autophagy (Lin et al., 2013), gradually disappears in 
cells treated with CRIBI-300 (Figure 29 B) indicating that its degradation occurs. 
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Figure 29. Effects of CRIBI-300 on cellular proteolytic systems. The indicated cells were treated 
with 80 mM CRIBI-300 for the indicated times, then 20mg of cell lysate proteins was analyzed by WB 
for LAMP1 (whose amount correlates with lysosomal protease activity) (A), or poly-ubiquitin, whose 
accumulation indicates proteasome function defects (B), or p62, whose degradation is a marker of 
autophagy (C). b-actin was analyzed as loading control. CTL = cells incubated for 24 h in the 
absence of CRIBI-300. 
 
EFFECTS OF CRIBI-300 ON THE AMOUNT OF OTHER 
CELLULAR PROTEINS  
 
Since we have found that CK2 amount rapidly decreases after CRIBI-300 treatment 
and that proteolytic system activities are affected by the peptide, we verify if also 
the amount of other proteins is changed. We therefore exploited WB with available  
antibodies to check the amount of several proteins which are particularly relevant, 
being known as CIGB-300 targets (B23 and S6, Perea et al., 2008) or involved in 
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CK2-dependent signaling (such as Akt, Hsp90 and Cdc37, Ruzzene and Pinna, 
2010). From WB analyses, we observed that also the amount of B23, the major 
target of CIGB-300 (Perea et al., 2008) and known substrate of CK2, decreases, 
although not as rapidly as CK2: figure 30 shows a B23 reduction of about 70% in 
LAMA84 cells after 2h treatment and an almost total disappearance in S-CEM and 
HL60. Another protein that we analyzed is the ribosomal protein S6 (rpS6), which 
was also reported to be a target of CIGB-300 (Perea et al., 2008). Also rpS6 is 
rapidly degraded after CRIBI-300 treatment; for example, in S-CEM, it completely 
disappears after 30 min at 80 mM treatment (Figure 30). Structural proteins, such as 
b-actin and a-tubulin seem to be more resistant to degradation, which however 
occurs after 2 h treatment in S-CEM (Figure 30). Other proteins such as Akt, Hsp90 
and Cdc37 seem to be more stable (Figure 30). Since we observed a powerful effect 
of CRIBI-300 on nuclear structure (see above) we also analyzed its effect on 
histones, by exploiting an antibody toward H2B and H3 histones. We found that 
they totally disappear after 30 min in LAMA84 and HL60 (not shown). From our 
results, therefore, we can conclude that not only CK2 but several other proteins 
undergo a probable degradation in response to CRIBI-300. However, with the 
exception of histones, CK2 cleavage seem to be one of the earliest event, consistent 
with the hypothesis that CRIBI-300 directly binds to CK2, as suggested by in vitro  
experiments. We also checked the effects on the amount of CK2 and of other 
proteins in response to CRIBI-300-ALA and EMO-Tat treatments; in all cases, as 
observed for CK2 activity in vitro and for CK2 viability, they were inactive on the 
protein level amounts up to 24 h treatment (Figure 31).  
 
 
 
 
 
 
 
155 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. Effects of CRIBI-300 on the amount of other cellular proteins compared to that of 
CK2 a. Cells were treated with increasing concentrations of CRIBI-300 as indicated and for the 
indicated times. 10 µg of total proteins was analyzed by WB with the indicated antibodies. 
Representative WB of three independent experiments are shown. 
 
 
 
 
Figure 31. Effects of EMO-TAT and CRIBI-300 ALA on the protein amounts. LAMA84 were 
treated with the indicated CRIBI-300 derived peptides, EMO-Tat and CRIBI-300 ALA, respectively, 
at 80mM concentrations for the indicated times. 10 µg of total proteins was analyzed by WB with the 
indicated antibodies. Representative WB of three independent experiments are shown. 
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EFFECTS OF CRIBI-300 IN CK2 KNOCKED-DOWN CELLS 
  
In order to understand if CK2 degradation is an initial and essential cellular event 
which mediates the effect of CRIBI-300, we checked if it is less effective in cells 
where CK2 a and β amounts are reduced. We therefore performed RNA 
interference experiments to silence a and β CK2 expression with specific siRNA. 
Then cell treatments of LAMA84 with CRIBI-300 were performed. Firstly we 
checked the level of a and β amount to confirm silencing. As shown in Figure 32, 
the approach proved successful for diminishing the level of CK2 a expression of 
about 50%, while CK2 β expression was reduced only of about 20%. Then we 
analyzed the effect of a 2 h treatment with 80 mM CRIBI-300. As shown in Figure 
32, when CK2 a is partially silenced, the effect of CRIBI-300 on its amount is less 
dramatic if compared with cells where CK2 expression is normally high. Compared 
to the relative control (not CRIBI-300 treated cells), CRIBI-300 induced a 25% 
reduction of CK2 a  in a knocked-down cells, while 70% reduction is observed in 
not knocked-down cells. The difference is even more dramatic when the effect of 
CRIBI on β is observed: CRIBI-300 is uneffective in a knocked-down cells (60% 
reduction in not a knocked-down). Also in the case of CK2 β knocked-down the 
effects of CRIBI-300 are reduced (a decrease of 10% instead of 80%, β of 10% 
instead of 70%). This suggests that knocking-down a or β CK2 partially removes 
from cells major CRIBI-300 targets and its effects are less dramatic. However, more 
work is necessary to better understand these results, since, when we analyzed the 
amount of other proteins, such as rpS6 (Figure 32) we found that it is strongly 
reduced even in cells were CK2 a or β are silenced. 
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Figure 32. Effects of CRIBI-300 in CK2 silenced cells. LAMA84 cells were transfected for 72h with 
specific CK2a or b siRNA, as indicated. Control cells were transfected with aspecific siRNA. Then 
cells were incubated with or without 80mM CRIBI-300 for 2 h, lysed, and 10 µg of total protein 
samples was analyzed by WB as indicated. A quantitation of CK2 a and b bands is presented in the 
histogram, performed by Kodak 4400MM PRO Software. The % of band decrease induced by 
CRIBI-300 compared to each control is reported above the bands. Representative WB of three 
independent experiments are shown. 
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DISCUSSION 
 
In this work we analyze the action in vitro and in cell of the CRIBI-300 cyclic 
peptide, whose structure resembles that of the compound CIGB-300 (Perea et al., 
2004) recently advanced in clinical trials (Perea et al., 2011). Both peptides are 
composed of a functional part, called P15, fused to the cell-penetrating peptide Tat 
(Holm et al., 2006). However, Tat sequence is at the C-terminal side of P15 in 
CIGB-300, at the N-terminal side in CRIBI-300. Our in vitro results are very 
similar for the two compounds, showing that they exert effects on recombinant 
CK2; therefore, most of the experiments were then performed only with CRIBI-
300, whose sequence was also variably modified, in order to obtain information on 
the minimal requirements for the peptide activity.  
Despite it was designed to interfere with the site of phosphorylation by CK2 in 
some of its substrates, CIGB-300 is frequently defined as a CK2 inhibitor (Perea et 
al., 2004). However, we found that the effect of CRIBI-300 on CK2 activity were 
different depending on the type of substrate used. In fact, an activation by CRIBI-
300 occurs towards substrates which are preferentially phosphorylated by the CK2 
monomeric a catalytic subunit (a-casein, total casein, p53, calmodulin, see Figure 
10), while the phosphorylation of substrates strictly dependent on the presence of 
CK2 b subunit is instead impaired (eiF2b-tide, see Figure 4). More complex are the 
effects observed on the CK2 substrate nucleophosmin/B23 (Louvet et al., 2006): we 
obtained poorly reproducible results (Figure 13). However this can be partially 
explained by a double effect, exerted by CRIBI-300 on both CK2 and B23, which is 
reported as the major target of CIGB-300 (Perea et al., 2008). We have also to 
consider that different results were observed using recombinant B23 or 
immunoprecipitated B23: the recombinant protein could produce artifacts due to the 
presence of a poly(His) tag (which can also leads to the formation of B23 oligomers 
or aggregates, as sometimes detectable on the top of the gel after Coomassie blue 
staining or by anti-B23 WB (not shown)); on the other hands, B23 
immunoprecipitated from cell lysate can be associated to cellular components 
producing a different action of CRIBI-300. 
These first in vitro evidences suggest that CRIBI-300 interferes with CK2 and has a 
direct effect on the catalytic activity, beside of being able to bind to CK2 substrates. 
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This is also confirmed by the analysis of the CK2 autophosphorylation in the 
absence of any substrate. In particular, we observed that CRIBI-300 provokes a 
decrease in CK2 autophosphorylation that normally occurs on β subunit, but this is 
accompanied by a concomitant exceptional induction of CK2 autophosphorylation 
of a subunit. This is the well-known effect exerted by polybasic effector or 
polyamines (Meggio et al., 1994) on CK2; we therefore hypothesized that, in the 
case of CRIBI-300, it was due to the Tat portion, whose aminoacidic composition is 
highly basic. However, the only Tat peptide was almost ineffective on CK2, 
excluding this possibility. Interestingly, also the mere P15 sequence was unable to 
produce any effect on CK2 autophosphorylation and in vitro activity, suggesting 
that the Tat sequence is necessary but not sufficient for CRIBI-300 binding to CK2 
(Figure 12). As far as the importance of the exact sequence is concerned, we can 
say that a certain composition, more than the sequence, is required to induce the 
reduction of CK2 activity towards b-dependent substrates, since a scramble peptide 
(with P15 composition) is also effective, while a completely different sequence has 
only weak effects (Figure 5 and 8). Moreover, peptide cyclization (whose rationale 
is based on an expected higher resistance to cellular protease action) seems to be 
not required for the effects on CK2 (see Figure 7, where linear peptide is even more 
active than the cyclic one). 
Altogether considered, our in vitro results suggest that CRIBI-300 could interfere 
with the CK2 holoenzyme structure, producing an unstable and/or unfunctional 
tetrameric conformation which prevents the phosphorylation of b-dependent 
substrates, increases that of a-preferred substrates, and induces a polybasic-like 
effect on autophosphorylation. This would also provoke a higher susceptibility to 
proteolytic cleavage (Marin et al., 1995), and is in perfect accordance with our in 
cell observation (see below). Indeed, preliminary results suggest that in vitro 
digestion of CK2 a by recombinant proteases is accelerated by the presence of 
CRIBI-300 (not shown).  
A compound that bind to CK2 by provoking b subunit removal or holoenzyme 
disruption could dramatically change the pattern of CK2-dependent 
phosphorylation since the free catalytic subunit and the holoenzyme have quite 
different substrate preferences (Pinna, 2002). Therefore, expanding our 
observations to a cellular environment, we can imagine that CRIBI-300 could 
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interfere with the crucial balance that regulates all the cellular processes governed 
by CK2. Indeed, when we moved to analyze the cellular effects of CRIBI-300 we 
observed a very fast induction of cell death in tumor cells, as already demonstrated 
for CIGB-300 (Perea et al., 2004). However, at variance to what reported for CIGB-
300, we have never found any symptom of apoptosis, such as PARP cleavage, 
caspase activation (Figure 21), DNA-laddering (Figure 22) or nucleosomes 
formation (not shown). We suppose that cell death occurs with the intervention of 
proteolytic system other than caspases (see below). 
Interestingly, we observed that tumor cells are differently sensitive to CRIBI-300: 
leukemic cells seem to be more susceptible to the peptide than cells deriving from 
solid tumors (Figure 18 and Table 2). We have hypothesized that cells deriving 
from blood tumors, growing in suspension in the culture medium, expose entirely 
their plasma membrane surface to the compound; on the contrary, cells from solid 
tumors, which grow adherent to plates, offer a lower surface available to the 
interaction with the peptide. We tested this possibility performing cell treatments 
with CRIBI-300 with solid tumors cells, but maintaining them in suspension; 
however, we did not observed an increased sensitivity towards CRIBI-300, 
compared to adherent cells (not shown). Another possibility is that the differences 
in the sensitivity to CRIBI-300 between leukemic and solid tumor cell lines is due 
to more efficient mechanisms of Tat-cargoes internalization of plasma membrane in 
blood tumor cells. Future studies will be necessary to shed line on this point. We 
have also found that CRIBI-300 is almost ineffective in inducing cell death in non-
tumor cells (Figure 18); this is in accordance with several other observations 
obtained by using canonical ATP-competitive CK2 inhibitors, and explained by the 
concept of the addiction of cancer cells to CK2 (Ruzzene and Pinna, 2010).  
In accordance to the observations already discussed from in vitro assays on 
recombinant CK2 activity, we found that also the induction of cell death by CRIBI-
300 requires the presence of both P15 and Tat sequence, but that a precise sequence 
is not essential, since the scramble peptide, containing the same aminoacidic 
composition of P15 but randomized compared to CRIBI-300, induces the same 
level of cell death then CRIBI-300. The two Cys of P15 (see Table 1) are essential, 
since their substitution to Ala completely abrogates CRIBI-300 effects in cells; 
however, their role in cyclization is not important, since a linear peptide where the 
two Cys are maintained is even more active than the cyclic peptide (Figure 20). 
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Furthermore, point substitutions on the hydrophobic aminoacids of P15 with 
alanines have shown that tryptophan could be particularly important for the action 
of CRIBI-300 on cell death, at least in LAMA84 cells; however more detailed 
analysis on the effects of CRIBI-300 derivatives on cell viability will be necessary 
to better understand which are the most important aminoacid residue responsible of 
CRIBI-300 action. When we treated tumor cells with CRIBI-300, cell death was 
accompanied by a marked reduction in the endocellular CK2 activity, which is in 
accordance with the pro-survival role of CK2. However, this reduction was 
accompanied by a dramatic loss in CK2 amount even after very short treatment 
times (Figure 15 and 16). This is not a common event, and is usually not observed 
when canonical CK2 inhibitors are administrated to cells. In the case of CRIBI-300, 
we conclude that the reduction of CK2 activity observed in treated cells is not a real 
inhibition but is due to a reduced enzyme amount.  
Considering the very short time required for its occurrence, we suppose that this 
reduction of CK2 amount is due to an increased degradation and not to a block in 
synthesis. This is also in accordance with our hypothesis formulated from in vitro 
data, assuming that CRIBI-300 interferes with the interaction between a and b in 
the holoenzyme structure; in fact, it is known that b protects a from proteolytic 
cleavage (Meggio et al., 1992).  By immunofluorescence experiments we also 
demonstrated that CK2 subcellular localization changes in a very short time after 
treatment, becoming more abundant in the cytosol in a punctuate pattern and 
apparently concentrated in the lysosomes, which are in turn activated as confirmed 
by increased level of LAMP1 (Figure 26).  
We than analyzed other proteins possibly involved in mediating the effect of 
CRIBI-300; we found that also the amount of some of them is rapidly reduced by 
CRIBI-300. Several signals of perturbation in the proteolytic pathways were found 
in CRIBI-300 treated cells: an increase in ubiquitinated protein signal, suggesting 
the alteration in the proteasome machinery (Figure 29 B), the degradation of p62 
protein, an autophagy marker (Figure 29 C), and a general activation of lysosomal 
proteases (Figure 29 A). Our evidences led us to formulate the following 
speculation: we noticed that the Ubiquitin Interacting Motif (UIM), a stretch of 
about 20 amino acid residues present in 26S proteasome subunit but also in other 
proteins known to recognize ubiquitinated molecules, is very similar to the CK2 
162 
 
consensus sequence (Miller et al., 2004). Since the P15 portion of CRIBI-300 was 
developed with the aim of binding to CK2 substrates (Perea et al., 2004), it could be 
able to bind not only to CK2 consensus site, but also to UIM. By this way, beside 
interfering with CK2 substrates phosphorylation, it could also block the 
proteasome-mediated degradation of ubiquitinated proteins. The consequent 
engulfment of proteasome machinery and accumulation of ubiquitinated proteins 
would in turn activate alternative pathways for their degradation. Indeed, functional 
links between the proteasome system and the lysosomal autophagic pathway are 
nowadays recognized (Koga and Cuervo, 2011), supporting switching toward 
different mechanisms for protein clearance. In this context, p62 protein could play 
an important role, since it is normally degraded during autophagy but also 
interacting with polyubiquitin chains and driving polyubiquitinated proteins to 
proteolytic pathways (Shin, 1998).  
From all our findings we assume that the molecular mechanisms by which CRIBI-
300 acts inside the cell are multiple. First, as already known for CIGB-300 (Perea et 
al., 2008), CRIBI-300 interacts with its main target B23 protein and probably other 
ribosomal proteins, blocking their phosphorylation by CK2; secondly, from our in 
vitro data we conclude that CRIBI-300 undoubtedly acts directly on CK2, 
interfering with the holoenzyme, probably disrupting its stability; finally, our 
cellular results suggest that CRIBI-300 could interfere with the proteasome activity, 
leading to a general perturbation of cellular proteolytic systems. 
We also wondered how much CK2 is involved in mediating the observed CRIBI-
300 effects. CK2 seems to be one of the earliest targets, being very promptly 
degraded (Figure 15 and 16); moreover, preliminary experiments of CK2 knocking-
down demonstrated that when CK2 amount is reduced, some CRIBI-300 effects are 
less evident (Figure 32). We also observed parallel effects induced by CRIBI-300 
derivatives on CK2 activity in vitro and on cell death induction (compare for 
example the effects of CRIBI-300 ALA or EMO-Tat in vitro and in cells, Figure 5 
and 6 with Figure 20), suggesting that cell death is indeed directly correlated to the 
targeting of CK2. However, it is evident that the profound cellular perturbation 
induced by CRIBI-300 is the results of several events involving multiple targets. 
This study has started to shed light on its complex mechanism of action, and we 
suggest that particular caution is required for its clinical employment. 
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INTRODUCTION 
 
Small cell permeable inhibitors of protein kinases have become very important 
molecules for dissecting signaling pathways mediated by each of them. Many 
compounds have been proposed as “specific” for a certain protein kinase. However, 
since the human kinome is composed of more than 500 members, the issue of 
selectivity is critical and only a limited number of inhibitors have been really shown 
to display a narrow selectivity window hitting only few or one individual protein 
kinases (Bain et al., 2007). Data presented in this chapter are the result of a 
collateral study, on a kinase, HIPK2, which was among those inhibited by some 
CK2-directed inhibitors. In fact, during the development of CK2 inhibitors, the  in 
silico modification of existing compounds was disclosed in order to obtain a 
molecule not effective on CK2, but selective for HIPK2. This kinase is a member of 
the so called “homeodomain-interacting protein kinases” (HIPKs) family, belonging 
to CMGC group of the kinome, and no specific inhibitor for this kinase was 
available.  
HIPK2 has been identified for its interaction with the homeodomain transcription 
factor NK-3 (Kim et al., 1998). It is a kinase conserved from flies to human, and 
plays a critical role in the regulation of cell growth, development, morphogenesis, 
transcription and cell death in multiple organisms and cell types (Hofmann et al., 
2002; D’Orazi et al., 2002). It is considered as a potent growth suppressor and 
apoptosis activator (Calzado et al. 2007; Rinaldo et al., 2007). The mechanism by 
which HIPK2 mediates apoptosis has been described; the phosphorylation of p53 
Ser46 in the C-terminal domain ì stabilizes the binding between p53 and DNA 
(Puca et al., 2008) and leads to p53-mediated transcriptional activation of 
proapoptotic factors such as Bax, Noxa, and Puma (D’Orazi et al., 2002; Di Stefano 
et al., 2004). As illustrated in Figure 1, the p53 Ser46 phosphorylation is considered 
to be a sensor for DNA-damage intensity that induces a fine change of p53 
conformation varying the p53 affinity for different promoters with a shift from cell 
cycle arrest related genes (i.e. MDM2) toward proapoptotic genes (i.e. p53AIP1) 
(Oda et al., 2000; Mayo et al., 2005). Accordingly, HIPK2 was found to be 
activated in response to DNA-damage inducing stimuli, including UV or infrared 
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(IR) irradiation, or treatment with genotoxic chemotherapeutic drugs such as 
adriamycin and cisplatin (Hofmann et al., 2002; Rouse et al., 2002).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.Schematic representation of p53 apoptotic regulation by HIPK2. HIPK2 phosphorylates 
p53 at Ser46 to direct p53 transcription toward proapoptotic genes rather than cell cycle (p21) or 
p53 regulatory (MDM2) genes. Important cofactors for HIPK2-induced p53 Ser46 phosphorylation 
(PML, Daxx, Axin and so on) and p53 acetylation (that is, p300, TIP60), which efficiently induce 
apoptosis, are reported in the box. The regulatory loop between p53 and HIPK2 leading to HIPK2 
proteolysis during the termination phase of apoptosis, through p53-induced caspase-6 activation, is 
shown (from Puca et al., 2010). 
 
HIPK2 can be therefore considered as a tumor-suppressor element, and this 
correlates with the tendency of human cancer cells to inactivate HIPK2 through 
different mechanisms. For instance, HIPK2 is transcriptionally downregulated in 
thyroid and breast carcinoma specimens (Pierantoni et al., 2002), and it was found 
to be mutated in a very small subset (2 out of 130 cases) of acute myeloid leukemia 
(AML) and myelodyplastic syndrome (MDS) patient, (Li et al., 2007), although 
these rare mutations do not clearly support a causative role of HIPK2 in the 
pathogenesis of these tumors. Interestingly, high-mobility group A1 protein 
(HMGA1), a proto-oncogene overexpressed in several cancer, (Fusco and Fedele, 
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2007), was shown to inactivate HIPK2 by removing it from the cell nucleus and 
retaining it in the cytoplasm. 
However, recent reports have presented data in contrast with a HIPK2 role as a 
tumor suppressor. In fact, HIPK2 amplification occurs in pilocytic astrocytomas, 
the most common glia cell-derived brain tumor (Deshmukh et al., 2008). 
Consistently, HIPK2 overexpression in a glioma cell line resulted in increased cell 
growth and not in growth arrest, as reported for several other tumors (D’Orazi et al., 
2002; Giraud et al., 2004; Doxakis et al., 2004), but the molecular mechanism by 
which HIPK2 can increase cell growth still needs to be clarified.  
Therefore, for all its implications in signaling pathways and its double role in 
controlling cell death/cell growth, HIPK2 represents an interesting kinase whose 
functions have not been entirely characterized yet.  
The only HIPK2 inhibitor mentioned in the literature, some years ago, was 
SB203580, a p38 MAP kinase inhibitor employed to block also HIPK2 (Di Stefano 
et al., 2004) due to its similarity to p38. Later, several laboratories exploited 
SB203580 as a “HIPK2 inhibitor” (Roscic et al., 2006; Yamada et al., 2009), 
considering it a selective agent for this kinase, even if, from profiling studies of 
SB203580 on a panel of 71 protein kinases at 1 μM concentration, inhibition of 
HIPK2 was negligible (14%) (Bain et al., 2007). Moreover, the members of the 
HIPK family are not among the kinases inhibited by SB203580 (nor by any other 
compound examined) in a comprehensive profiling of kinase inhibitor selectivity 
(Anastassiadis et al., 2011). This sheds doubts on the interpretation of the effects of 
SB203580 as really mediated by cellular HIPK2 blockage.  
During studies conducted on CK2 in our laboratory, it has been observed that 
several and potent CK2 inhibitors such as TBB, TBI and other related tetrabromo-
benzimidazole derivatives, also exert a drastic effect on HIPK2 (Pagano et al., 
2008; Sarno et al., 2011) and a few other protein kinases. Therefore, modifications 
of the tetrabromo-benzimidazole scaffold were designed, focused on decreasing the 
efficacy toward CK2 and other kinases drastically inhibited by TBI and TBB, while 
maintaining or eventually improving that toward HIPK2. One of these derivatives, 
4,5,6,7-tetrabromo-2-(1H-imidazol-2-yl)isoindoline-1,3-dione (TBID), has been 
found that selectively inhibit HIPK2 in vitro.  
 
 
168 
 
TBID STRUCTURE, IN VITRO ACTIVITY AND SELECTIVITY 
 
Previous studies have shown that TBB and TBI, two commonly used CK2 
inhibitors, also share the ability to inhibit HIPK2 besides CK2 (Pagano et al., 
2008). These compounds present a number of bromine atoms clustered on their 
benzene ring, which are essential for interaction with the kinase active site 
(Battistutta R et al., 2001; Battistutta et al., 2007). This is especially true for TBI 
whose IC50 values with either HIPK2 or CK2 are nearly identical, 0.7 vs 0.6 μM, 
(Pagano et al., 2008 and Table 1). From these observations it has been decided to 
insert bulky side chains in order to reduce affinity toward CK2 as compared to 
that toward HIPK2. This goal was obtained by derivatizing a 
tetrabromoisoindoline-1,3-dione scaffold (nearly super-imposable to that of TBI) 
with an imidazole group, to give rise to 4,5,6,7-tetrabromo-2-(1H-imidazol-2-
yl)isoindoline-1,3-dione (TBID, 5a). TBID (5a) inhibits HIPK2 with the same 
efficiency as TBI, while shows a more than 10-fold higher IC50 value toward 
CK2 (see Table 1). Modifications in the position of basic nitrogen atom of the 
imidazole ring have disclosed the crucial role of position 3, as displayed by the 
loss of inhibitory activity toward HIPK2 of compound 5e (Cozza et al., 2014) 
(see Table 1).  
 
 
 
 
 
 
 
 
 
169 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. IC50 (μM) of  TBID (5a) and compound 5e for HIPK2, CK2, PIM1, CK. The scaffold 
structure of TBID-derived compound is shown in the upper part. R- is represented by the different 
moieties indicated in the table. TBB and TBI values are drawn from Pagano et al., 2008. n.d.= not 
determined (from Cozza et al., 2014). 
The selectivity of the newly developed HIPK2 inhibitor TBID was tested by 
analyzing its effect at 10 μM concentration, on a panel of 70 protein kinases 
(Figure 2): the activity of HIPK2 was entirely suppressed while none of the other 
protein kinases underwent a similar inhibition; the residual activity of the second 
(BTK) and third (CAMKKb) most inhibited kinases were 29% and 34%, 
respectively. In addition, the activity of other kinases generally inhibited by CK2 
inhibitors (i.e. PIM1 and ERK8) and CK2 itself, was less affected or almost 
totally unaffected. More detailed information about selectivity of TBID were 
obtained by profiling analysis at 1 instead of 10 μM concentration on a larger 
panel of 125 protein kinases, including other members of the HIPK sub-family 
and many protein tyrosine kinases which were scarcely represented in the 
smaller panel.. The data (Cozza et al., 2014) have displayed that HIPK2 is the 
most susceptible kinase to TBID (31% residual activity). HIPK1 and HIPK3 
however are also significantly inhibited, with residual activities of 39% and 53%, 
respectively. In contrast none of the protein tyrosine kinases tested is appreciably 
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affected by TBID with the only possible exception of IGF-IR (68% residual 
activity). This, together with CAMK1 and CAMKKb, are the only kinases 
inhibited more than 20%, a part from the HIPKs. 
 
 
 
 
 
 
 
 
 
Figure 2. Selectivity profile of TBID (10 μM) against 70 kinases panel. Residual activity expressed 
as per cent of activity in the absence of TBID is shown (from Cozza et al., 2014). 
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AIM OF THE STUDY 
 
The aim of my work in this study was to check the cell permeability of the 
compound TBID (4,5,6,7-tetrabromo-2-(1H-imidazol-2-yl)isoindoline-1,3-dione). 
This is the first specific inhibitor of HIPK2 (IC50=0.33mM) but its properties have 
been analyzed only in vitro so far. The physiological role of HIPK2 is presently 
only partially understood, therefore the availability of a specific inhibitor for 
cellular studies would be of great advantage to shed light on it. We thus tested if 
TBID administrated to intact cells induces inhibition of endogenous HIPK2. For 
this purpose, we exploited phosphorylation assays of lysates from treated cells, 
using a synthetic peptide as specific substrate for HIPK2; otherwise we checked the 
phosphorylation level of p53 HIPK2 sites with a phosphor-specific antibody. We 
also wanted to verify the absence of cytotoxicity of TBID under the condition used 
for cell treatment. 
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RESULTS 
  
INHIBITION OF ENDOGENOUS HIPK2 IN CELL TREATED 
WITH TBID  
To check if TBID is cell permeable, we treated intact cells with increasing 
concentrations of TBID, then we lysed cells and measured HIPK2 activity by an 
immunoprecipatation assay. HIPK2 was pulled down with a specific antibody, that 
recognized only HIPK2 kinase and no other HIPK isoforms, and its activity was 
assayed using a HIPK2 specific peptide substrate, in the presence of a mixture 
containing radioactive ATP. As shown in Figure 3, endogenous HIPK2 activity is 
reduced in a dose dependent manner upon cell treatment with TBID, without any 
effects on the amount of HIPK2. As a control, we treated cells with the TBID 
analog 5e, which is inactive towards HIPK2 in vitro (see Table1). As evident in 
Figure 3, HIPK2 immunoprecipitated from cells treated with 5e does not display 
any reduction of catalytic activity. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Cell treatment with TBID inhibits endogenous HIPK2. HIPK2 was 
immunoprecipitated from lysates of HepG2 cells treated with different concentrations of TBID or 
the inactive analog 5e, as indicated; HIPK2 activity was measured towards the specific peptide 
substrate, as detailed in Materials and Methods. The amount of immunoprecipitated HIPK2 is 
shown by WB (from Cozza et al., 2014). 
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To reinforce the analysis of HIPK2 inhibition in cells, we evaluate the 
phosphorylation state of a HIPK2 endocellular substrate in treated cells. We 
checked the phosphorylation state of p53 at Ser46, which is a known target of 
HIPK2 (Puca et al., 2008). As shown in Figure 4, treatment with TBID markedly 
reduces the phosphorylation level of this residue, without affecting the amount of 
p53. 
 
 
 
 
 
Figure 4. Phosphorylation level of p53ser46. CEM cells were treated as indicated, then 10 mg of 
cell lysate proteins was analyzed by WB with anti-Sp46 of p53, anti-total p53, or anti-actin, as 
loading control. A representative experiment is shown on the left, while a histogram is presented 
on the right where Sp46 p53 of three separate experiments has been quantified, normalized to the 
p53 total level, and reported as means + SEM (from Cozza et al.,2014). 
We finally wanted to exclude that TBID exerts a cytotoxic effect under the 
conditions used for the inhibition of endogenous HIPK2. The absence of 
cytotoxicity was demonstrated by checking cell viability with an MTT assay, and 
excluding that apoptosis occurs, as judged by the absence of any cleavage of the 
caspase substrate PARP, whose amount seems instead to increase in response to 
TBID. 
 
 
 
 
 
Figure 5. Effects of TBID on cell viability. Cell viability was assessed by the method of MTT, 
treating HepG2 or CEM cells as indicated (left panel) or by evaluating the amount of the 
caspase substrate PARP (HepG2 cells, right panel), whose reduction would denote apoptosis. 
The recognized band corresponds to the full length PARP protein of 116kDa (from Cozza et 
al.,2014). 
116 kDa 
42 kDa 
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DISCUSSION 
Data obtained by in vitro experiments had demonstrated that TBID is a very 
effective and selective inhibitor of HIPKs and of HIPK2 in particular. It displays 
an IC50 of 0.33 mM towards HIPK2 and, tested at 1mM on 125 PKs, only HIPK 
family members are inhibited more than 50% (Cozza et al., 2014). My work has 
focused on cell experiments, and has demonstrated that TBID is suitable for in 
cell studies where the role of HIPK kinases in signal transduction needs to be 
investigated.  This availability is particular significant for a protein kinase whose 
role is emerging as regulator of cell growth/apoptosis, with implication in the 
mode of action of chemotherapeutic agents, but whose mechanism of action is 
still largely unknown. The only compound available until now as an HIPK2 
inhibitor was SB203580, which however inhibits different classes of protein 
kinases and has a questionable efficacy in inhibiting HIPK2 activity (Bain et al., 
2007). On the other hand, a number of compounds are known which inhibit both 
protein kinase CK2 and HIPK2 (Sarno et al., 2008), and indeed TBID is the 
result of modification operated on a CK2/HIPK2 inhibitor to render it selective 
for HIPK2. In this context, it should be noted that the concentrations required to 
inhibit HIPK2 in cells are much higher in vitro, with half maximal inhibition two 
orders magnitude higher (50 μM vs 0.33 μM). However, this is not unusual 
among protein kinase inhibitors (Davies et al., 2000), and similar ratio has been 
frequently observed for other kinase inhibitors (e.g. Ruzzene et al., 2002; Sarno 
et al., 2012; Zanin et al., 2012). This may be explained by possible adsorbance 
of lipophilic compounds to cellular structures and to the fact that ATP 
competitive inhibitors (such as TBID) have to overcome a very high ATP 
concentration (in the mM range) within the cell.  
In conclusion, the TBID properties in conjunction with its ability to permeate 
cells, make TBID the first choice and for the time being the only tool to down 
regulate HIPK2 in cells. 
 
 
 
 
  
 
 
 
 
 
 
GENERAL CONCLUSIONS 
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In this thesis we have analyzed different inhibition strategies to target protein kinase 
CK2, and their cellular effects on tumor and non-tumor cell lines. In accordance 
with its pro-survival and anti-apoptotic function and its overexpression in cancer 
cells, CK2 can be considered as a suitable pharmacological target. For this reasons 
we have analyzed three different approaches to hit CK2, all with the final goal to 
block its activity and induce cell death in tumor cells. We compare the cellular 
effects of two canonical ATP-competitive CK2 inhibitors, CX-4945 (at present in 
clinical trials) and its analog CX-5011 (Pierre et al., 2011); a bi-functional CK2 
inhibitor called K137-E4, very recently developed in our laboratory, designed to 
block both the ATP and the peptide sites of CK2; the cyclic peptide called CRIBI-
300, derived from CIGB-300, which was designed to prevent the phosphorylation 
of some CK2 substrates (Perea et al., 2004) and in clinical trials as well (Perea et 
al., 2011).  
From our results we conclude that compounds which act as ATP-competitive 
inhibitors remain, until now, the best choice to target CK2 in tumor cells. In fact, 
we demonstrated that ATP-competitive CX-4945 and CX-5011 inhibitors are able 
to efficiently induce apoptosis also in tumor resistant cells, overcoming the problem 
of multi-drug resistance. Moreover CX-4945 is able to sensitize resistant cells, 
expressing the P-gp pump, to the conventional chemotherapeutics, displaying a 
synergistic effect when co-administrated with vinblastine. 
 K137-E4 has been demonstrated to be the most specific and potent CK2 inhibitor 
presently available, but it is not exploitable for in vivo studies, since we found that it 
is not cell permeable; future improvements will be necessary to render it more 
hydrophobic, thus able to cross the plasma membrane.  
On the other hand, alternative strategies to target CK2 without interfering with the 
ATP binding site have been also taken into account as they avoid some issues of 
most conventional ATP-competitive inhibitors: they overcome the problem of 
competition with intracellular high ATP concentration, and they are expected to be 
more specific, not relying on residues of the ATP binding site conserved in all the 
kinases. CRIBI-300, a cyclic peptide whose sequence has been modeled with the 
aim of interfering with the phosphorylation of some specific CK2 substrates, could 
display some of these advantages. From our findings, however, CRIBI-300 has 
proved to have multiple sites of action: besides targeting CK2 substrates, we found 
that it directly hits CK2 and produces its early degradation; moreover, it causes 
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perturbation in the proteolytic activity of the cells and other dramatic effects, with 
the final outcome of cell death, which however is not due to apoptosis. Thus, further 
studies at a molecular level are necessary, in order to rationalize and optimize its 
therapeutic employment.  
One of the major aims of this work, and in general of the research on kinase 
inhibitors, was the finding of very selective compounds, able to block only one 
specific target. This would be of course a great advantage for the usage of the 
inhibitor in cell experiments aimed to investigating the role of the target kinase; in 
this case, collateral and often unknown targets can produce results difficult to be 
interpreted or even misunderstood. However, it is worth to note that, when the 
inhibitor has to be developed as a possible pharmacological tool, its absolute 
selectivity might not be really preferred. For example in cancer, redundancies of 
pathological signaling pathways very often occur, and they can not be effectively 
controlled by a too selective inhibitor. In this case, down regulating more than one 
target could be an alternative and fruitful strategy. In fact, the combination of two 
or more compounds is often shown to produce a synergistic instead of additive 
effect; moreover, agents that are able to address simultaneously two or more targets 
could be useful in this context. Research is moving on this direction, and dual 
inhibitors are now very promising compounds; also in the field of CK2, a dual 
inhibitor has been recently proposed, TDB (Cozza et al., 2014), able to 
simultaneously block CK2 and another cancer related kinase, PIM1 (Brault et al., 
2010). 
On this regard, in this thesis preliminary but interesting results are presented 
concerning the synergism between CX-4945 and CX-5011, both selective CK2 
inhibitors, but for some reasons able to produce a higher degree of apoptosis (also 
in resistant cells) when administrated together instead than separately. 
The results here presented of cell death induction by CK2-targeting compounds 
have confirmed that tumor cells are more sensitive respect to non-tumor cells. This 
is in accordance with other observations already done (e.g. Piazza et al., 2006; Di 
Maira et al., 2007), and it is explainable considering that cancer cells seem to be 
addicted to CK2: they display higher amount of CK2 if compared to normal cells, 
and they rely more on it for they survival; as a consequence, when CK2 is blocked, 
they are more susceptible and more inclined to die.  
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In this study, we had also the opportunity to investigate on a still poorly known 
form of CK2, the so called ecto-CK2, corresponding to the pool of this kinase 
present at the external side of the plasma membrane. In fact, the CK2 inhibitor 
K137-E4, not able to cross membranes has been exploited to this purpose. We 
demonstrated that ecto-CK2 is active both in tumor and non tumor cells, 
presumably at similar levels, and we provided the first evidence that its inhibition 
does not correlate with the induction of apoptosis. Thus we conclude that the CK2 
ectokinase roles are probably not related to the well-established pro-survival and 
anti-apoptotic functions of endocellular CK2. 
Considering the importance of inhibitor development for the investigation of a 
kinase function, the collateral study presented in this thesis is of great relevance, 
since it characterizes TBID, a very selective and cell-permeable HIPK2 kinase 
inhibitor, the only compound presently available to investigate the cellular 
physiological role, still poorly understood, of HIPK2 kinase. TBID was developed 
in our laboratory by a modification of an ATP-competitive CK2 inhibitor, and it is 
an example of how unexpected (or even unwanted) results, such as limited 
specificity, can be exploited and improved to obtain new and useful biochemical 
tools. 
In summary, the study presented in this thesis has shown different strategies of 
kinase inhibition and possible employments of CK2 inhibitors as promising tools in 
cancer therapy. 
Although in the past years the developing of CK2 inhibitors has been concentrated 
on ATP-competitive compounds, which still seem to be the first-choice strategy, we 
can imagine that alternative possibilities will become applicable in future, and will 
be optimized to block only those CK2-dependent events which are strictly related to 
cancer or other diseases.  
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Abstract
CK2 is a pleiotropic protein kinase, which regulates many survival pathways and plays a global anti-apoptotic function. It is
highly expressed in tumor cells, and is presently considered a promising therapeutic target. Among the many inhibitors
available for this kinase, the recently developed CX-4945 and CX-5011 have proved to be very potent, selective and effective
in inducing cell death in tumor cells; CX-4945 has recently entered clinical trials. However, no data are available on the
efficacy of these compounds to overcome drug resistance, a major reasons of cancer therapy failure. Here we address this
point, by studying their effects in several tumor cell lines, each available as variant R resistant to drug-induced apoptosis,
and normal-sensitive variant S. We found that the inhibition of endogenous CK2 was very similar in S and R treated cells,
with more than 50% CK2 activity reduction at sub-micromolar concentrations of CX-4945 and CX-5011. A consequent
apoptotic response was induced both in S and R variants of each pairs. Moreover, the combined treatment of CX-4945 plus
vinblastine was able to sensitize to vinblastine R cells that are otherwise almost insensitive to this conventional antitumor
drug. Consistently, doxorubicin accumulation in multidrug resistant (MDR) cells was greatly increased by CX-4945. In
summary, we demonstrated that all the R variants are sensitive to CX-4945 and CX-5011; since some of the treated R lines
express the extrusion pump Pgp, often responsible of the MDR phenotype, we can also conclude that the two inhibitors can
successfully overcome the MDR phenomenon.
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Introduction
CK2 is a Ser/Thr protein kinase usually present in the cells as a
tetrameric enzyme composed of two catalytic (a and/or a’) and
two regulatory (b) subunits. It is constitutively active and
ubiquitously expressed, and phosphorylates such a striking number
of substrates to be considered the most pleiotropic protein kinase
[1]. It is involved in several cellular processes, such as cell cycle,
gene expression, protein synthesis, signal transduction and
metabolism; however, its hall-mark is considered its prosurvival
and anti-apoptotic function [2–5]. This is supported by the
observation that many CK2 substrates are proteins involved in cell
death/survival, and, more importantly, that the reduction of CK2
activity or expression (induced by cell treatment with specific
inhibitors or by RNA interference technology, respectively) is
invariantly followed by cell death, mainly due to apoptosis
(reviewed in [6]).
Consistent with the anti-apoptotic function of CK2, cancer cells,
which are characterized by rapid proliferation and defective
apoptosis, express particularly high levels of CK2. It has a special
role in tumorigenesis [7], potentiating pathways that are frequently
up-regulated or untimely activated in cancer [8], and it has
consequently been defined as ‘‘a key player in cancer biology’’ [9].
Whenever comparison has been performed, CK2 has been shown
significantly more abundant in tumor cells than in healthy
counterparts. However, at the same time tumors rely more on
CK2 for their survival, and this phenomenon, described as
‘‘addiction’’ to CK2 of cancer cells [6], explains why they are
more sensitive to its inhibition or knocking-down, compared to
normal cells.
On these bases, CK2 is presently considered a promising
therapeutic target [7,10], also exploiting the fact that, due to the
peculiar structure of the CK2 catalytic site [11,12], several very
specific inhibitors are available (reviewed in [13]). Many of them
have already proved to be able to kill cancer cells and in some
cases also employed for successful animal treatment (e.g. [14–18]).
The two compounds CX-4945 and CX-5011 are among the
most selective and effective CK2 inhibitors developed so far. They
are tricyclic ATP-competitive compounds, displaying a Ki in vitro
,1 nM [17,19], and an unprecedented selectivity for CK2,
proved by profiling them against a panel of 235 protein kinases
[19]. Both CX-4945 and CX-5011 are able to cause apoptosis in a
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number of cancer cell lines and are effective in reducing tumor size
in animal models of cancer [17,20]; CX-4945 is orally bio-
available, and is presently in clinical trial for treatment of different
kinds of cancer [17]. However, CX-4945 and CX-5011 have
never been tested in cells that are resistant to drug-induced
apoptosis.
Apoptosis resistance is a major reason of cancer therapy failure;
its mechanisms can be different and multifaceted, and is only
partially understood. In many cases it is due to the (over)expression
of extrusion pumps of the ABC-transporter family, such as Pgp,
which drive drugs outside the cell and reduce their effective
concentration [21]. Cells expressing these pumps are selected for
their survival in response to treatment with a certain drug, but
usually a cross-resistance occurs towards other compounds, even
not structurally related; in these cases, cells are indicated as
multidrug-resistant (MDR). Many other mechanisms have been
reported to be involved in apoptosis resistance, including alteration
in genetic features, DNA repair, drug target molecules, metabolic
and growth pathways [22,23]. In some cases, specific resistance is
observed, such as that towards Imatinib and its derivatives
targeting Bcr-Abl tyrosine kinase, frequently due to kinase
mutations, but also to epigenetic changes, alternative splicing or
induction of compensatory signaling pathways [24].
CK2 has been already associated to the phenomenon of drug
resistance: it phosphorylates Pgp [25] and another extrusion
pump, MRP1 [26] and its inhibition allows a higher accumulation
of drugs in Pgp [27] or MRP1 [26] expressing cells, suggesting that
Figure 1. Pgp expression. 10 mg of proteins from total lysates of the
indicated cells were loaded onto an SDS-PAGE, blotted and analyzed by
WB with anti-Pgp or anti-actin.
doi:10.1371/journal.pone.0049193.g001
Figure 2. CK2 activity in CX-4945-treated cells. (A) CK2 activity was measured towards a synthetic specific peptide. 1–2 mg of proteins from
total lysates of the indicated cells were incubated with the peptide and a radioactive phosphorylation mixture (see Materials and Methods). Activity is
reported as percentage of that found in vehicle-treated control cells. Mean6 SE values of four independent experiments are shown. (B) 10 mg of total
proteins were analyzed with the indicated antibodies; actin was used to normalize the loading. Representative WB of three independent experiments
are shown.
doi:10.1371/journal.pone.0049193.g002
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CK2 can up-regulate the Pgp function. Moreover, we have
previously found that the CK2 catalytic subunit is overexpressed in
a MDR cell line compared to the non-MDR counterpart, and that
its overexpression contributes to the maintenance of the resistant
phenotype [27].
Here we evaluate the efficacy of the CK2 inhibitors CX-4945
and CX-5011 in a number of different cell lines, available as pairs,
each pair containing a variant selected for resistance to drug-
induced apoptosis, and we demonstrate that these compounds can
overcome the problem of drug resistance.
Materials and Methods
Antibodies
CK2a-subunit antisera were raised in rabbit against the
sequence of the human protein at C-terminus [376–391], total
Akt and total Cdc37 antibodies were from Santa Cruz Biotech-
nology, b-actin monoclonal antibodies were from Sigma, PARP
antibodies were from Roche, Pgp monoclonal antibodies were
from Calbiochem, Akt Sp129 phospho-specific antibodies were
raised in rabbit and purified as elsewhere described [28]; Cdc37
Sp13 phospho-specific antibodies were from Abcam; secondary
antibodies towards rabbit and mouse IgG, conjugated to horse
radish peroxidase, were from PerkinElmer.
Cell lines
The following cell lines were used in this study: human T
lymphoblastoid CEM cells (normal sensitive, S-CEM, and their
MDR variant, R-CEM, selection with 0.1 mg/ml vinblastine, Vbl
[27]); human osteosarcoma U2OS cells (normal sensitive, S-
U2OS, and their MDR variant, R-U2OS [29]); human ovarian
carcinoma 2008 cells (normal sensitive, S-2008, and their cisplatin-
resistant variant, R-2008 [30]); chronic myeloid leukemia (CML)
LAMA84 [31], KCL22 [32], and K562 [32] cell lines, sensitive or
resistant to Imatinib, kindly supplied by Dr. C. Gambacorti-
Passerini.
Inhibitors
CX-4945 (5-(3-chlorophenylamino)benzo[c][2,6]naphthyri-
dine-8-carboxyliuc acid) and CX-5011 (5-(3-ethynylphenylami-
no)pyrimido[4,5-c]quinoline-8-carboxylic acid) were synthetized
by Cylene Pharmaceutical. Solutions were made in dimethylsulf-
oxide (DMSO).
Cell culture and treatment
Cells were cultured in an atmosphere containing 5% CO2;
CEM, LAMA84, K562 and KCL22 cell lines were maintained in
RPMI 1640 medium (Sigma), U2OS and 2008 lines were
maintained in D-MEM medium (Sigma); both media were
supplemented with 10% (v/v) fetal calf serum (FCS), 2 mM L-
glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin.
Cell treatments with inhibitors were performed in the culture
medium, but with 1% FCS, where not differently indicated.
Control cells were treated with equal amounts of the inhibitor
solvent. At the end of the incubations, cells were harvested by
centrifugation, washed, and lysed as indicated below.
Cell viability
Cell viability was detected by means of MTT (3-(4,5-
dimethylthiazol-2-yl)-3,5-diphenyltriazolium bromide) reagent:
cells (105 cells/100 ml) were incubated for variable times in a 96-
well plate under the indicated conditions. 1 h before the end of the
incubation, 10 ml of MTT solution (5 mg/ml in PBS) were added
to each well. Incubations were stopped by addition of 20 ml of lysis
solution at pH 4.7, as described elsewhere [33]. Plates were read
for OD at l590 nm, in a Titertek Multiskan Plus plate reader
(Flow Laboratories). DC50 (concentrations inducing 50% of cell
death) values were calculated with Prism 4.0c software (GraphPad
Software).
Apoptosis assay
Apoptosis was evaluated by means of the Cell Detection Elisa kit
(Roche), based on the quantification of nucleosomes present in the
cytosol of the apoptotic cells, by measuring the absorbance at
l405–l490, following the manufacturer’s instructions. About
10 000 cells were used for each determination.
Cell lysis and western blot analysis
For lysate preparation, cells were lysed as described in [27].
Protein concentration was determined by the Bradford method.
Equal amounts of proteins were loaded on 11% SDS-PAGE,
blotted on Immobilon-P membranes (Millipore), and processed in
western blot (WB) with the indicated antibody, detected by
chemiluminescence. Quantitation of the signal was obtained by
chemiluminescence detection on a Kodak Image Station 440MM
PRO and analysis with the Kodak 1D Image software.
CK2 activity assay
1–2 mg of lysate proteins were incubated for 10 min at 30uC
with 0.1 mM CK2-specific peptide RRRADDSDDDDD, in the
presence of phosphorylation reaction mixture [34]. Phosphoryla-
tion of endogenous proteins was performed on 5 mg of lysate
proteins under the same conditions, but without the addition of the
Figure 3. CK2 activity in CX-5011-treated cells. S-CEM and R-CEM
cells were treated for 24 h with different concentrations of CX-5011.
Cell lysates were analyzed for the activity of CK2 towards a synthetic
specific peptide (upper graph), or by WB with the indicated antibodies
(lower panel, separate development for S- and R-CEM cells). See details
in the legend of Figure 2.
doi:10.1371/journal.pone.0049193.g003
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peptide substrate, and analyzed by SDS/PAGE and digital
autoradiography (CyclonePlus, PerkinElmer).
Combined treatments
Drug interactions were assessed by treating cells with increasing
concentrations of both Vbl and CX-4945, at fixed concentration
ratio, as indicated. The combination index (CI) [35], was
calculated with the software Calcusyn (Biosoft); CI,1, CI= 1,
and CI.1 indicate synergistic, additive and antagonistic effects,
respectively. Values are reported as mean of three separate
experiments 6 SE.
Doxorubicin accumulation measurement
Doxorubicin measurements were performed as previously
described [27]. Briefly, CEM cells were treated with 25 mM
doxorubicin (Sigma) for 30 min, after 30 min preincubation in the
absence or in the presence of CX-4945. After washing with
phosphate-buffered saline, cells were lysed in the same buffer,
supplemented with 1% (w/v) SDS. Doxorubicin content was
determined fluorimetrically (lexc.485 nm, lem.590 nm).
Statistical analysis
All experiments were performed at least 3 times, each time in
duplicate; graphs and statistical analysis were performed with
Prism 4.0c software (GraphPad Software).
Results
For this study, we used 6 different pairs of cell lines, each
available in two variants: the S variant, corresponding to cells
normally sensitive to drug-induced apoptosis, and the R variant,
characterized by drug resistance due to different reasons. As
shown in Figure 1, CEM and U2OS resistant cells express the Pgp
pump, responsible for the extrusion of a variety of drugs from the
cell (reviewed by Goda et al., [36]); thus R-CEM and R-U2OS are
considered MDR (multi-drug resistant) lines. Pgp is not apprecia-
bly expressed by the R variants of the other cell lines, which
instead display resistance for specific drugs: 2008 cells were
selected for their resistance to cisplatinum, while R-LAMA84, R-
KCL22 and R-K562 are resistant to Imatinib [37].
Figure 4. Protein phosphorylation in lysates from cells treated with CX-4945, CX-5011, or staurosporine. S-CEM (upper panel) or R-CEM
(lower panel) were treated with the indicated concentrations of the CX inhibitors or staurosporine for 16 h, then lysed. 5 mg of total proteins were
incubated with a radioactive phosphorylation mixture, resolved by SDS-PAGE, blotted, and analyzed by digital autoradiography (radioactivity). WB for
actin was used as loading control. Asterisk * denotes samples where the inhibitors were added in vitro during the phosphorylation assay (not
administrated to the cells). Representative results of five independent experiments are shown.
doi:10.1371/journal.pone.0049193.g004
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Figure 5. Cell viability of CX-4945 and CX-5011 treated CEM cells. Cells were incubated with increasing concentrations of the CX
compounds; the FCS concentration in the medium and the treatment time are indicated on each graph. Cell viability was assessed by the MTT
method, assigning 100% value to the vehicle-treated control cells. Mean 6 SE values of at least four independent experiments are reported.
doi:10.1371/journal.pone.0049193.g005
CK2 Inhibitors and Drug Resistance
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Figure 6. Cell viability of CX-4945 and CX-5011 treated U2OS cells. See legend of Figure 5 for details.
doi:10.1371/journal.pone.0049193.g006
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We first measured CK2 activity in cells treated for different
times with increasing concentrations of the compounds. To this
purpose we exploited two strategies: in vitro assays of endogenous
CK2 present in total lysates from treated cells [34], and evaluation
of the phosphorylation state of CK2 specific intracellular
substrates, by means of phospho-specific antibodies towards two
key targets of CK2, namely Akt S129 [28] and Cdc37 S13 [38].
Both approaches indicated that the compounds promptly inhibit
CK2 in S and R cells, with similar efficacy, without affecting the
amount of CK2. Figure 2 shows the results obtained with CX-
4945, in CEM, U2OS, and LAMA84 cells, while in Figure 3 the
effects of CX-5011 on CEM cells is shown; similar results were
observed in response to treatment of the other cell lines (not
shown). As evident in Figure 2B, the expression of CK2
significantly differs in S- and R- CEM cells, as already reported
[27], and, in untreated cells (see control lanes, marked as ‘‘-’’ in
Figure 2B), it correlates with the phosphorylation level of
endogenous substrates Cdc37 Sp13 (phospho-Ser13) and Akt
Sp129 (phospho-Ser129), despite the low level of Akt in R-CEM.
In all cases, at submicromolar concentrations of the compounds,
CK2 activity is reduced by more than 50%, and a parallel
dephosphorylation of endogenous substrates occurs. Interestingly,
a 6 h treatment is sufficient to inhibit CK2 to almost the maximal
level, and longer treatment times only minimally increase the
degree of inhibition (Figure 2A). The reduction of Akt Sp129 is
also promptly induced (6 h, 0.5 mM CX-4945), while the CK2
target site on Cdc37 seems to be more resistant to dephosphor-
ylation, which is clearly observed only at higher concentrations
and longer treatments (Figure 2B). Similar results are observable in
response to CX-5011 (not shown and Figure 3 for 24 h treatment).
Inhibition of CK2 was also confirmed by analyzing the
radioactive phosphorylation of endogenous proteins in treated
cells. Figure 4 shows that several protein bands are less
phosphorylated in S- and R-CEM cells treated with CX-4945 or
CX-5011 (similarly to what is observable when the compounds are
added in vitro, during the phosphorylation assay). To rule out the
possibility of a non-specific effect, we treated cells with
staurosporine, at concentrations which inhibit the majority of
protein kinases but not CK2 [39]. This treatment, while inducing
a high degree of cell death (not shown) similarly to what caused by
the CK2 inhibitors (see below), it is almost ineffective on
endogenous protein phosphorylations; this also suggests that,
under the used conditions, CK2 is the major kinase responsible for
the observed radioactivity, as expected for a highly expressed,
pleiotropic and constitutively active enzyme.
To ascertain if CK2 inhibition by CX-4945 and CX-5011 is
effective in inducing cell death also in case of drug resistance, we
treated cells with increasing concentrations of the compounds, and
measured cell viability by the MTT method. Figures 5, 6, 7, 8
show representative results obtained under different time and
assay conditions. We found that both inhibitors are able to induce
appreciable cell death also in R cells, in a manner quite similar to
S cells (at least when 10% FCS is present, see Discussion). In
particular, the responsiveness of MDR cells (R-CEM and R-
U2OS) indicates that these compounds are not substrate of the
Pgp. Table 1 shows the DC50 values calculated from the MTT
assays shown in Figure 5, 6, 7, 8; the 48 h assays were used for
calculation, except for CEM cells in the presence of 10% FCS,
where 24 h assays were considered.
To understand if cell death induced by CX-4945 and CX-5011
in our cell lines was due to apoptosis, we evaluated the formation
of nucleosomes in treated cells; the results, shown in Figure 9 for
CEM cells, and confirmed for the other cell lines (not shown),
indicated that apoptosis occurs to a similar degree in S and R cells,
in response to these CK2 inhibitors. The results are also confirmed
by the cleavage of the caspase substrate PARP (Figure 9).
Then we assessed if the treatment with CX compounds can
sensitize resistant cells towards conventional antitumor drugs; in
particular, we considered the Vbl-resistant R-CEM cells, and we
evaluated if the combined treatment with CX-4945 induces a
higher degree of cell death in response to Vbl. As shown in
Figure 10 (lower panels), very low concentrations of CX-4945 are
able to significantly reduce the DC50 of Vbl (from 39.4 to 6.2 mg/
ml). The calculated Combination Index (CI) is indeed 0.6660.04,
where values ,1 indicate synergism [35]. Interestingly, CX-4945
exerts a synergistic effect with Vbl also in S-CEM: as shown in
Figure 10, upper panels, the effect of very low concentrations of
Vbl on cell viability is increased by the simultaneous administra-
tion of the CK2 inhibitor (CI = 0.7060.08), indicating that the
combined treatment can be applied for therapy with significantly
lower drug doses. An important synergistic effect is also observable
between Imatinib and CX-4945 on Imatinib-resistant cells
(manuscript in preparation).
Figure 7. Cell viability of CX-4945 and CX-5011 treated 2008 cells. See legend of Figure 5 for details.
doi:10.1371/journal.pone.0049193.g007
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Figure 8. Cell viability of CX-4945 and CX-5011 treated Imatinib-resistant cells. See legend of Figure 5 for details.
doi:10.1371/journal.pone.0049193.g008
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Since the extrusion pumps expressed in MDR cells are
phosphorylated by CK2 [25,26], and an activation effect has
been clearly demonstrated, at least in the case of MRP1 [26], we
finally assessed whether a short treatment with CX-4945 allows a
higher accumulation of conventional drugs inside resistant cells.
To this purpose, exploiting the fluorescence of doxorubicin, we
measured its uptake in CEM cells pre-treated with CX-4945,
compared to untreated cells (Figure 11), and we found that the
inhibitor markedly increases the amount of drug retained inside R-
CEM cells, while it is almost ineffective in S-CEM cells.
Discussion
Although CK2 is not considered a direct cause of cancer and
cannot be strictly defined as an oncogene, its high abundance in
cancer cells is indicative of its importance in tumorigenesis. We
have previously hypothesized [40] that, whenever, for any reason,
a cell displays a higher level of CK2, that cell will have a survival
advantage over the other cells, and will be selected to proliferate
under the pressure represented by treatment with pro-apoptotic
drugs. CK2 is thus expected to play a major role in the apoptosis
resistant phenotype, as also suggested by previous studies [27,41].
Moreover, since CK2 expression is not linked to specific types of
cancers, its targeting could be a successful strategy, because of its
very general applicability and widespread effects.
Importantly, cancer cells are expected to be more sensitive to
CK2 inhibition than normal cells, since they are addicted to CK2,
strongly relying on it for their survival [6]. Accordingly, the CK2
inhibitors have proved to be more effective in tumor cell lines than
in normal ones [17,42], and, on these bases, CX-4945 has entered
clinical trials, with promising initial results. Here we demonstrate
that the CX inhibitors are also able to overcome the problem of
resistance to apoptosis, since they are similarly effective in resistant
cells (R) and their normally sensitive counterparts (S). Interestingly,
our R cell lines display different kind of apoptosis resistance: R-
2008 cells are resistant to cisplatinum; R-LAMA84, R-KCL22 and
R-K562 are resistant to Imatinib, while R-CEM and R-U2OS are
MDR cells, expressing the Pgp pump. Therefore, the first outcome
of our data is that CK2 inhibition has a general effect on resistant
cells, by reducing the efficacy of cellular equipment to escape
apoptosis; secondly, we can conclude that CX-4945 and CX-5011
inhibitors are not recognized by the Pgp, since their effects are
visible in cells expressing this MDR pump.
An observation from our results is that the CX compounds,
especially CX-5011, seem to be less effective with U20S cells than
with the other cell lines (compare Figure 6 with Figures 5, 7 and 8);
the reasons are presently unknown, however they are not related
to the MDR phenomenon, being the response very similar in the S
and R variants of this cell line.
It can also be observed that the inhibitors are slightly less
effective in R-CEM than in S-CEM; however the difference
between the two variants is detectable on cell viability and not on
endogenous CK2 inhibition, and is abrogated when cell viability
assays are performed in the presence of 10% instead of 1% FCS
(Figure 5). Although we do not know the exact reason of the
different results observed at 10% or 1% FCS, our interpretation is
that, at quite critical conditions (such as 1% FCS), the anti-
apoptotic machinery of R-CEM is more effective than that of S-
CEM in protecting cells from the stress represented by CK2
inhibition; on the contrary, under fully healthy conditions (10%
FCS), the two cell variants are equally equipped to counteract
apoptosis. In any case, these findings suggest that any observed
difference is not due to extrusion of the inhibitors by the Pgp, as
also confirmed by the results obtained with other Pgp-expressing
cells (compare S-U2OS and R-U2OS, Figure 6).
We have previously found that R-CEM display a higher level of
the CK2 catalytic subunit compared to S-CEM [27], and this is
confirmed by the results here shown in Figure 2B, where it is also
evident that the phosphorylation state of CK2-dependent sites
(particularly of Akt Sp129) in R-CEM is higher than in S-CEM.
Interestingly, despite the different endogenous CK2 activity, the
degree of inhibition induced by CX-4945 and CX-5011 is very
similar in S- and R-CEM cells (Figure 2A).
While it is obviously confirmed that CK2 blockade causes
apoptosis, an interesting observation emerging from our results is
that cell death is appreciable only when the degree of CK2
inhibition induced by the CX compounds is sufficiently high to
ensure a dephosphorylated state of major substrates. In fact we
found that, while the endogenous CK2 activity towards a peptide
substrate is already halved in cell treated with ,0.5 mM inhibitors
(see for example 24 h treatment in CEM cells, Figure 2),
significantly higher concentrations are required to induce 50%
cell death (see Figure 5). However, if we consider the phosphor-
ylation states of the CK2 sites analyzed by phospho-specific
antibodies, we observe that while Akt Sp129 is promptly reduced,
Cdc37 Sp13 phosphorylation is much more stable. Of course,
extending our considerations to the multitude of CK2 substrates,
we can presume that each one has its own susceptibility to CK2
inhibition, that will mainly depend on the turnover of its
phosphorylation state; since this is obviously the result of the
balance between kinase and phosphatase activity, there will be a
variability depending on cell type and conditions. We cannot
exclude that the dephosphorylation of one or few specific CK2
substrates is required before cell death occurs; alternatively, we
Table 1. DC50 of CX-4945 and CX-5011.
CEM CEM* U2OS 2008 LAMA84 K562 KCL22
1% FCS 10% FCS 1% FCS 1% FCS 10% FCS 10% FCS 10% FCS
S R S R S R S R S R S R S R
CX-4945 1.92 4.09 8.62 6.50 4.58 4.33 4.87 6.56 8.55 5.79 3.41 3.72 3.30 2.95
(mM) 61.00 60.27 60.68 61.40 60.44 60.63 62.50 60.48 61.10 60.86 60.55 60.42 61.46 60.89
CX-5011 2.40 2.51 7.51 7.59 .10 8.59 2.13 2.01 5.07 2.68 3.58 3.05 3.01 3.10
(mM) 60.07 60.60 62.33 61.35 60.62 60.02 60.21 61.42 60.81 61.18 60.78 61.39 60.86
The values, calculated from 48 h MTT assays reported in Figures 5, 6, 7, 8 (except for CEM*= 24 h treatment), are the mean of 4–6 independent experiments 6 Standard
Deviation. FCS concentration (v/v) during the treatment is also indicated.
doi:10.1371/journal.pone.0049193.t001
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Figure 9. Apoptosis induction by CX-4945 and CX-5011. (A) Apoptosis was assessed by evaluation of nucleosomes present in the cytosol,
using the Cell Detection Elisa kit (Roche), after 8 h of CEM cell treatment as indicated. Nucleosome enrichment was calculated from the ratio between
the signal in treated and untreated cells; reported values are the means 6 SE of four independent experiments. (B) Caspase-dependent PARP
cleavage was analyzed by WB on 10 mg proteins of lysate from CEM or U2OS cells treated as indicated. Actin WB was used as loading control.
Representative WB of three independent experiments are shown. f.l. PARP: full length PARP.
doi:10.1371/journal.pone.0049193.g009
CK2 Inhibitors and Drug Resistance
PLOS ONE | www.plosone.org 10 November 2012 | Volume 7 | Issue 11 | e49193
can assume that only a massive dephosphorylation of CK2
substrates will produce cell death, whose extent, therefore, does
not necessarily correlate with the decrease of CK2 catalytic
activity.
Another important outcome of our data is that CX-4945 can be
useful to sensitize resistant cells to conventional chemotherapeutic
drugs. It has already been reported that CX-4945 augments the
anti-tumor efficacy of gemcitabine and cisplatin on ovarian
cancers [43]. The association of CX-4945 with Erlotinib, an
Figure 10. Effect of combined treatment with CX compounds and chemotherapeutic drugs. S-CEM and R-CEM viability was assessed by
the MTT method after 24 h treatment with increasing concentrations of both CX-4945 and Vbl, administrated alone or in combination, at fixed ratio
(1 mM CX-4945 : 0.8 mg/ml Vbl for S-CEM, 1 mM CX-4945 : 2 mg/ml Vbl for R-CEM, due to their different sensitivity to Vbl). Viability (mean values 6 SE
of four experiments) was plotted as function of Vbl concentrations (left panels), or CX-4945 concentrations (right panels).
doi:10.1371/journal.pone.0049193.g010
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EGF-receptor inhibitor, has also been proposed [44]; in this case,
interestingly, the enhanced killing effect of the combined treatment
is accompanied by a reduction of the PI3K-Akt-mTOR pathway,
with the complete abrogation of Akt phosphorylation. Here we
extend the drug-combination experiments to MDR cells, showing
that R-CEM are six fold more sensitive to Vbl when simulta-
neously treated with sub-lethal doses of CX-4945, compared to
when treated with Vbl alone. Moreover, we also found that the
CK2 inhibition by CX-4945 allows an increased accumulation of
doxorubicin in R-CEM (Figure 11), most probably blocking the
positive effect that CK2 exerts on Pgp. As expected, the drug
accumulation is unaffected by CX-4945 in S-CEM, not expressing
Pgp; since the synergism between CX-4945 and chemotherapeutic
drug is instead observable also in S-CEM (Figure 10), we have to
assume that additional mechanisms of increased cell death, other
than the effect on the Pgp pump, are induced by the combined
treatment.
A parallel study has been undertaken for the synergistic effect of
Imatinib and CX-4945 in Imatinib-resistant LAMA84 cell line
(manuscript in preparation).
In summary, our results show that CX-4945 and CX-5011 are
internalized in resistant cells, inhibit endogenous CK2, and, alone
or in combination with other drugs, induce significant cell death.
We suggest that they can be seriously considered as a valid
therapeutic strategy also in case of pharmacological resistance
occurrence.
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ABSTRACT 
Homeodomain-interacting protein kinase 2 (HIPK2) is a Ser/Thr kinase controlling cell 
proliferation and survival, whose investigation has been hampered by the lack of specific inhibitors 
able to dissect its cellular functions. SB203580, a p38 MAP kinase inhibitor, has been used as a tool 
to inhibit HIPK2 in cells, but here we show that its efficacy as HIPK2 inhibitor is negligible 
(IC50>40μM). In contrast by altering the scaffold of the promiscuous CK2 inhibitor TBI a new class 
of HIPK2 inhibitors has been generated. One of these, TBID, displays toward HIPK2 
unprecedented efficacy (IC50= 0.33 μM) and selectivity (Gini coefficient 0.592  out of a panel of 76 
kinases). The two other members of the HIPK family, HIPK1 and HIPK3, are also inhibited by 
TBID albeit less efficiently than HIPK2. The mode of action of TBID is competitive with respect to 
ATP, consistent with modelling. We also provide evidence that TBID is cell permeable by showing 
that HIPK2 activity is reduced in cells treated with TBID , although with an IC50 two orders of 
magnitude higher (about 50μM) than in vitro. 
 
INTRODUCTION 
The CMGC group of the human kinome is split into several branches, one of which, also including 
DYRKs and CLKs, gives rise to a sub-branch composed by so called “homeodomain-interacting 
protein kinases” (HIPKs). Four HIPKs are present in human, with HIPK2 attracting special 
attention for its role as a regulator of growth and apoptosis in various types of cells [1]. HIPK1/2 
double deficient mice exhibit defects in hematopoiesis, vasculogenesis and angiogenesis [2]. HIPK2 
was firstly recognized as a DNA damage responsive kinase exerting a tumor suppressor function by 
mediating p53 activation  [3,4]. HIPK2 however can also mediate apoptosis in the absence of p53 
[5,6,7] and a number of observations summarized in [1] strongly argue for additional non apoptotic 
roles of HIPK2, whose precise understanding will require the identification of new HIPK2 targets.  
These studies have been hampered by the lack of selective inhibitors of HIPK2. Small cell 
permeable inhibitors of protein kinases have become invaluable reagents for dissecting signaling 
pathways mediated by each of them. In recent years a huge repertoire of compounds purported to be 
“specific” toward a large number of protein kinases have become available. Since however the 
human kinome is composed by some 500 members the issue of selectivity is critical and only in a 
limited number of cases inhibitors have been shown to display a really narrow selectivity window 
hitting only few and in very rare cases one individual protein kinases [8,9]. 
In the case of HIPK2 the rational design of specific inhibitors has never been reported, the only 
HIPK2 inhibitor mentioned in the literature being SB203580, a compound firstly employed as 
HIPK2 inhibitor [10] because this kinase displays features similar to p38 like MAP kinase, whose 
susceptibility to SB203580 was already established. Consequently several laboratories exploited 
SB203580 as a “HIPK2 inhibitor” (e.g. [11,12]), based on the assumption that its targeting of 
HIPK2 is selective. However by profiling SB203580 on a panel of 71 protein kinases at 1 μM 
concentration, inhibition of HIPK2 was negligible (14%) as compared to that of 6 protein kinases 
which were inhibited >60%, and it remained below the average inhibition of the whole panel 
(17.7%) [9].  Moreover the members of the HIPK family are not among the kinases inhibited by 
SB203580 (nor by any other compound examined) in a comprehensive profiling of kinase inhibitors 
selectivity [13]. This sheds doubts on the interpretation of the effects of SB203580 as really 
mediated by cellular HIPK2 blockage. 
In the course of our studies aimed at the identification and development of compounds able to 
inhibit CK2, a highly pleiotropic kinase [14,15], playing a key role as an anti-apoptotic agent [16] 
and whose abnormally high level enhances the tumor phenotype through a non oncogene addiction 
mechanism [17,18], we observed that several potent CK2 inhibitors also exert a drastic effect on a 
few other protein kinases, notably DYRK1A, PIMs and HIPK2 [19,20]. This was especially true of 
the most common CK2 inhibitors, TBB (TBBt) and TBI (TBBz) and of related tetrabromo-
benzimidazole derivatives. 
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These observations prompted us to design modifications of the tetrabromo-benzimidazole scaffold 
aimed at decreasing the efficacy toward CK2 and other kinases drastically inhibited  by TBI and 
TBB, while maintaining or eventually improving that toward HIPK2. 
Here we describe the properties of one of these derivatives, 4,5,6,7-tetrabromo-2-(1H-imidazol-2-
yl)isoindoline-1,3-dione (TBID) which is able to inhibit HIPK-2 with a selectivity much higher than 
that of TBI, not to say of SB203580, whose ability to inhibit HIPK2 is in our hands negligible. 
These properties in conjunction with cell permeability, make TBID the first choice inhibitor of 
HIPK2 presently available for both in vitro and in cell studies. 
 
MATERIALS AND METHODS 
 
Chemistry 
Synthesis and details concerning compounds 5a-5i are provided in Supporting Information. 
Instruments were used and procedures for compound characterization were carried out as published 
before [21,22]. 
 
Source and purification of protein kinases 
Native CK2 and CK1 were purified from rat liver [23]. 
The source of HIPK2 and of all of the other protein kinases used for specificity assays is as 
described elsewhere [9]. 
 
Kinase inhibition assays 
HIPK2 (63 ng) was preincubated at 37 °C for 10 minutes either in the absence or in the presence of 
increasing amounts of each inhibitor in a final volume of 20 μl of solution containing  50 mM Tris-
HCl pH 7.5, 0.1% (v/v)  2-mercaptoethanol, 0.1 mM EGTA, 10 mM magnesium acetate. The 
reaction was started by addition of 5 μl of a reaction mixture containing 20 μM [
33P-ATP] (500-
1000 cpm/pmol), and the synthetic peptide substrate NKRRRSPTPPE [24] (600 μM, unless 
differently indicated). Similar results were obtained by replacing the peptide with MBP (0.33 
mg/ml). The reaction was stopped by addition of 5 μl of 0.5 M orthophosphoric acid before spotting 
aliquots onto phosphocellulose filters. Filters were washed in 75 mM phosphoric acid (5-10 
ml/each) four times and then once in methanol and dried before counting.  
PIM1, CK2, CK1 phosphorylation assays were performed following similar procedures used for 
HIPK2 except that preincubation was omitted. In detail, PIM1 activity was determined at 100 μM 
ATP concentration  and in the presence of 30 μM synthetic peptide substrate RKRRQTSMTD.  
CK2 and CK1 activities were assayed in a buffer containing 50 mM Tris/HCl (pH 7.5), 100 mM 
NaCl, 12 mM MgCl2, 100 μM specific peptide substrate RRRADDSDDDDD (for CK2), or 200 μM 
IGDDDDAYSITA (for CK1) and 20 μM [γ -33P]ATP (500–1000 c.p.m./pmol).  
Conditions for the activity assays of all other protein kinases tested in selectivity experiments are as 
described or referenced in [9]. 
 
Kinetics  
Initial velocities were determined at each of the ATP concentration tested, at 1 mM 
NKRRRSPTPPE peptide concentration. Km values were calculated either in the absence or in the 
presence of increasing concentrations of inhibitor, from Lineweaver-Burk double-reciprocal plots of 
the data. Inhibition constants were then calculated by linear regression analysis of Km/Vmax versus 
inhibitor concentration plots. 
 
Selectivity parameters.  
Lorenz curves were derived from the selectivity data. Gini coefficients  and Hit Rates (expressing 
the percent of kinases inhibited >50% by a given compound) were calculated as described in [25]. 
 
Molecular modeling 
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Model Building: Human HIPK2 protein kinase was built using an homology modeling approach 
implemented into Molecular Operating Environment (MOE) [26] with DYRK1A as template (PDB 
code: 2WO6)[27].  All the ligands and cofactors were removed; hydrogen atoms were added using 
standard geometries to the protein structure with the MOE program. To minimize contacts between 
hydrogen’s, the structures were subjected to Amber99 force field minimization until the rms of 
conjugate gradient was <0.05 kcal mol-1 Å-1 keeping all the heavy atoms fixed [26]. To strictly 
validate the model generated and to calibrate our high-throughput docking protocol, a small 
database of known HIPK2 inhibitors was built and a set of docking runs was performed. 
Molecular docking: After the calibration phase, all compound structures were docked directly into 
the ATP binding site  of the human HIPK2 model, by using the docking tool part of the GOLD suite 
[28]. Searching was conducted within a user-specified docking sphere (12 Å from the center of the binding 
cleft), using the Genetic Algorithm protocol and the GoldScore scoring function. GOLD performs a user-
specified number of independent docking runs (50 in our specific case) and writes the resulting 
conformations and their energies in a molecular database file. Prediction of small molecule-enzyme 
complex stability (in terms of corresponding pKi value) and the quantitative analysis for non-bonded 
intermolecular interactions (H-bonds, transition metal, water bridges, hydrophobic, electrostatic) were 
calculated and visualized using several tools implemented in MOE suite. 
 
Cell culture and treatment  
HepG2 cells (human hepatocellular carcinoma) were cultured in Dulbecco's modified Eagle's 
medium (DMEM; Sigma) supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 unit/ml 
penicillin and 100 μg/ml streptomycin; CEM cells  (human T lymphoblastoid cells) were cultured n 
RPMI-1640 (Sigma) with the same supplements. Cells were cultured in an atmosphere containing 5% 
CO2, at 37 °C. Treatments with TBID were performed in the same medium but with 1% fetal calf 
serum; control cells were treated with the solvent (DMSO). Total cell lysates were prepared as in [29]. 
 
Cellular HIPK2 kinase assays  
Endogenous HIPK2 activity was evaluated by measuring the phosphorylation level of its  target site 
Ser46 of p53: to this purpose, CEM cells were treated for 6 h as indicated, then lysed. 10 mg of total 
proteins were loaded on 11 % SDS-PAGE, blotted on Immobilon-P membranes (Millipore), and 
analyzed by western blot (WB) using an anti-phospho Ser46 p53 antibody (BD Biosciences); 
chemiluminescence signals were acquired with a Kodak 4000MM Pro Image Station. Bands were 
quantified by Carestream Molecular Imaging Software  (Kodak) and the obtained values were 
normalized to total p53 signal with a Cell Signaling Technology antibody; anti-actin (Sigma) was 
used as loading control.  
Alternatively, HIPK2 was immunoprecipitated with 2.5 ml anti-HIPK2 (Epitomics) from 350 mg of total 
lysate proteins deriving from HepG2 cells either treated  or not with TBID following a protocol 
elsewhere described [30]. An aspecific antibody was used as negative control.  Immunoprecipitated 
HIPK2 activity was measured towards the specific peptide substrate (NKRRRSPTPPE) at 1.6 mM 
concentration, for 10 min at 30 °C, under the same conditions described above for the in vitro kinase 
assay. Peptide radioactivity was measured after sample spotting on phospho-cellulose paper, washing 
and scintillation counting, as in [30], while the amount of HIPK2 immunoprecipitated was evaluated by 
WB.  
 
Cell viability and apoptosis assays 
Cell viability was evaluated by means of MTT (3-(4,5-dimethylthiazol-2-yl)-3,5-diphenyltriazolium 
bromide) reagent; 105cells/100 μl were incubated in a 96-well plate and treated for 6 h as indicated. 1 h 
before the end of the incubation, 10 μl of MTT solution (5 mg/ml in PBS) was added to each well. 
Incubations were stopped by addition of 20 μl of lysis solution at pH 4.7, as described elsewhere [30]. 
Plates were read for OD at λ 590 nm, in a Titertek Multiskan Plus plate reader (Flow Laboratories).  
Apoptosis was evaluated looking for the cleavage of the caspase substrate PARP with anti-PARP 
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antibody (Roche), recognizing both the full length (116 kDa) and the cleaved fragment (85 kDa) of 
PARP 
 
 
 
 
RESULTS AND DISCUSSION 
 
1. Synthesis of tetrabromoisoindoline-1,3-dione derivatives that inhibit HIPK2. 
The structures of two commonly used CK2 inhibitors, TBB and TBI are shown in Figure  1. These 
compounds share a number of bromine atoms clustered on their benzene ring which are essential for 
interaction with the kinase active site [31,32]; they also share the ability to inhibit HIPK2 besides 
CK2. This is especially true of TBI whose IC50 values with either HIPK and CK2 are nearly 
identical (0.7 vs 0.6 μM, [19] and Table 1). Since these compounds have been shown to become 
entrapped in a hydrophobic cavity adjacent to the ATP binding site, whose size in CK2 is 
particularly small, owing to a number of bulky side chains which are replaced by smaller ones in the 
majority of protein kinases, HIPK2 included, we reasoned that a device to reduce affinity toward 
CK2 as compared to that toward HIPK2 could be to increase the size of the tetrabrominated ligand. 
This goal was attained by derivatizing a tetrabromoisoindoline-1,3-dione scaffold (nearly super-
imposable to that of TBI) with an imidazole group, to give rise to 4,5,6,7-tetrabromo-2-(1H-
imidazol-2-yl)isoindoline-1,3-dione (TBID, 5a), The synthesis of TBID (5a) and analogs 5b-5i was 
carried out following a published general synthesis protocol [33] by reacting tetrabromophthalic 
anhydride with suitable aminosubstituted hetarenes (See Supporting Information, Figure S1).  
 
As shown in Table 1, TBID (5a) inhibits HIPK2 with the same efficiency as TBI, while displaying 
toward CK2 a more than10-fold higher IC50 value. 
Compared to TBID, all analogs 5b-5i were less potent HIPK2 inhibitors (Table 1). The outcome of 
this analysis underscores the crucial role of the 5-membered imidazole ring to achieve high 
inhibitory efficiency toward HIPK2: in fact its replacement with 6-membered aromatic rings or 
even with 5-membered rings with different spacing between the nitrogen atoms promotes big rises 
in IC50 values. Especially telling in this respect is the loss of inhibitory efficacy underwent by 
compound 5e, whereas compounds 5c and 5d, albeit less potently than TBID, still inhibit 
significantly HIPK2, highlighting the crucial role of a basic nitrogen atom at position  3.  
Modeling accounts for the above observations disclosing the role of this nitrogen for binding. 
HIPK2 models were built and prepared as described in the experimental section; after a docking 
calibration phase, a small database of tetrabromo phthalimides was built and a series of docking 
experiments were performed. As shown in Figure 2 TBID interacts with the hinge region through 
hydrophobic interactions between Val 213, Val 261, Phe 277, Leu 280, Met 331, Ile 345, and the 
tetrabromine moiety, while the symmetric nitrogen atom at position 3 interacts with the catalytic 
Lys 228, thus playing a crucial role in the binding architecture. In fact compounds 5b, 5c, 5d, 5g, 
5h  and 5i  still inhibit HIPK2 in the low micromolar range establishing the same electrostatic 
interaction found in the case of TBID. By contrast 5e, a TBID isomer, presenting a pyrazol ring 
instead of the imidazole of TBID cannot perform the same interaction with Lys 228 due to the 
different position of the nitrogen atom.  
As expected from modeling, the kinetics reported in Figure 3 show that inhibition of HIPK2 by 
TBID is competitive with respect to ATP. From these experiments a Ki value of 200 nM was 
calculated.  
 
2. Selectivity of TBID 
The selectivity of the newly developed HIPK2 inhibitor TBID was firstly tested at 10 μM 
concentration on a panel of 76 protein kinases. As shown in Figure  4 the activity of HIPK2 was 
entirely suppressed while none of the other protein kinases underwent a similar inhibition, the 
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residual activity of the second (BTK) and third (CAMKKb) most inhibited kinases being 29% and 
34%, respectively. To note in particular the modest inhibition of those kinases which generally tend 
to be susceptible to CK2 inhibitors, notably CK2 itself (48% residual activity), DYRK1A (72% 
residual activity) and PIM1 (entirely unaffected). 
To gain more information about the selectivity of TBID the compound was profiled at 1 instead of 
10 μM concentration on a larger panel of 125 protein kinases, implemented with other members of 
the HIPK sub-family and many protein tyrosine kinases which were scarcely represented in the 
smaller panel. The data, shown in Supporting Information (Table S1), corroborate the concept that 
HIPK-2 is the kinase most susceptible to TBID (31% residual activity). HIPK1 and HIPK3 however 
are also significantly inhibited with residual activities of  39% and 53%, respectively. In contrast 
none of the protein tyrosine kinases tested is appreciably affected by TBID with the only possible 
exception of IGF-IR (68% residual activity). This together with CAMK1 and CAMKKb are the 
only kinases inhibited more than 20% a part from the HIPKs.  
Collectively taken these data denote TBID as a very selective inhibitor of HIPKs in general and 
HIPK2 in particular, and they highlight the striking superiority of this new compound over both 
TBI and SB203580. To note that in our hands SB203580 is not appreciably affecting HIPK2 
activity up to 40 μM concentration (Table 1) consistent with  previous reports [9,13]. In contrast the 
IC50 values with TBI (1 μM) was only slightly higher than that with TBID, the latter however being  
much more selective as also highlighted by the observation that the number of  kinases inhibited 
>90% by either 10 μM TBID or TBI in the same panel is 1(HIPK2, see Figure 4) and 10 (see ref. 
[20]) respectively. From the selectivity data of Figure 4 it was possible to draw a Lorenz curve 
(Figure 5) allowing to calculate a Gini coefficient (0.592) whose  value denotes a remarkable 
selectivity, especially if compared to that of TBI (0.310). The difference in selectivity between 
TBID and TBI is also striking if their hit rates (0.10 vs 0.55) are compared. 
  
3. Cell permeability of TBID 
Dealing with protein kinase inhibitors, a crucial issue is their cell permeability which is essential to 
make these reagents useful for in vivo studies. Cell permeability of TBID was firstly assessed by 
treating HepG2 cells with increasing concentrations of either TBID or its very close analog 5e 
almost devoid of inhibitory efficacy (see Table 1) and measuring HIPK2 activity in the cell lysate : 
HIPK2 was immunoprecipitated and  then assayed for its activity using a specific peptide substrate. 
As shown in Figure 6A endogenous HIPK2 activity is reduced in a dose dependent manner upon 
cell treatment with TBID, but not with its inactive analog 5e, providing the evidence that TBID is 
cell permeant. Incidentally this outcome places TBID in that category of protein kinase inhibitors 
whose efficacy persists after the kinase has been isolated from the treated cells. Such a behaviour is 
typical of many CK2 inhibitors [30,34,35], TBB and TBI included, but it has also been reported in 
the case of other kinases, e.g. PIM-1 [36]. The molecular features underlying persistent inhibition, 
suggestive of a very low Koff rate, are presently unclear, but it is plausible to assume that these 
compounds, once entrapped in the hydrophobic pocket of the kinase (see also Figure 2), undergo a 
thermodynamic advantage, hindering their release into the surrounding aqueous medium. We also 
considered the possibility that intracellular TBID could irreversibly inactivate HIPK-2 by 
preventing the phosphorylation of its up-regulatory tyrosine, an event occurring only during 
translation [37,38]. In our cell model, however, we couldn’t detect any phospho-Tyr signal in 
HIPK-2 immunoprecipitated from either untreated or treated cells  (not shown). 
To reinforce the view that endogenous HIPK-2 is inhibited upon cell treatment with TBID, 
advantage has been also taken of p53 Ser46, a known target of the kinase [39].  As shown in Figure 
6B, TBID treatment markedly reduces the phosphorylation level of this residue, without affecting 
the amount of p53, under conditions devoid of cell toxicity (Figure 6C). To note that, although p53 
Ser46 is not targeted exclusively by HIPK2, other putative phosphorylating agents of this residue, 
notably DYRK2 [40] and PKC [41], are nearly unaffected by the inhibitor under conditions where 
HIPK2 is >70% inhibited (see Table S1). This observation, in conjunction with the similar dose 
dependency of HIPK2 activity inhibition and decrease of p53 Ser46 phosphorylation (compare the 
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histograms of panels A and B in Figure 6), support the view that the reduction of p53 Ser46 
phosphorylation is mainly due to HIPK2 inhibition. It should be noted in this connection that the 
concentration required for half maximal inhibition is two orders of magnitude higher in cells than it 
is in vitro (50 μM vs 0.33 μM). This is not unusual among protein kinase inhibitors [42] as 
exemplified elsewhere [30,35,43] and may be accounted for by massive sequestration of lipophilic 
compounds to cellular structures and to the fact that ATP competitive inhibitors (such as TBID) 
have to cope with a very high ATP concentration (in the mM range) within the cell.   
 
Collectively taken, the data presented fill a gap in the field of signal transduction mediated by protein 
phosphorylation by making available for the first time a specific and cell permeable inhibitor for 
HIPK2, a protein kinase whose emerging role as regulator of cell growth and apoptosis in various 
tissues and whose implication in the mode of action of chemotherapeutic agents is rising remarkable 
interest. The only compound used so far as an HIPK2 inhibitor in fact (SB203580) was developed to 
inhibit different classes of protein kinases and its efficacy to inhibit HIPK2 activity is questionable, as 
clearly shown here and elsewhere [9,13]. On the other hand a number of compounds able to drastically 
inhibit both protein kinase CK2 and HIPK2 [17,19] display a wide promiscuity, which hampers their 
usage as selective HIPK2 inhibitors. In contrast, the compound whose synthesis and characterization are 
described here, TBID, displays a good efficacy and a remarkable selectivity towards the members of the 
HIPK family, with special reference to HIPK2, as shown both by profiling it on large panels of kinases 
and by molecular modelling, accounting for its ATP competitive mode of action. These properties, in 
conjunction with ability to permeate cells, as judged from inhibition of  endogenous HIPK2, make 
TBID the first choice and for the time being the only pharmacological tool to down regulate cellular 
HIPK2, with the caveat that the concentrations of the compound effective in cells are much higher than 
the IC50 values calculated in vitro. 
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FIGURE LEGENDS 
 
Figure 1. Structures of TBB and TBI 
 
Figure  2. Molecular docking of TBID (yellow) bound to the active site of the human HIPK2 model 
(green). 
 
Figure  3. Inhibition of HIPK2 by TBID is competitive with respect to the phosphodonor substrate 
ATP. Kinetics were performed as described in Materials and Method either in the absence or in the 
presence of the indicated TBID concentrations. The data represent means of triplicate experiments 
with SEM never exceeding 15%. 
 
Figure  4. Selectivity profile of TBID (10 μM) against 70 kinases panel. Inhibition assays were 
performed with 10 μM TBID under conditions described or referenced in the Experimental section. 
Residual activity expressed as per cent of activity in the absence of TBID is shown. 
 
Figure  5.  Lorenz Curves, Gini coefficients and Hit Rates for TBID and TBI. For details see 
experimental section and [25]. Lorenz Curves were drawn from the selectivity profile of Figure  4 
and from analogous data published in ref. [19] for TBID and TBI, respectively. 
 
Figure  6. Cell treatment with TBID inhibits endogenous HIPK. A. HIPK2 was immunoprecipitated 
from lysates of HepG2 cells treated with different concentrations of TBID or the inactive analog 5e, 
as indicated; HIPK2 activity was measure towards the specific peptide substrate, as detailed in 
Materials and Methods. The amount of immunoprecipitated HIPK2 is shown by WB. B. CEM cells 
were treated as indicated, then 10 mg of cell lysate proteins were analysed by WB with an antibody 
against pS46  of p53, anti-total p53, or anti-actin, as loading control. A representative experiment is 
shown on the left, while a histogram is presented on the right where Sp46 p53 of three separate 
experiments has been quantified, normalized to the p53 total level, and reported as means + SEM. 
C. Cell viability was assessed by the method of MTT, treating HepG2 or CEM cells as indicated (left 
panel) or by evaluating the amount of the caspase substrate PARP  (HepG2 cells, right panel), 
whose reduction would denote apoptosis.  The recognized band corresponds to the full length 
PARP protein of 116 kDa. 
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Table 1: IC50 (μM) of 2-aryl-4,5,6,7-tetrabromoisoindoline-1,3-diones 5 for HIPK2, CK2, PIM1, 
CK1; TBB and TBI (Figure 1) values are drawn from [19]. n.d.= not determined                                     
 
1
2
3
4
5
6
7
 
 
Entry R- HIPK2 CK2 PIM1 CK1 
TBID (5a) 
 
1H
2
3
 
0.33 5.50 >40.0 >40.0 
5b  
 
  
0.72 16.0 40.0 9.3 
5c  
 
 
2.6 24.0 >40.0 >40.0 
5d  
  
2.5 35.0 >40.0 >40.0 
5e  
 
  
>40.0 23.0 >40.0 >40.0 
5f  
 
  
>40.0 >40.0 >40.0 >40.0 
5g  
  
22.7 25.0 >40.0 >40.0 
5h  
  
23.6 >40.0 >40.0 >40.0 
5i  
 
  
3.62 >40.0 >40.0 >40.0 
12 
 
TBB  5.3 0.15 1.04 >40.0 
TBI  0.7 0.60 0.115 15 
SB203580  >40.0 n.d. n.d. n.d. 
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